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Abstract 
 
We used the hydrogen-bond propensity (HBP) protocol for predicting if a co-crystal would form 
or not for six different target molecules in combination with 25 potential co-formers each. The 
correct outcome was successfully predicated 92-95% of the time, which indicates that for a series 
of small molecules, HBP is a very reliable indicator for determining if a co-crystal will form. 
 
In order to examine if hydrogen and halogen-bonded systems can mimic each other, we conducted 
co-crystallization experiments using eight targets in combination with 25 co-formers. Molecular 
electrostatic potential surface (MEPS) calculations were used to guide the experimental space. The 
results suggested that in all the cases, hydrogen and halogen-bonds mimic each other. Validation 
studies of MEPS gave a prediction accuracy range of 64-84%. 
 
Three different factors, hydrogen-bond propensity (HBP), hydrogen-bond coordination (HBC), 
and hydrogen-bond energies (HBE), were evaluated to predict the experimental outcomes of 
attempted co-crystallizations between two known drug molecules, Nevirapine and Diclofenac, and 
a series of potential co-formers. HBP gave the correct result in 26 out of 30 cases, whereas the 
HBC method predicted the correct outcome in 22 out of 30 cases. Finally, HBE gave the correct 
result in 23 out of 30 experiments. In those cases, where the crystal structure of a co-crystal of 
either Nevirapine or Diclofenac was known, we also examined how well the three methods 
predicted which primary hydrogen-bond interactions were present in the crystal structure. HBP 
correctly predicted 6 out of 6 cases, HBC could not predict any of the synthon formations correctly, 
and HBE successfully predicted 1 out of 6 cases. 
 
Three different factors, hydrogen-bond propensity (HBP), hydrogen-bond energy (HBE), and 
molecular complementarity (MC), were used for predicting co-crystallization outcomes of seven 
active pharmaceutical ingredients (APIs) in combination with 42 potential co-formers. Validation 
studies indicate that individually the methods did not offer high accuracy. Hence, we implemented 
a combination of methods using Venn diagrams. The results suggested that the combination of MC 
and HBP method yielded the highest accuracy of 80%. 
 
In order to ease the complexity of the predictive approaches, we designed CoForm, an automatic 
app for predicting co-crystallization outcomes. CoForm was used to predict co-crystallization 
outcomes for Loratadine and Desloratadine in combination with 42 generally regarded as safe 
(GRAS) list co-formers. The predictive abilities of CoForm were compared to commercially 
available tools such as HBP and MC. The results indicate that CoForm delivered a success rate of 
80% for both Loratadine and Desloratadine in comparison to HBP 76% and 54%, respectively, 
and MC 39% and 22%, respectively. 
 
Six cavitands were synthesized to explore the guest encapsulation via cavity inclusion, using five 
solvents (xylene, dichloromethane, ethyl acetate, acetonitrile, and dimethyl sulfoxide) with 
varying dipole moment as a potential guest. Cavity inclusion studies indicated that the cavitands 
could encapsulate a guest in five different orientations, with stoichiometries 1:1 to 1:2. A 
selectivity study showed that the cavitands were more selective towards DMSO, which also had 
the highest dipole moment. 
 
Finally, cavitands were used as molecular containers for fragrant compounds and heterocyclic-N-
oxides. In both cases, the host interacted with guests in 1:2 stoichiometry, as indicated by NMR 
titrations and TGA analysis. The host-guest interaction of cavitands with fragrant compounds 
lowered the volatility of the fragrant compounds from 5-10 mins to over a month. 
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Abstract 
 
We used the hydrogen-bond propensity (HBP) protocol for predicting if a co-crystal would form 
or not for six different target molecules in combination with 25 potential co-formers each. The 
correct outcome was successfully predicated 92-95% of the time, which indicates that for a series 
of small molecules, HBP is a very reliable indicator for determining if a co-crystal will form. 
 
In order to examine if hydrogen and halogen-bonded systems can mimic each other, we conducted 
co-crystallization experiments using eight targets in combination with 25 co-formers. Molecular 
electrostatic potential surface (MEPS) calculations were used to guide the experimental space. The 
results suggested that in all the cases, hydrogen and halogen-bonds mimic each other. Validation 
studies of MEPS gave a prediction accuracy range of 64-84%. 
 
Three different factors, hydrogen-bond propensity (HBP), hydrogen-bond coordination (HBC), 
and hydrogen-bond energies (HBE), were evaluated to predict the experimental outcomes of 
attempted co-crystallizations between two known drug molecules, Nevirapine and Diclofenac, and 
a series of potential co-formers. HBP gave the correct result in 26 out of 30 cases, whereas the 
HBC method predicted the correct outcome in 22 out of 30 cases. Finally, HBE gave the correct 
result in 23 out of 30 experiments. In those cases, where the crystal structure of a co-crystal of 
either Nevirapine or Diclofenac was known, we also examined how well the three methods 
predicted which primary hydrogen-bond interactions were present in the crystal structure. HBP 
correctly predicted 6 out of 6 cases, HBC could not predict any of the synthon formations correctly, 
and HBE successfully predicted 1 out of 6 cases. 
 
Three different factors, hydrogen-bond propensity (HBP), hydrogen-bond energy (HBE), and 
molecular complementarity (MC), were used for predicting co-crystallization outcomes of seven 
active pharmaceutical ingredients (APIs) in combination with 42 potential co-formers. Validation 
studies indicate that individually the methods did not offer high accuracy. Hence, we implemented 
a combination of methods using Venn diagrams. The results suggested that the combination of MC 
and HBP method yielded the highest accuracy of 80%. 
 
In order to ease the complexity of the predictive approaches, we designed CoForm, an automatic 
app for predicting co-crystallization outcomes. CoForm was used to predict co-crystallization 
outcomes for Loratadine and Desloratadine in combination with 42 generally regarded as safe 
(GRAS) list co-formers. The predictive abilities of CoForm were compared to commercially 
available tools such as HBP and MC. The results indicate that CoForm delivered a success rate of 
80% for both Loratadine and Desloratadine in comparison to HBP 76% and 54%, respectively, 
and MC 39% and 22%, respectively. 
 
Six cavitands were synthesized to explore the guest encapsulation via cavity inclusion, using five 
solvents (xylene, dichloromethane, ethyl acetate, acetonitrile, and dimethyl sulfoxide) with 
varying dipole moment as a potential guest. Cavity inclusion studies indicated that the cavitands 
could encapsulate a guest in five different orientations, with stoichiometries 1:1 to 1:2. A 
selectivity study showed that the cavitands were more selective towards DMSO, which also had 
the highest dipole moment. 
 
Finally, cavitands were used as molecular containers for fragrant compounds and heterocyclic-N-
oxides. In both cases, the host interacted with guests in 1:2 stoichiometry, as indicated by NMR 
titrations and TGA analysis. The host-guest interaction of cavitands with fragrant compounds 
lowered the volatility of the fragrant compounds from 5-10 mins to over a month. 
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Glossary of terms 
Hydrogen-bond Coordination (HBC): It is a structure informatics-based model which indicates 
how many coordination numbers a hydrogen-bond donor and acceptor can form.  
Hydrogen-bond Energy (HBE): It is simple model based on molecular electrostatic potential 
surfaces (MEPS) to calculate the interaction energies between a hydrogen-bond donor and 
acceptor.  
Hydrogen-bond Propensity (HBP): It is the probability of formation of a hydrogen-bond 
interaction based on structure informatics of more than a million structures present in Cambridge 
Structural Database (CSD).  
 
Molecular Complementarity (MC): It is a structure informatics-based model, which indicates if 
a given pair of molecules have complementary shape and size to result in a dense structure with 
minimum volume. 
 
  
 xxiii 
 
Acknowledgements 
This work was carried out at the Department of Chemistry, Kansas State University during years 
2015-2020. These years were the most demanding, frustrating and stressful of my life, but at the 
same time, they have been the most rewarding, exciting and unforgettable. During this journey I 
have met a lot of great people, who I want to express my sincere gratitude.  
 
First and foremost, I want to express my deepest gratitude to my supervisor, Prof. Christer B. 
Aakeröy, for providing me with the opportunity to be a part of his group and introducing me into 
the exciting world of supramolecular chemistry. I am grateful for all the advice, support, patience, 
and encouragement throughout my five years of PhD.  I am thankful for his continuous motivation 
and attention that have helped me shape into a better researcher, presenter and writer. I am 
fortunate to be a part of his group and could not have asked for a better mentor. Finally, all of this 
work could not have been possible without Dr. Aakeröy’s sense of humor and his ability to lighten 
the mood in a high stress environment.  
 
I would also like to thank my Ph.D. advisory committee; Professor Larry Erickson for accepting 
to be a part of my committee at the very last moment, Professor Tendai Gadzikwa for her immense 
support and guidance. Professor Paul Smith and Professor Bret Flanders for their invaluable time 
and encouragement.  
 
I would also like to extend a special thank you to Professor Eric Matta and Dr. Emily McLaurin 
for helping me widen my knowledge in Chemistry. 
 
I also wish to extend my deepest gratitude to Dr. Victor Day, Marijana Đaković, and Dr. Abhijeet 
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Chapter 1 – Introduction 
 
1.1. Structure-property relationship 
 
A relationship between structure and property was investigated in the pioneering research by 
Wiener1,2, where the boiling points varied with molecular bulk and branching3. Since then the 
study of structure-property relationships has played an essential role in all fields including 
chemistry, environmental studies, biology, biochemistry, and engineering. The crystal structure of 
a compound is dependent on the crystallization process which yields crystals of different sizes and 
morphologies that can impact its solubility, and physical and chemical stability4.  
The importance of structure-property relationship is identified specifically in pharmaceutics as in 
the case of antiviral compound ritonavir. Ritonavir, marketed as Norvir in 1996, is a semi-solid 
capsule for treatment of Acquired Immunodeficiency Syndrome (AIDS)5. In 1998, several 
capsules of Norvir failed the dissolution experiment, upon examination a new structural 
arrangement (polymorph) was identified6. The new polymorph had completely different properties 
compared to Norvir’s original form. This led to Norvir being removed from the market, resulting 
in huge loss of money and time, Figure 1.1. 
 
                 
Figure 1.1. Different structural arrangement of Norvir, Form I (left), Form II (right)5. 
 
In order to achieve the desired properties in a compound either covalent modification or 
supramolecular syntheses via non-covalent interactions needs to be carried out. 
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1.2. Covalent vs supramolecular syntheses 
 
Covalent synthesis involves making or breaking of a covalent bond in a reaction to isolate products 
with desired yield7. Covalent synthesis has been carried out over many years by organic chemists 
to understand the structure, reactivity, and pathways to produce better yields, Figure 1.2.  
 
Figure 1.2. Covalent vs supramolecular syntheses. 
 
Supramolecular synthesis, on the other hand, is a newer concept which is defined as the chemistry 
of non-covalent bonds. Supramolecular chemistry grew exponentially after the Nobel Prize in 
Chemistry 1987 was awarded to three of the pioneers, Charles Pedersen, Jean-Marie Lehn and 
Donald Cram8. The most common representative of a supramolecular system is a crystal lattice 
that is held together by weak non-covalent interactions between the molecules9 some non-covalent 
interactions that play a role in supramolecular chemistry are hydrogen-bonds, halogen-bonds, - 
and van der waal’s interactions, Table 1.1.  
 
Table 1.1. Strength of intermolecular interactions. 
Type of interactions Strength (kJ/ mol) 
Covalent bond 100-4400 
Hydrogen bond 10-70 
Halogen bond 5-180 
- interaction 0-50 
Van der Waal’s interaction <5 
 
Covalent bonds Non- Covalent interactions
Recrystallization Co-crystallization
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Crystal engineering involves strategies to organize different molecules in solid-state10. In a 
supramolecular synthesis the structure of a solid is dependent on the supramolecular synthon which 
is defined as11, a structural unit within a supermolecule which can be formed and/or assembled by 
known or conceivable synthetic operations involving intermolecular interactions. Supramolecular 
interactions can be categorized as homomeric interactions, that occur within the individual 
molecules leading to re-crystallization; and heteromeric interactions which occur between 
different molecules leading to co-crystallization12,13, Figure 1.2. 
 
1.3. Co-crystallization 
 
There is an extensive debate on the definition of co-crystals however, for the scope this dissertation 
we will define co-crystals as solids that are crystalline single-phase materials composed of two or 
more different molecular compounds in a stoichiometric ratio14,15,16. Co-crystallization is an 
attempt to bring forward a target with a potential partner, generally known as co-former within 
one periodic crystalline lattice via heteromeric interactions. The probability of formation of a co-
crystal is around 1% since it is competing with a natural phenomenon of formation of homomeric 
interactions i.e. recrystallization, Figure 1.2.  
The characterization of co-crystals is done by IR spectroscopy, TGA, DSC, single crystal X-ray 
crystallography, and powder X-ray diffraction17,18,19. The ability to form co-crystal is dependent 
on various factors such as solvent, stoichiometry, temperature, pressure, etc. Co-crystals are 
formed by breaking the homomeric interactions and subsequently replacing them with heteromeric 
interactions. The homomeric and heteromeric interactions are particularly non-covalent 
interactions, Table 1.1. In this dissertation we will focus on hydrogen and halogen bonds. 
 
1.3.1. Hydrogen-bond based co-crystals 
 
Hydrogen-bonds are the most commonly used intermolecular interactions for formation of co-
crystals20,21,22,23,24 due to their directionality and strength. Hence, even after a century of 
investigations it is still of utmost interest, which is reflected by the proposed change in the 
definition of hydrogen-bonds in 2011. A hydrogen bond (HB) is defined as25 an attractive 
interaction between a hydrogen atom from a molecule or a molecular fragment, X−H⋯A in which 
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X is more electronegative than H, and an atom or a group of atoms in the same or different 
molecule, in which there is evidence of bond formation. 
 
Figure 1.3. An example of a binary co-crystal between glutaric acid and 1,2-bis(4-
pyridyl)ethane26. 
 
1.3.2. Halogen-bond based co-crystals 
 
Halogen bonding is a non-covalent interaction, which is comparable in strength to hydrogen-bonds 
(~5-180 kJ/mol) and it has gained increasing importance in crystal engineering because of its 
effectiveness as a structure-directing force27,28. A halogen bond is defined as29 a net attractive 
interaction between an electrophilic region on a halogen atom X belonging to a molecule or a 
molecular fragment R–X (where R can be another atom, including X, or a group of atoms) and a 
nucleophilic region of a molecule, or molecular fragment, A−Z30,31,33, Figure 1.4.  
 
 
Figure 1.4. Representation of anisotropic distribution of electron density around covalently 
bound halogen atom31,33. 
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An interesting feature of the halogen-bond is that the strength of this interaction can be effectively 
increased by “activating” the halogen atom (“σ-hole” activation) with electron withdrawing 
substituents or by introducing an sp-hybridized carbon next to the halogen atom32,33.  
 
 
Figure 1.5. An example of a binary co-crystal between bis(N,N-dimethylpyridin-4-amine) 
1,2,4,5-tetrafluoro-3,6-diiodobenzene34. 
 
1.4. Applications of co-crystallization 
 
Co-crystallization and co-crystal-based approaches have been used to alter the physical properties 
of compounds relevant in pharmaceutics35, energetic materials36, agrochemicals37, 
nutraceuticals38, organic semiconductors39, optoelectronic materials40, ferroelectric materials41,42, 
charge transfer complexes43, non-linear optics44,45, and liquid crystals46. Furthermore, co-
crystallization can be applied in solid state solvent free synthesis47, separation and purification 
processes48, chiral resolution49, and crystallization of non-solid compounds50 to facilitate 
manufacturing processes.  
 
1.4.1. Drug discovery and development timelines 
 
Drug discovery and development timelines are risky, lengthy, and expensive. Typically, an 
investigation of more than 10,000 compounds is needed in order to deliver a single drug to the 
marketplace at the cost of approximately 1 billion dollars, Figure 1.6. What happens if a potentially 
useful drug fails to satisfy some critical characteristic physical demand, e.g., sufficient aqueous 
solubility and chemical stability51,52?  
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Figure 1.6. Drug discovery and development timeline. 
 
There are various approaches that have been developed to improve bioavailability of the drugs 
such as particle size reduction, solid dispersion, complexation, salt formation, nanoparticles, 
self-emulsifying drug delivery system (SEDDS), addition of co-solvents, nano-suspension 
and emulsion and cocrystal formation53,54. Each technique has its own merits and demerits. 
Amongst all these techniques, co-crystallization is unique since it does not affect the 
pharmacological properties of the drug but may improve the drugs’ bioavailability and also 
improve several of its physicochemical characteristics, such as melting point, tabletability, 
solubility, stability, bioavailability and permeability55,56. 
 
1.4.2. Agrochemical co-crystals 
 
Agrochemicals such as pesticides, herbicides, insecticides, and fungicides, are important for crop 
production since they help in controlling pest for better quality and quantity of crops. The high 
solubility of many such chemicals in water make them susceptible to runoff in ground water where 
they cause environmental damage. Co-crystallization can be used to alter the physical properties 
of such chemicals by decreasing the water solubility, hygroscopicity, thermal stability, filterability 
and flowability and thereby affecting the overall usability and efficacy of a given agrochemical. 
Recent study by Bhupinder et al. shows the effect of co-crystallization in decreasing the water 
solubility of urea, commonly used as a pesticide37, Figure 1.7. 
Drug development process
10,000 compounds 250 compounds 5 compounds 1 approved drug
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Figure 1.7. Solubility profile of urea and urea co-crystals37. 
 
1.5. Will it co-crystallize? 
 
Co-crystal synthesis can be performed via several methods which includes slow solvent 
evaporation, slurry methods, liquid assisted grinding, melt, solution crystallizations, sonochemical 
methods60, spray drying techniques, and co-sublimation techniques. Among all these methods, 
liquid assisted grinding has been reported to be the most cost-effective, green, and reliable method 
for discovery of new co-crystals61. 
In order to successfully make a co-crystal, the choice of an optimal co-former represents a key 
challenge, and the selection is typically driven by extensive screening experiments which can be 
both time consuming and costly. In order to facilitate the selection process and to reduce the 
amount of experimental work that is needed before a co-crystal can be made, there has been a 
growing interest in developing predictive methods that can help to narrow and inform the 
experimental search space. Various co-crystal prediction methodologies based on molecular 
electrostatic potentials62,63, hydrogen bond energies (HBE)64, pKa65,66, Hansen solubility 
parameters67, and lattice energy comparisons68 are reported. Since more than a million small 
molecule crystal structures are available in the Cambridge Structural Database (CSD)64,69,70,71, 
structure-informatics methods have considerable potential for being uniquely valuable for 
informing and guiding the screening efforts. Galek et al introduced hydrogen-bond propensity as 
a predictive tool70,71 and Fábián used molecular shape and polarity to predict co-crystallization.72,73 
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1.6. Host-guest chemistry 
 
Supramolecular chemistry has been developed for small, low molecular weight compounds (200-
600 g/mol) to larger supramolecular building blocks with molecular weight (1000-1500 g/mol). 
Nature shows examples of elaborate complexes of proteins and nucleic acids to carry out 
transformations in the living cell, and these systems have been mimicked by synthetic chemistry 
as prototypes for supramolecular machines74.  The first supramolecular host was a crown ether 
which was synthesized accidently by Pedersen75. Since then Lehn, Cram, and Pedersen carried out 
pioneering work on inclusion chemistry of molecular hosts such as crown ethers, cryptands, 
cavitands, and carcerands76. The synthesis of other scaffold such as spherands, pillararenes77, 
cyclophanes, cryptophanes, calixarenes78, cavitands79,80, cyclodextrins81, cucurbiturils82 and more 
have been discovered in past few decades. These receptors can have high affinity and selectivity 
in binding due to the presence of pre-organized binding pockets. In a binding event, several non-
covalent interactions play roles as the driving forces. Hence, they are good candidates to study the 
importance of structure-property relationships in molecular recognition. Figure 1.8 shows an 
example of different host-guest binding via non-covalent interactions. 
 
Figure 1.8. Weaker intermolecular binding motifs A = CH···π, B = X···O, C = (X···O)2, D = 
X···π, E = π···π previously observed in tetrahaloethynyl cavitands-ligand crystals83. 
 
1.7. Goals of the thesis 
 
Over the past two decades the emergence of pharmaceutical co-crystals to develop better drugs 
with enhanced physiochemical properties has helped the pharmaceutical industry84,85,86,87,88,89,90,91. 
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In 2013 (with updates from 2016 & 2018), USFDA (United States Food and Drug Administration) 
and in 2014, EMA (European Medical Agency) recognized co-crystals as a drug product.54,92 To 
deliver pharmaceutical co-crystals with high value in minimum time, a systematic and reliable 
approach to the design of co-crystallization experiments is important. The significant step in 
designing co-crystallization experiments is identification of potential co-formers which might 
interact with the active pharmaceutical ingredient (API). First this thesis will explore the design, 
development, and evaluation of predictive methodologies that can guide the experimental space 
with high reliability. The second goal of this thesis is to employ the understanding of 
supramolecular synthetic strategies from small molecules to larger molecular receptors in order to 
probe molecular recognition events in solution. 
This dissertation will focus on the following goals: 
 
Chapter 2 describes a systematic investigation of hydrogen-bond propensity (HBP) for informing 
co-crystal design and assembly of 150 combinations of targets and co-formers, in comparison to 
experimentally observed outcomes. 
Chapter 3 explores molecular electrostatic potential surface (MEPS) based selectivity for 
hydrogen and halogen bonded systems with similar molecular backbone. 
Chapter 4 evaluates hydrogen-bond propensity (HBP), hydrogen-bond energy (HBE), and 
hydrogen-bond coordination (HBE) to predict co-crystal screening outcomes of two known drug 
molecules, Nevirapine and Diclofenac.  
Chapter 5 focuses on validation studies of HBP, HBE and molecular complementarity (MC) for 
predicting co-crystallization outcomes of seven compounds that are larger and flexible, in 
combination with 42 GRAS list co-formers.  
Chapter 6 will focus on design and development of CoForm, an automatic app for predicting co-
crystallization outcomes, in comparison to commercially available tools, for Loratadine and 
Desloratadine in combination with 42 GRAS list co-formers.  
Chapter 7 explores design and synthesis of functionalized cavitands for molecular recognition via 
cavity inclusion, of a series of solvent molecules with increasing dipole moment.  
Chapter 8 describe synthesis of cavitands functionalized with hydrogen-bond donor and acceptor 
groups. The binding ability of these cavitands will be tested towards volatile fragrant compounds 
and heterocyclic-N-oxides. 
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Chapter 2 - Systematic Investigation of Hydrogen-Bond Propensity 
as a Tool for Predicting Co-crystal Screening Experiments 
 
2.1. Introduction 
 
Co-crystals and co-crystallization-based approaches1,2,3 have been used to access new solid forms 
with improved properties4,5,6,7,8,9,10,11,12,13 in pharmaceutics, agrochemicals, energetics, etc. In 
particular, pharmaceutical co-crystals14,15 have gained considerable attention as solubility and 
stability are important defining factors in determining drug dosage, delivery, and storage. Other 
applications include agrochemicals16, where co-crystallization has decreased the water solubility 
and hygroscopicity17 of the targets. Co-crystallization of energetics18 has altered the impact 
sensitivity and stability, resulting in safer handling and transportation of explosives.  
The co-crystallization technique involves combination of a target and a potential partner (co-
former) in the same crystalline lattice held together by intermolecular interactions. The formation 
of a co-crystal is highly dependent on which intermolecular interactions will prevail between the 
target•••target (homomeric), co-former•••co-former (homomeric), and target•••co-former 
(heteromeric). A co-crystal is likely to be formed if the heteromeric interactions are stronger than 
the homomeric interactions; consequently, if homomeric is more dominant the outcome is a 
recrystallization. Although co-crystallization and recrystallization is a competition between 
heteromeric and homomeric interactions, the probability of formation of a co-crystal is small. 
Hence, understanding of intermolecular interactions is essential for designing successful co-crystal 
screening experiments.  
The most commonly used intermolecular interaction in co-crystallization is hydrogen 
bonding19,20,21,22,23,24,25,26,27, due to its directionality and strength. The first step to co-crystallization 
is to select potential partners or co-formers. The selection of the ideal co-formers is generally based 
on a combinatorial and extensive experimental screening, which is relatively time consuming and 
expensive. Therefore, to make co-crystallization technology faster and cheaper, we need methods 
for predicting the outcome of an attempted co-crystallization. 
Hunter and co-workers developed approaches based on molecular electrostatic potential surfaces 
(MEPS) and hydrogen-bond energies28,29,30 for predicting the dominant interactions in the solid 
and solution phase. Lattice energy comparison of the co-crystal and pure compound was carried 
out by Price and co-workers to predict co-crystallization31. Valega considered Hansen solubility32 
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parameters, and Aakeröy et al. implemented pKa33,34 values as a basis for predicting co-
crystallization.   
Several knowledge-based tools based on structural informatics of more than a million small 
molecule structures available in the Cambridge Structural Database (CSD) have been developed 
in Mercury30,35,36,37. Galek et al. introduced hydrogen-bond propensity35,37 as a predictive tool, and 
Fábián38,39 used molecular shape and polarity to predict co-crystallization. However, it still 
remains a challenge to accurately predict which specific hydrogen-bond(s) will likely dominate in 
the presence of numerous competing intermolecular forces and within widely different structural 
environments. 
In order to examine the versatility and possible limitations of structure-based methods for 
predicting co-crystal formation, we carried out a systematic comparison of hydrogen-bond 
propensity-based predictions with experimental data on small multi-functional organic compounds 
for 150 co-crystal experiments. The hydrogen-bond propensity (HBP) tool, developed by the 
Cambridge Crystallographic Data Centre (CCDC)38,40,41,42 and available within the Mercury 
software, was used to predict whether a co-crystal would form when a particular target molecule 
was combined with a potential co-former.  
The hydrogen-bond propensity is the probability of forming a specific motif, which is dependent 
on the relative occurrence of the interaction in the given fitting data.  When two different molecules 
are combined, we need to consider both homomeric and heteromeric interactions and use HBP to 
establish which possible outcome is likely to prevail, Figure 2.1.  
 
 
 
           
 
 
 
 
Figure 2.1. Hydrogen-bond propensity approach for co-crystal screening. 
       
A     +     B  
Homomeric interactions 
propensity = (A•••B) best – (A•••A) best 
A•••A  B•••B 
A-B   +   B-A 
> 
Heteromeric interactions  
A•••B > B•••A 
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Six different molecules were selected as target compounds. The target compounds consist of 
pyrazole rings, amide and nitrile groups all of which are present in many pharmaceutically active 
compounds43,44,45. The targets T1-T4 have two hydrogen-bond donors and two acceptor sites, and 
the presence of multiple donor-acceptor sites which means that co-crystallization can be driven 
through different paths. The targets T5-T6 were deliberately selected in such a way that they are 
more likely to form co-crystals with suitable partners since both of them present two hydrogen-
bond acceptor sites and no hydrogen-bond donor sites. The pairs T1&T3, T2&T4, and T5&T6 
are structural isomers, and T1&T3 and T2&T4 differ by the presence of methyl groups, Scheme 
2.1. Each target was screened against 25 potential co-formers ranging from aliphatic diacids with 
increasing size of alkyl chains (Group 1), aromatic acids with varying electron withdrawing and 
electron donating groups (Group 2), hydrogen-bond acceptors with a pyridine back bone (Group 
3), and mixed hydrogen-bond donor-acceptors with amino pyridine as a back bone (Group 4), 
Scheme 2.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.1. Target molecules (top) and potential co-formers (bottom). 
  
 
 
 
 
 
 
 
 
 
T5 T6 
T1 T2 T3 T4 
Donors 
Group 1 
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Acceptors 
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 23 
 
 
The study is done to answer the following questions: 
1. Will targets T1-T4 replace the self-complementary homomeric with heteromeric interactions to 
form co-crystals? 
2. Will targets T5-T6 co-crystallize with a higher supramolecular yield than T1-T4?  
3. How accurate is HBP based co-crystal prediction? 
 
2.2. Experimental  
 
4-bromo-1H-pyrazole, 3-bromo-1H-pyrazole, 4-(bromomethyl)benzonitrile, 3-(bromomethyl)
benzonitrile, THF were purchased from Alfa Aesar and were utilized without further purification. 
All 25 co-formers were purchased from commercial sources and used as received. Melting points 
were measured using a Fisher-Johns melting point apparatus. Solution 1H NMR data were 
collected in CDCl3 on a Varian Unity plus 400 MHz NMR spectrometer. IR spectra of the solids 
resulting from the co-crystal screening experiments were recorded with a Nicolet 380 FT-IR 
spectrometer (ATR) and a ZnSe crystal. 
 
2.2.1. Synthesis of target compounds 
 
2.2.1.1. Synthesis of 4-((4-bromo-1H-pyrazol-1-yl)methyl)benzonitrile (T5) 
 
To a round bottom flask, 4-bromo-1H-pyrazole (1.50g, 9.32 mmol) and THF (80,0 mL) were 
added. To this solution, NaOH pellets (4.10g, 103 mmol) were added and the reaction was stirred 
at room temperature for 2 hours. On completion of the stir, 4-(bromomethyl)benzonitrile (2.00 g, 
10.2 mmol) in THF (80.0mL) was added and the reaction mixture stirred at room temperature 
overnight. On completion, water was added to dissolve any excess NaOH, the organic layer was 
separated, dried over MgSO4 and the solvent removed under vacuum to yield a white solid (2.00 
 24 
 
g, 96%). M.P.: 55-57 ºC. 1H NMR (400MHz, CDCl3): 8.10 (1H, s), 7.83 (2H, d), 7.58 (1H, s), 
7.28 (2H, d), 5.37 (2H, s). IR υ: 2223, 1665, 1609, 1509, 1441, 1391, 1334 cm-1. 
2.2.1.2. Synthesis of 4-((3-bromocyclopenta-2,4-dien-1-yl)methyl)benzamide 
 
 
To a round bottom flask, 4-((4-bromo-1H-pyrazol-1-yl)methyl)benzonitrile (2.00g, 8.81 mmol) 
and 85% H2SO4 (10.0mL) were added. The mixture was heated to 80
0C and stirred for 4 hours. 
On completion, the solution was poured slowly over ice and the resulting brown solution was 
adjusted to basic pH using 5M NaOH. The aqueous solution was washed with CHCl3 and the 
organic extracts were separated, dried over MgSO4 and reduced to yield a white solid (1.90g, 88%).  
M.P.: 135-137 ºC. 1H NMR (400MHz, DMSO-d6): 7.81 (1H, s), 7.83 (1H, s), 7.80 (1H, d), 7.55 
(1H, d), 7.36 (1H,d), 7.24 (1H,d), 5.37 (2H, s). IR υ: 3365, 3210, 1665, 1480, 1301, 1334 cm-1. 
 
2.2.1.3. Synthesis of 4-((4-((trimethylsilyl)ethynyl)-1H-pyrazol-1-yl)methyl)benzamide 
 
A stirred solution of 4-((3-bromocyclopenta-2,4-dien-1-yl)methyl)benzamide (1.50 g, 6.12 mmol), 
CuI (83.0 mg, 0.46 mmol), and Pd (PPh3)2Cl2 (163 mg, 0.23 mmol) in 80.0 mL of trimethylamine 
was degassed with N2 for 20 minutes. A solution of trimethylsilylacetylene 0.80 g (8.00 mmol) 
was added to the stirred solution. The mixture was refluxed overnight under N2. Upon completion 
of the reaction, the solvent was evaporated by rotavap. The residue was dissolved in ethyl acetate 
and washed three times with water followed by a saturated NaCl solution. The organic layer was 
dried with MgSO4 and the solvent was evaporated by rotavap. The residue was chromatographed 
on a silica column with hexanes as the eluent to obtain the pure the product. Yield: 1.80 g (85%). 
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M.P.: 150-157 ºC. 1H NMR (400MHz, CDCl3): 7.77 (2H, d), 7.64 (2H, d), 7.44 (1H, s), 5.21 (2H, 
s), 0.02 (m).  
2.2.1.4. Synthesis of 4-((4-ethynyl-1H-pyrazol-1-yl)methyl)benzamide (T1) 
 
 4-((4-((Trimethylsilyl)ethynyl)-1H-pyrazol-1-yl)methyl)benzamide (1.00 g, 2.89 mmol) and 
potassium carbonate (0.60g, 4.24 mmol) were dissolved in 50.0 mL of methanol. The reaction 
mixture was stirred for 24 hrs. and after completion of the reaction, the solvent was evaporated 
under vacuum. The solid mixture was dissolved in ethyl acetate and washed with brine. The 
organic layer was dried over magnesium sulfate and the solvent was evaporated to get a white 
powder as the product T1. Yield 0.70 g, (89%). M.P.: 130-135ºC, 1H NMR (400MHz, DMSO-
d6): 8.20 (1H, s), 8.06(1H, s), 7.84(1H, d), 7.67(1H, d), 7.6(1H, d), 7.27(1H, d), 5.4 (2H, s), 4.01 
(1H, s). 
 
2.2.1.5. Synthesis of 3-((4-bromo-1H-pyrazol-1-yl)methyl)benzonitrile (T6) 
 
To a round bottom flask, 4-bromo-1H-pyrazole (1.50g, 9.32 mmol) and THF (80.0mL) were 
added. To this solution, NaOH pellets (4.10g, 103 mmol) were added and the reaction was stirred 
at room temperature for 2 hours. On completion of the stir, 3-(bromomethyl)benzonitrile (2.00 g, 
10.2 mmol) in THF (80.0mL) was added and the reaction mixture stirred at room temperature 
overnight. On completion, water was added to dissolve any excess NaOH, the organic layer was 
separated off, dried over MgSO4 and the solvent removed under vacuum to yield a white solid 
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(1.78 g, 84%). M.P.: 55-57 ºC, 1H NMR (400 MHz, DMSO-d6): 7.93 (1H, s), 7.81 (1H, d), 7.34 
(1H, t), 7.17 (1H, d), 7.15 (2H, s), 5.32 (2H, s) IR υ: 2223, 1666, 1609, 1509, 1441, 1391, 1334 
cm-1. 
2.2.1.6.  Synthesis of 3-((3-bromocyclopenta-2,4-dien-1-yl)methyl)benzamide 
 
To a round bottom flask, 3-((4-bromo-1H-pyrazol-1-yl)methyl)benzonitrile (2.00g, 8.81 mmol) 
and 85% H2SO4 (10.0mL) were added. The mixture was heated to 80
0C and stirred for 4 hours. 
On completion, the solution was poured slowly over ice and the resulting brown solution was 
adjusted to basic pH using 5M NaOH. The aqueous solution was washed with CHCl3 and the 
organic extracts were separated, dried over MgSO4 and reduced to yield a white solid (1.98g, 92%).  
M.P.: 155-157 ºC, 1H NMR (400 MHz, DMSO-d6): 8.04 (1H, s), 7.97 (1H, d), 7.77 (1H, t), 7.54 
(1H, d), 7.38 (2H, s), 5.35 (2H, s). 
 
2.2.1.7. Synthesis of 3-((3-((trimethylsilyl)ethynyl)cyclopenta-2,4-dien-1-yl)methyl)benzamide 
 
A stirred solution of 3-((3-bromocyclopenta-2,4-dien-1-yl)methyl)benzamide (1.50 g, 6.12 mmol), 
CuI (83.0 mg, 0.46 mmol), and Pd (PPh3)2Cl2 (163 mg, 0.23 mmol) in 80 mL of trimethylamine 
was degassed with N2 for 20 minutes. A solution of trimethylsilylacetylene (0.80 g, 8.00 mmol) 
was added to the stirred solution. The mixture was refluxed overnight under N2. Upon completion 
of the reaction, the solvent was evaporated by rotavap. The residue was dissolved in ethyl acetate 
and washed three times with water followed by a saturated NaCl solution. The organic layer was 
dried with MgSO4 and the solvent was evaporated by rotavap. The residue was chromatographed 
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on a silica column with hexanes as the eluent to obtain the pure product. Yield: 1.91 g (91%). M.P.: 
160-163 ºC, 1H NMR (400 MHz, CDCl3): 7.67 (1H, s), 7.59 (2H, d), 7.47 (1H, t), 7.47 (2H, s), 
5.32 (2H, s) 0.02 (m). 
2.2.1.8. Synthesis of 3-((3-ethynylcyclopenta-2,4-dien-1-yl)methyl)benzamide (T2) 
 
 
To 3-((3-((trimethylsilyl)ethynyl)cyclopenta-2,4-dien-1-yl)methyl)benzamide (1.00 g, 2.89 
mmol) and potassium carbonate (0.60g, 4.24 mmol) were dissolved in 50.0mL of methanol. The 
reaction mixture was stirred for 24 hrs. and after completion of the reaction, the solvent was 
evaporated under vacuum. The solid mixture was dissolved in ethyl acetate and washed with brine. 
The organic layer was dried over magnesium sulfate and the solvent was evaporated to get a white 
powder as the product T2. Yield 0.69 g, (88%).  M.P.: 132-140ºC, 1H NMR (400MHz, DMSO-
d6): 8.20 (1H, s), 7.95(1H, s), 7.82(1H, d), 7.60(1H, t), 7.37(1H, s), 7.26(1H, d), 5.40 (2H, s), 4.01 
(1H, s). 
 
2.2.1.9. Synthesis of 4-((4-bromo-1H-pyrazol-1-yl)methyl)benzonitrile 
 
 
To a round bottom flask, 4-bromo-3,5-dimethyl-1H-pyrazole (1.50g, 7.85 mmol) and THF 
(80.0mL) were added. To this solution, NaOH pellets (4.10g, 103 mmol) were added and the 
reaction was stirred at room temperature for 2 hours. On completion of the stir, 4-
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(bromomethyl)benzonitrile (2.00 g, 10.2 mmol) in THF (80.0mL) was added and the reaction 
mixture stirred at room temperature overnight. On completion, water was added to dissolve any 
excess NaOH, the organic layer was separated off, dried over MgSO4 and the solvent removed 
under vacuum to yield a white solid (1.98 g, 98%). MP: 72-75 ºC. 1H NMR (400MHz, DMSO-
d6): 7.92 (1H, d), 7.79 (1H, d), 7.34 (1H, d), 7.13 (1H, d), 5.33 (2H, s), 2.17 (3H, s), 2.09 (3H, s). 
 
2.2.1.10. Synthesis of 4-((3-bromocyclopenta-2,4-dien-1-yl)methyl)benzamide 
 
To a round bottom flask, 4-((4-bromo-1H-pyrazol-1-yl)methyl)benzonitrile (2.00g, 7.78 mmol) 
and 85% H2SO4 (10.0mL) were added. The mixture was heated to 80
0C and stirred for 4 hours. 
On completion, the solution was poured slowly over ice and the resulting brown solution was 
adjusted to basic pH using 5M NaOH. The aqueous solution was washed with CHCl3 and the 
organic extracts were separated, dried over MgSO4 and reduced to yield a white solid (1.72g, 80%).  
M.P.: 195-198 ºC, 1H NMR (400 MHz, DMSO-d6): 7.97 (2H, s), 7.75 (1H, d), 7.66 (1H, d), 7.41 
(1H, d), 7.23 (1H, d), 5.32 (2H, s), 2.18 (3H, s), 2.09 (3H, s). 
 
2.2.1.11. Synthesis of 4-((3,5-dimethyl-4-((trimethylsilyl)ethynyl)-1H-pyrazol-1-
yl)methyl)benzamide 
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A stirred solution of 4-((3-bromocyclopenta-2,4-dien-1-yl)methyl)benzamide (1.50 g, 5.45 mmol), 
CuI (83.0 mg, 0.46 mmol), and Pd (PPh3)2Cl2 (163 mg, 0.23 mmol) in 80.0mL of trimethylamine 
was degassed with N2 for 20 minutes. A solution of 0.80 g (8.00 mmol) of trimethylsilylacetylene 
was added to the stirred solution. The mixture was refluxed overnight under N2. Upon completion 
of the reaction, the solvent was evaporated by rotavap. The residue was dissolved in ethyl acetate 
and washed three times with water followed by a saturated NaCl solution. The organic layer was 
dried with MgSO4 and the solvent was evaporated by rotavap. The residue was chromatographed 
on a silica column with hexanes as the eluent to obtain the pure product. Yield: 1.76 g (87%). MP: 
210-213 ºC. 1H NMR (400MHz, DMSO-d6): 7.99 (2H, s), 7.75 (2H, d), 7.67 (2H, d), 7.38 (1H, 
s), 7.25 (1H, s), 5.32 (2H, s), 2.51 (3H, s), 2.31 (3H, s), 0.02 (m). 
 
2.2.1.12. Synthesis of 4-((3-ethynyl-2,4-dimethylcyclopenta-2,4-dien-1-yl)methyl)benzamide (T3) 
 
 
To 4-((3,5-dimethyl-4-((trimethylsilyl)ethynyl)-1H-pyrazol-1-yl)methyl)benzamide (1.00 g, 2.69 
mmol) and potassium carbonate (0.60g, 4.24 mmol) were dissolved in 50ml of methanol. The 
reaction mixture was stirred for 24 hrs. and after completion of the reaction, the solvent was 
evaporated under vacuum. The solid mixture was dissolved in ethyl acetate and washed with brine. 
The organic layer was dried over magnesium sulfate and the solvent was evaporated to get a white 
powder as the product T3. Yield 0.63 g, (78%). M.P.: 200-205 ºC, 1H NMR (400MHz, DMSO-
d6): 7.93 (1H, d), 7.80 (1H, d), 7.16(1H, d), 7.19(1H, d), 5.40 (2H, s), 4.36 (1H, s), 2.19 (3H, s), 
2.1 (3H, s). 
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2.2.1.13. Synthesis of 3-((4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzonitrile 
 
To a round bottom flask, 4-bromo-3,5-dimethyl-1H-pyrazole (1.50g, 7.85 mmol) and THF 
(80.0mL) were added. To this solution, NaOH pellets (4.10g, 103 mmol) were added and the 
reaction was stirred at room temperature for 2 hours. On completion of the stir, 3-
(bromomethyl)benzonitrile (2.00 g, 10.2 mmol) in THF (80.0mL) was added and the reaction 
mixture stirred at room temperature overnight. On completion, water was added to dissolve any 
excess NaOH, the organic layer was separated off, dried over MgSO4 and the solvent removed 
under vacuum to yield a white solid (1.95 g, 97%). M.P.: 61-63ºC, 1H NMR (400MHz, DMSO-
d6): 7.97 (1H, s), 7.75 (1H, d), 7.38 (1H, t), 7.22 (1H, d), 5.32 (2H, s), 2.20 (3H, s), 2.08 (3H, s). 
 
2.2.1.14. Synthesis of 3-((3-bromo-2,4-dimethylcyclopenta-2,4-dien-1-yl)methyl)benzamide 
 
To a round bottom flask, 3-((4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzonitrile (2.00g, 
7.78 mmol) and 85% H2SO4 (10.0mL) were added. The mixture was heated to 80
0C and stirred 
for 4 hours. On completion, the solution was poured slowly over ice and the resulting brown 
solution was adjusted to basic pH using 5M NaOH. The aqueous solution was washed with CHCl3 
and the organic extracts were separated, dried over MgSO4 and reduced to yield a white solid 
(1.85g, 86%).  
M.P.: 132-140ºC, 1H NMR (400MHz, CDCl3): 8.54 (2H, s), 7.99 (1H, t), 7.93 (1H, d), 7.79 (1H, 
d), 7.41 (1H, d), 5.25 (2H, s), 3.92 (1H, s), 2.25 (3H, s), 2.15 (3H, s). 
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2.2.1.15. Synthesis of 3-((3,5-dimethyl-4-((trimethylsilyl)ethynyl)-1H-pyrazol-1-
yl)methyl)benzamide 
 
A stirred solution of 3-((3-bromo-2,4-dimethylcyclopenta-2,4-dien-1-yl)methyl)benzamide (1.50 
g, 5.45 mmol), CuI (83.0 mg, 0.46 mmol), and Pd (PPh3)2Cl2 (163 mg, 0.23 mmol) in 80.0mL of 
trimethylamine was degassed with N2 for 20 minutes. A solution of 0.80g (8.00 mmol) of 
trimethylsilylacetylene was added to the stirred solution. The mixture was refluxed overnight 
under N2. Upon completion of the reaction, the solvent was evaporated by rotavap. The residue 
was dissolved in ethyl acetate and washed three times with water followed by a saturated NaCl 
solution. The organic layer was dried with MgSO4 and the solvent was evaporated by rotavap. The 
residue was chromatographed on a silica column with hexanes as the eluent to obtain the pure 
product. Yield: 1.77 g (87%). M.P.: 175-178ºC, 1H NMR (400MHz, CDCl3): 7.79 (1H, t), 7.64 
(1H, t), 7.54 (1H, d), 7.44 (1H, s), 5.31 (2H, s), 2.04 (6H, m). 
 
2.2.1.16. Synthesis of 3-((3-ethynyl-2,4-dimethylcyclopenta-2,4-dien-1-yl)methyl)benzamide (T4) 
 
To 3-((3,5-dimethyl-4-((trimethylsilyl)ethynyl)-1H-pyrazol-1-yl)methyl)benzamide (1.00g, 2.69 
mmol) and potassium carbonate (0.60g, 4.24 mmol) were dissolved in 50.0mL of methanol. The 
reaction mixture was stirred for 24 hrs. and after completion of the reaction, the solvent was 
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evaporated under vacuum. The solid mixture was dissolved in ethyl acetate and washed with brine. 
The organic layer was dried over magnesium sulfate and the solvent was evaporated to get a white 
powder as the product T4. Yield 0.68 g, (84%).  M.P.: 203-205ºC, 1H NMR (400MHz, CDCl3): 
7.59 (1H, s), 7.57 (1H, d), 7.45 (1H, t), 7.3 (1H, d), 5.25 (2H, s), 3,92 (1H, s), 2.25 (3H, s), 2.15 
(3H, s). 
 
2.2.2. Experimental co-crystallization 
 
T1-T6 were subjected to co-crystallization with the 25 co-formers. Each target and co-former were 
combined in a 1:1 stoichiometric ratio and ground together with a drop of methanol. The mixture 
was grinded for 30-40 seconds or until the solvent dried to yield a solid or glue-like paste. The 
resulting solid was analyzed using IR spectroscopy, to determine whether a co-crystal had formed 
or if the resulting solid was just a physical mixture of the two reactants. This procedure was 
performed for all the 150 combinations. In each reaction, 5-10 mg of the target was used with 
respective stoichiometric co-former. After IR spectroscopy was employed, the mixtures were 
dissolved in a minimum amount of solvent in a 2-dram borosilicate vial for slow evaporation in 
order to obtain single crystals for X-ray diffraction. In cases were slow evaporation failed, vapor 
diffusion, and anti-solvent crystallization techniques were employed. 
 
2.2.3. Predicting co-crystallization using HBP 
 
HBP calculations were employed to identify the most likely interactions between the 
target•••target and co-former•••co-former (homomeric interactions) and target•••co-former 
(heteromeric interactions). Each pair of targets and co-formers were sketched and auto edited. The 
first step in the process was to define the functional groups of both the target and co-former pair. 
Scheme 2.2 represents the defined functional groups of the targets. Step2 was to autogenerate the 
structures, in this step Mercury automatically searches through all the structures in the database 
with the functional groups as defined in step1. In step3 the fitting data, which is the number of 
structures (generated from step2) which will be used in the calculations, were selected. The final 
step was to define a model with seven given descriptors step4, Scheme 2.2. Each descriptor has a 
significance depending on the targets used in the study.  However, for co-crystal screening all the 
seven descriptors were used in the calculations to keep the parameters constant.  
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The propensity values were calculated using a logistic regression model with Receiver Operator 
Curve (ROC) curve greater than 0.80. All the calculations were performed with the CSD38,46,47,48 
database 5.40, 2019 (updated on May 2019).   
If propensity  0 it was assumed to indicate a “YES” to co-crystallization which means that a 
heteromeric interaction is more likely to occur than either of the two prevalent homomeric 
possibilities. Conversely, for propensity <0 the outcome was assumed to be equivalent to a “NO” to 
co-crystallization since homomeric interactions are more likely than heteromeric interactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.2. Steps involved in predicting co-crystallization using HBP. 
 
2.2.4. Single crystal x-ray crystallography 
 
All datasets were collected on a Bruker Kappa APEX II system using MoKα radiation. Data were 
collected using APEX2 software49. Initial cell constants were found by small widely separated 
“matrix” runs. Data collection strategies were determined using COSMO50.  Scan speed and scan 
widths were chosen based on scattering power and peak rocking curves. Datasets were collected 
at 23 °C using an Oxford Cryostream low-temperature device. 
Step2
Step3
Step4
Step1
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The unit cell constants and orientation matrix were improved by least-squares refinement of 
reflections thresholded from the entire dataset. Integration was performed with SAINT51, using 
this improved unit cell as a starting point. Precise unit cell constants were calculated in SAINT 
from the final merged dataset. Lorenz and polarization corrections were applied. Multi-scan 
absorption corrections were performed with SADABS52.  
The data were reduced with SHELXTL53. The structure was solved with the XT54 structure 
solution program using Intrinsic Phasing and refined with the XL55 refinement package using Least 
Squares minimization. Also, the structures were finalized using OLEX2 1.2 suite of program56,57. 
Except as noted, hydrogen atoms were located in idealized positions and were treated with a riding 
model. All non-hydrogen atoms were assigned anisotropic thermal parameters. Refinements 
continued to convergence, using the recommended weighting schemes. 
T1 – Coordinates of the amide protons H16A and H16B were allowed to refine. 
T5 – Coordinates of the acid proton H19 was allowed to refine. 
 
2.3. Results 
 
2.3.1. Experimental co-crystallization 
 
The solvent assisted grinding experiments were analyzed using IR spectroscopy. The IR analysis 
were focused on the positions of O=C targets, N-H co-formers, and O=C of acid co-formers as 
they have readily identifiable vibrational modes. In addition, these functional groups form the 
characteristic homomeric interactions that are subsequently broken when a co-crystal is formed, 
with new heteromeric interactions. The most likely homomeric and heteromeric interactions of the 
targets and co-formers are illustrated in Figure 2.2. 
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Figure 2.2. The possible homomeric and heteromeric interactions. 
 
Instances where co-crystals were formed, we observed a shift in wavenumber by more than 3 cm-
1 for the characteristic functional groups mentioned above, Table 2.1. In cases where co-crystals 
were not formed the peaks remained consistent.  
 
Table 2.1. The IR data for experimentally observed positive co-crystallization outcomes in cm-1.  
 T1 T2 T3 T4 T5 T6 
Co-former 
CC 2359 
C=O 1711 
CC 2338 
C=O 1665 
CC 2335 
C=O 1665 
CC 2349 
C=O 1666 
CN 2227 
C=C 1609 
CN 2229 
C=C 1605 
2-Amino-3,5-
dibromopyridine 
Ground Mixture 
N-H 3463, 3270 
C=C 1623 
N-H 3350, 3166 
CC 2359 
C=O 1716 
N-H 3369, 3166 
CC 2338 
C=O 1667 
N-H 3362, 3167 
CC 2333 
C=O 1666 
N-H 3352, 3143 
CC 2350 
C=O 1666 
- - 
2-Amino-4-methoxy-6-
methylpyrimidine 
Ground Mixture 
N-H 3366, 3184 
C=C 1632 
N-H 3341, 3164 
CC 2357 
C=O 1712 
N-H 3357, 3181 
CC 2338 
C=O 1668 
N-H 3351, 3169 
CC 2336 
C=O 1664 
N-H 3346, 3159 
CC 2350 
C=O 1664 
N-H 3362, 3180 
CN 2222 
C=C 1633 
N-H 3360, 3164 
CN 2229 
C=C 1633 
2-Amino-5-bromopyridine Ground Mixture 
Homomeric interactions
Heteromeric interactions
Synthon I Synthon II
Group 1&2
Synthon III No conventional 
hydrogen-bonds
Synthon IV
Group 4
Group 3
Group 1&2
Synthon V Synthon VI
Group 3
Synthon VII
Group 4
Synthon VIII Synthon IX
No conventional 
hydrogen-bonds
Group 1&2
Synthon X
Group 3
No conventional 
hydrogen-bondsT5-T6
Group 4
Synthon XI
T1-T4
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N-H 3443, 3290 
C=C 1621 
N-H 3352, 3166 
CC 2355 
C=O 1712 
N-H 3377, 3170 
CC 2101 
C=O 1665 
N-H 3367, 3189 
CC 2335 
C=O 1670 
N-H 3360, 3148 
CC 2348 
C=O 1665 
- - 
2-Aminopyridine Ground Mixture 
N-H 3437, 3284 
C=C 1623 
N-H 3351, 3169 
CC 2356 
C=O 1715 
N-H 3367, 3180 
CC 2100 
C=O 1670 
N-H 3370, 3187 
CC 2336 
C=O 1659 
N-H 3352, 3153 
CC 2349 
C=O 1664 
- - 
2-Aminoterephthalic acid Ground Mixture 
N-H 3455, 3076 
C=C 1681 
N-H 3353, 3171 
CC 2357 
C=O 1706 
N-H 3364, 3144 
CC 2102 
C=O 1668 
N-H 3373, 3178 
CC 2336 
C=O 1664 
N-H 3362, 3189 
CC 2349 
C=O 1665 
N-H 3341,3148 
CN 2226 
C=C 1684 
N-H 3354, 3180 
CN 2229 
C=C 1636 
2-Chloro-4-fluorobenzoic 
acid 
Ground Mixture 
C=O 1673 - - - - 
CN 2229 
C=O 1663 
CN 2229 
C=O 1672 
2,4-Difluorobenzoic acid Ground Mixture 
C=O 1646 - - - - 
CN 2230 
C=O 1669 
CN 2231 
C=O 1687 
2,5-Dimethylbenzoic acid Ground Mixture 
C=O 1668 - - - - 
CN 2222 
C=O 1678 
CN 2228 
C=O 1679 
2,6-Difluorobenzoic acid Ground Mixture 
C=O 1679 - - - - 
CN 2224 
C=O 1686 
CN 2226 
C=O 1689 
2,6-Dimethylbenzoic acid Ground Mixture 
C=O 1684 - - - - 
CN 2230 
C=O 1667 
CN 2225 
C=O 1671 
Adipic acid Ground Mixture 
C=O 1683 - - - - 
CN 2227 
C=O 1686 
CN 2226 
C=O 1678 
Azelaic acid Ground Mixture 
C=O 1683 - - - - 
CN 2225 
C=O 1691 
CN 2224 
C=O 1689 
Glutaric acid Ground Mixture 
C=O 1682 - - - - 
CN 2228 
C=O 1709 
CN 2227 
C=O 1710 
Malonic acid Ground Mixture 
C=O 1690 - - - - 
CN 2225 
C=O 1712 
CN 2227 
C=O 1714 
Oxalic acid Ground Mixture 
C=O 1677 - - - - 
CN 2224 
C=O 1687 
CN 2227 
C=O 1686 
Pimelic acid Ground Mixture 
C=O 1680 - - - - 
CN 2228 
C=O 1701 
CN 2229 
C=O 1684 
Sebacic acid Ground Mixture 
C=O 1684 - - - - 
CN 2224 
C=O 1689 
CN 2230 
C=O 1680 
Suberic acid Ground Mixture 
C=O 1686 - - - - 
CN 2230 
C=O 1706 
CN 2229 
C=O 1702 
Succinic acid Ground Mixture 
C=O 1679 - - - - 
CN 2227 
C=O 1686 
CN 2226 
C=O 1713 
Supramolecular yield 20% 20% 20% 20% 64% 64% 
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T1- T4 experimentally co-crystallizes with 20% supramolecular yield and T5-T6 co-crystallizes 
with 64% supramolecular yield. Specific trends were observed across the groups where; Groups 
1-2 does not co-crystallize with T1-T4 and co-crystallizes with T5-T6. Group3 with pyridine 
back-bone does not co-crystallize with any of the targets. And finally, Group4 with mixed donors 
and acceptors was found not to have any specific trend, this group of co-formers provided mixed 
results for formation of co-crystal.  
 
2.3.2. HBP calculations 
 
Based on Scheme 2.3. the homomeric, heteromeric and propensity values were calculated and 
summarized in Table 2.2. for the 150 combinations of targets and co-formers. (HBP for a few 
target•••co-former pair could not be calculated since the pair had zero donor, labeled as N/A).  
 
Table 2.2. HBP calculations of attempted co-crystals on T1-T6. 
Co-formers T1 T2 T3 T4 T5 T6 
2-Amino-3,5-dibromopyridine 0.08 0.08 0.08 0.08 -0. 07 -0.08 
2-Amino-4-methoxy-6-methylpyridine 0.07 0.07 0.07 0.07 -0.05 -0.07 
2-Amino-5-bromopyridine 0.01 0.01 0.01 0.01 -0.06 -0.09 
2-Aminopyridine 0.08 0.08 0.08 0.08 -0.03 -0.07 
2-Aminoterephthalic acid -0.03 -0.03 -0.03 -0.03 0.07 0.06 
2-Bromo-5-methylpyridine -0.31 -0.31 -0.31 -0.31 N/A N/A 
2-Chloro-4-fluorobenzoic acid -0.2 -0.2 -0.2 -0.2 0.3 0.29 
2,4-Difluorobenzoic acid -0.13 -0.13 -0.13 -0.13 0.3 0.3 
2,5-Dibromopyridine -0.27 -0.27 -0.27 -0.27 N/A N/A 
2,5-Dimethylbenzoic acid -0.15 -0.15 -0.15 -0.15 0.34 0.31 
2,6-Dibromopyridine -0.2 -0.2 -0.2 -0.2 N/A N/A 
2,6-Dichloropyridine -0.07 -0.07 -0.07 -0.07 N/A N/A 
2,6-Difluorobenzoic acid -0.13 -0.13 -0.13 -0.13 0.3 0.34 
2,6-Dimethylbenzoic acid -0.18 -0.18 -0.18 -0.18 0.34 0.41 
3-Benzoylpyridine -0.15 -0.15 -0.15 -0.15 N/A N/A 
6-Methylnicotinamide 0 0 0 0 -0.1 -0.09 
Adipic acid -0.13 -0.13 -0.13 -0.13 0.32 0.33 
Azelaic acid -0.14 -0.14 -0.14 -0.14 0.32 0.33 
Glutaric acid -0.13 -0.13 -0.13 -0.13 0.32 0.32 
Malonic acid -0.12 -0.12 -0.12 -0.12 0.27 0.28 
Oxalic acid -0.15 -0.15 -0.15 -0.15 0.2 0.19 
Pimelic acid -0.13 -0.13 -0.13 -0.13 0.33 0.33 
Sebacic acid -0.13 -0.13 -0.13 -0.13 0.32 0.32 
Suberic acid -0.23 -0.23 -0.23 -0.23 0.32 0.32 
Succinic acid -0.13 -0.13 -0.13 -0.13 0.3 0.3 
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2.3.3. Single crystal x-ray crystallography 
 
We were able to get crystal data for only three structures for which the crystallographic parameters 
are summarized in Table 2.3. 
 
Table 2.3. Crystallographic parameters of single crystal X-ray diffraction. 
Code T1 T5 (T5)2:oxa 
Formula moiety C11H10N3OI C11H8N3I (C13H13N3) (C2H2O4)0.5 
Empirical formula C11H10N3OI C11H8N3I C14H14N3O2 
Molecular weight 327.12 309.10 256.28 
Color, Habit Colorless, Blocks Colorless, Needles Colorless, Plates 
Crystal system Monoclinic Orthorhombic Monoclinic 
Space group, Z P21/c, 4 P212121, 4 P21/c, 4 
a, Å 26.035(8) 4.4460(14) 10.478(3) 
b, Å 4.7746(16) 13.030(4) 10.115(3) 
c, Å 9.927(4) 19.520(7) 13.052(4) 
α, º 90 90 90 
β, º 99.80(2) 90 106.830(12) 
γ, º 90 90 90 
Volume, Å3 1216.0(7) 1130.8(7) 1324.0(7) 
Density, g/cm3 1.787 1.816 1.286 
T, ºK 296.(2) 296.(2) 296.(2) 
Crystal size, min x mid x max 0.084 x 0.114 x 0.242 0.078 x 0.102 x 0.282 0.138 x 0.264 x 0.459 
X-ray wavelength, Å 0.71073 0.71073 0.71073 
µ, mm-1 2.617 2.802 0.089 
Trans min / max 0.57 / 0.81 0.51 / 0.81 0.67 / 0.75 
θmin, º 0.79 2.61 2.031 
θmax, º 25.34 25.91 25.468 
Reflections    
collected 26370 11996 13912 
independent 2204 2154 2426 
observed 1378 1183 1429 
Rint 0.0612 0.1091 0.0605 
Threshold expression > 2σ(I) > 2σ(I) > 2σ(I) 
No. parameters 153 137 179 
No. restraints 1 0 1 
R1 (observed) 0.0463 0.0539 0.0489 
wR2 (all) 0.1792 0.1061 0.1422 
Goodness of fit (all) 1.081 0.972 1.017 
ρmax, ρmin, e Å
−3 0.505, -1.043 0.439, -0.407 0.148, -0.174 
Completeness to 2θ limit 0.995 0.974 0.989 
 
2.4. Discussions 
 
2.4.1. Experimental co-crystal screening 
 
The supramolecular yield for T1-T4 was 20% which indicates that the homomeric interactions 
between the target•••target and co-former•••co-former was more dominant than the heteromeric 
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interactions. There are two possible homomeric interactions in T1-T4, synthon I (amide•••amide) 
and synthon II (amide•••pyrazole) where either one or both the interactions can exist, Scheme 2.3. 
HBP values indicated that synthon I (0.71) was more likely to form in comparison to synthon II 
(0.67).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.3. Postulated homomeric (top) and heteromeric (bottom) synthons and hydrogen-bond 
propensities in targets and co-formers. 
 
Synthon I Synthon II 
 T1-T4 
No conventional 
hydrogen-bonds 
T5-T6 Group 1&2 
Synthon III 
No conventional 
hydrogen-bonds 
Synthon IV 
Group 4 Group 3 
0.71 0.67 0.43 0.75 
Homomeric interactions 
Group 1&2 
Synthon V 
Group 1&2 
Synthon VI 
Group 3 
Synthon VII 
Group 4 
Synthon VIII 
Group 4 
Synthon IX 
T1-T4 
Group 1&2 
Synthon X 
Group 3 
No conventional hydrogen-bonds 
T5-T6 
Group 4 
Synthon XI 
0.55 
0.52 0.54 
0.51 
0.68 
0.59 
0.67 
Heteromeric interactions 
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Although we were unable to obtain crystal structures with either of T1-T4, we did obtain a crystal 
structure of the iodo analogue of T1, Figure 2.3.  
 
 
 
 
 
 
 
 
Figure 2.3. Crystal structure of iodo analogue of T1. 
 
The crystal structure shows the formation of only synthon I and no synthon II (amide•••pyrazole). 
Such interactions are well-known from the literature and a CSD survey of comparable compounds 
shows exactly similar interactions in the crystal packing where only synthon I is formed58, 59, 60, 61.  
In all the attempted co-crystallization reactions in T1-T4 with groups 1&2, the heteromeric 
synthons were not competitive enough to break the homomeric interactions. For groups 1&2 co-
formers the homomeric interactions is self-complementary acid•••acid interactions, Scheme 2.3. 
Co-formers in group 3 have no conventional homomeric hydrogen-bonds. Since, the dominant 
amide•••amide interaction exists, and there was no potential competition, co-formers in this group 
do not co-crystallize with T1-T4, Scheme 2.3. Co-formers in group 4 can either form homomeric 
synthon IV (synthon III in case of 2-aminoterephtahlic acid and synthon I in case of 6- methyl 
nicotinamide) or heteromeric synthons VIII or IX. For a heteromeric interaction to exist in these 
pairs of co-formers and targets, it was not absolutely necessary to break homomeric synthon I. A 
heteromeric synthon VIII can co-exist with synthon I. Consequently, this group of co-formers had 
a higher probability to co-crystallize with T1-T4, which matches with our experimental outcomes.  
In order to break the strong homomeric interactions of the amide group (synthon I) and to shift the 
balance from homomeric to heteromeric interactions. We replaced the amide group with a nitrile 
functional group that cannot engage in any conventional self-complementary hydrogen-bonds, 
Scheme 2.4.    
 41 
 
 
 
 
 
 
 
 
 
Scheme 2.4. Manipulating the structure to shift balance from homomeric to heteromeric 
interactions (A denotes hydrogen-bond acceptor and D corresponds to hydrogen-bond donor). 
 
We did obtain a crystal structure of the iodo analogue of T6. As expected, there were no 
conventional hydrogen-bonds in the crystal structure, Figure 2.4. 
 
  
 
  
 
 
 
 
 
Figure 2.4. Crystal structure of iodo analogue of T6. 
 
For targets T5-T6 to co-crystallize with co-formers in group 1&2, the homomeric synthon III 
needs to be broken and subsequently replaced by heteromeric synthon X. Experimentally, we were 
able to get one crystal structure of T6 with oxalic acid, Figure 2.5. 
  
 
 
 
D1
D2
A1
A2
Strong homomeric 
interactions
In order to 
decrease the 
homomeric 
interactions
A2
A1
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Figure 2.5. Crystal structure of (T5)2:oxa. 
 
T1-4 did not deliver similar interactions (acid•••pyrazole) with groups 1&2 co-formers. Further 
analysis gave an insight on why there was a difference in interactions between the targets. The 
preference of synthon X over synthon VI could be explained on the basis of short contacts which 
exist between CH2•••pyrazole in T1-T4 with bond distance of 3.643 Å and bond angle of 157.95o. 
These interactions are commonly known as non-conventional hydrogen-bonds consisting of chains 
built from CH•••N interactions62, 63, 64. These short contacts inhibit the formation of synthon II, VI, 
VII and IX. Whereas, in T5-T6 these short contacts were absent which facilitated the formation of 
synthon X resulting in co-crystallization. Group3 co-formers contain only acceptors and no 
potential conventional donor•••acceptor interactions were possible and hence no co-crystals were 
obtained. In case of group4 co-formers similar to T1-T4, either synthon XI or both synthon XI and 
IV can exist together to form co-crystals which can lead to formation of co-crystals. 
Experimentally, we observed an increase in the supramolecular yield from 20% for T1-T4 to 64% 
for T5-T6. 
2.4.2. Experimental co-crystal screening results vs predictions 
 
HBP calculations were used to predict co-crystallization of the 150 experiments. The training 
dataset step3, Scheme 2.3 was kept between 300-500 structures. When the calculations were 
repeated using a larger dataset than 500, we found that the structures included in the calculations 
were very different from the defined functional group step1, Scheme 2.3. We faced problems 
where the calculations were non-reproduceable and therefore, it was important to define a range 
for the fitting data. After testing the fitting dataset with a different range of structures, the dataset 
of 300-500 structures was found to be most reproducible.  
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A confusion matrix35 was employed to analyze the true positives; HBP and experiment agree on 
formation of co-crystals, true negatives; HBP and experiment agree on formation of no co-crystals, 
false positives; HBP and experiment do not agree on formation of co-crystals and false negatives; 
HBP and experiment do not agree on formation of no co-crystals, Figure 2.6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Confusion matrices from HBP results. a) explanation of matrix b) confusion matrix 
for T1-T4 c) confusion matrix for T5-T6. 
 
In addition, a success rate was calculated, which is the number of predictions that match with the 
experimental outcome divided by the total number of experiments, Figure 2.7. The match between 
prediction and experiment was excellent across the six compounds examined in this study.   
 
Figure 2.7. Comparison between HBP calculations and experimental co-crystal formation. 
 
92% 92% 92% 92% 95% 95%
0%
20%
40%
60%
80%
100%
T1 T2 T3 T4 T5 T6
Success  rate
Predicted Outcomes
Co-crystal No co-crystal
Ex
p
e
ri
m
e
n
t
Co-crystal True Positive False Negative
No co-crystal False Positive True Negative
Predicted Outcomes
Co-crystal No co-crystal
Ex
p
e
ri
m
e
n
t
Co-crystal 16 4
No co-crystal 4 76
Predicted Outcomes
Co-crystal No co-crystal
Ex
p
er
im
en
t
Co-crystal 38 0
No co-crystal 2 0
b)
a)
c)
Dpropensity³ 0.0 Dpropensity ³ 0.0
 44 
 
The consistency for the in-house compounds was reassuring since the members of this series 
maintain similar functional groups with different molecular geometry. Notably, both the results 
where a co-crystal was formed and not formed experimentally, matched the HBP predictions 
equally well. An important factor to be considered here is that this approach takes into account 
only enthalpic characteristics and does not include entropy terms65. Obviously, the crystal structure 
itself does not provide any information about the kinetics of seed formation. However, the 
structural preference might reflect thermodynamic and kinetic bias towards a crystal packing.  
Although it is possible that the relatively limited structural diversity among T1-T6 produces a very 
high prediction accuracy, there is no reason to believe that co-crystallizations with much larger 
and more flexible molecules with similar functional groups cannot also be predicted with high 
reliability. The next phase of this effort will be to examine compounds with more diverse 
functional groups (e.g. pyridines, pyrimidines, sulphonamides, methoxy etc.), rotatable bonds (>3) 
and molecular weight (>250 g/mol) to expand HBP as a tool to predict co-crystallization with high 
efficiency.  The results presented herein underscore that systematic structure-informatics methods 
can provide important guidelines for defining the experimental space that needs to be explored in 
the efficient pursuit of new solid forms of high-value chemicals.36,35 
 
2.5. Conclusions 
 
1. The strong amide•••amide interactions (synthon I) in targets T1-T4 dominates 80% of the co- 
     crystallization experiments. T1-4 co-crystallizes only with aminopyridine co-formers. 
2. Altering the balance between homomeric and heteromeric interactions displayed very different 
    supramolecular yield of 64% for T5-T6.  
3. HBP produces an accuracy of 92-95% for the 150 combinations examined in this study.  
 
HBP is a simple technique which is much less time consuming and labor intensive than actual 
experiments. The ability for HBP to predict co-crystallization with such high accuracy can be of 
considerable use in areas and applications that require new solid crystalline forms with improved 
bulk properties36,35,37,5. Therefore, the success of the cheminformatics in predicting co-
crystallization will help narrow down the potential experimental search space which will save both 
time and cost. 
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Chapter 3 – The Role of Molecular Electrostatic Potentials in 
Crystal Engineering 
 
3.1. Introduction 
 
Crystal engineering involves intermolecular interactions as the primary tool for building 
supramolecular architectures1,2. Therefore, understanding the behavior of these interactions is 
essential in order to design supramolecular frameworks. Chapter 2 explores the importance of 
hydrogen-bonding, the most commonly used intermolecular interactions in the design and 
development of these frameworks. Halogen-bonding3 is another emerging non-covalent 
interaction that has similar fundamental characteristics in terms of strength and directionality as 
that of hydrogen-bond4. However, halogen-bonds are intrinsically lipophilic and hydrophobic, 
which makes them well suited in biomedical applications such as drug delivery and transport. It 
is, therefore, imperative to compare the structural outcomes of halogen and hydrogen bonds when 
they are confronted with similar chemical environments to identify the synthons that can mimic 
each other to form the desired motif.     
In a system with several structural outcomes, an established set of guidelines is required to design 
supramolecular architecture in a rational and predictable manner. In such a context, Etter5 proposed 
that the best hydrogen-bond donor preferentially interacts with the best hydrogen-bond acceptor. 
With respect to co-crystallization, if the best donor-acceptor pair corresponds to heteromeric 
interaction (target•••co-former), it is called co-crystallization. If the best donor-acceptor pair forms 
homomeric interactions (target•••target or co-former•••co-former) it is likely to be 
recrystallization6,7. The major challenge is to determine what is “best”. In Chapter 2 we used 
hydrogen-bond propensity (HBP) to define the best donor-acceptor pair. Although HBP was highly 
reliable, it has not been developed for halogen-bond driven co-crystals. It is therefore necessary to 
recognize a convenient method for predicting the co-crystallization screening experiments driven 
by halogen bonds. A more general approach to define “best” utilizes molecular electrostatic 
potential surfaces (MEPS), where the highest positive potential represents the best donor and the 
highest negative potential corresponds to the best acceptor. Although MEPS was conventionally 
designed for hydrogen-bonded systems, considering the fundamental similarity of hydrogen and 
halogen bond, MEPS can potentially be utilized in the same manner. 
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Hydrogen and iodine are far apart in the periodic table with a dramatic difference in the chemical 
and electronic properties, Table 3.1. However, in a given chemical environment, hydrogen and 
iodine possess similar 8,9,10 MEPS values, Figure 3.1. 
 
Table 3.1. Comparison between hydrogen and iodine. 
 Hydrogen Iodine 
Atomic weight (amu) 1.0079 126.90 
Atomic radius (Å) 0.25 1.40 
Atomic volume (Å)3 0.065 11.49 
Electronic configuration 1s2 [Kr] 4d10 5s2 5p5 
1st Ionization energy (KJ/mol) 1312 1008 
 
 
 
 
 
 
 
 
 
Figure 3.1. MEPS of structurally similar hydrogen-bond (left) and halogen-bond (right) 
compound (calculated using DFT and 6-311++G** basis set in vacuum). 
 
There are various examples in the solid-state where hydrogen-bond and halogen-bond11 
structurally imitate each other. For example, 4,4’-bipyridine interacts with hydrogen-bond donor 
hydroquinone in the same fashion as halogen-bond donor, 1,4-diiodotetrafluorobenzene, Figure 
3.212.  
 
 
+153 Kj/mol +167 Kj/mol 
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Figure 3.2. a) Hydrogen-bond interaction between 4,4’-bipyridine and hydroquinone, b) 
Halogen-bond interaction between 4,4’-bipyridine and 1,4-diiodotetrafluorobenzene12. 
Furthermore, a few studies report13 that when hydrogen-bond and halogen-bond are present 
together in the same compound, there is a competition between the interactions. For example, 
equimolar amounts of 1,2-bis(4-pyridyl)-ethane, 1,4- diiodotetrafluorobenzene and hydroquinone 
yielded a dominating hydrogen-bond14,15. However, in an equimolar mixture of N,N,N',N'-
tetramethylethylenediamine, 1,2- diiodo-tetrafluoroethane and ethylene glycol, the halogen-bond 
was more dominant, Figure 3.3.   
 
Figure 3.3. a) Hydrogen-bond as a dominant outcome b) Halogen-bond as a dominant outcome 
 
There is a scarcity of reports where synthon mimicry is examined when a hydrogen-bond donor is 
replaced with a halogen-bond donor in the same molecular backbone. In order to explore this idea, 
we designed four iodo-analogous of T1-T4 which were investigated in Chapter 2, Scheme 3.1. 
The potential co-formers used in this study were also kept same as in Chapter 2, Scheme 3.1.  
a) b)
N
N
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F
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OH
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O
O
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H N N
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Scheme 3.1. Target compounds and co-formers of choice. 
 
Each of these targets carries multiple binding sites. All the targets have two acceptor sites pyrazole-
N and carbonyl (C=O) and one donor site amide-NH2. T1-T4 have additional hydrogen-bond 
ethynyl donor, and T7-T10 have iodo-ethynyl as a halogen-bond donor. There are various 
homomeric and heteromeric interactions possible between the targets and co-formers. Scheme 3.2. 
summarizes all the potential interactions.  
 
Donors
Group 1
Group 3
Acceptors
Donors/ Acceptors
Group 2
Group 4
T1 T2 T3 T4
T7 T8 T9 T10
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Scheme 3.2. Potential homomeric and heteromeric interactions. 
 
In this chapter we will investigate if T7-T10 will form similar homomeric and heteromeric 
interactions as that of T1-T4 in combination with 25 co-formers. We will use MEPS to define the 
best donor-acceptor pair to predict the most likely synthon formation. The predicted interactions 
will be compared to the experimentally observed synthons to examine the role of electrostatics in 
crystal engineering. 
This research is carried out to answer the following questions: 
1. Can electrostatics determine the potential homomeric and heteromeric interactions observed  
    between a target and co-former? 
2. Will T7-T10 produce similar homomeric and heteromeric synthons as that of T1-T4? 
 
3.2. Experimental 
 
The synthesis and characterization of T1-T4 are described in Chapter 2. 4-bromo-1H-pyrazole, 3-
bromo-1H-pyrazole, 4-(bromomethyl)benzonitrile, 3-(bromomethyl)benzonitrile, THF were 
purchased from Alfa Aesar and were utilized without further purification. All 25 co-formers were 
purchased from commercial sources and used as received. Melting points were measured using a 
Fisher-Johns melting point apparatus. Solution 1H NMR data were collected in CDCl3 and DMSO 
Homomeric interactions
Heteromeric Interactions
No conventional 
hydrogen-bonds
T1-T4
Group 1&2 Group 4Group 3
T7-T10
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on a Varian Unity plus 400 MHz NMR spectrometer. IR spectra of the solids resulting from the 
co-crystal screening experiments were recorded with a Nicolet 380 FT-IR spectrometer (ATR) and 
a ZnSe crystal. 
 
3.2.1. Syntheses 
 
3.2.1.1. Synthesis of 4-((4-(iodoethynyl)-1H-pyrazol-1-yl)methyl)benzamide (T7) 
 
T7 was synthesized by dissolving T1 (0.50g, 1.85 mmol) in THF (50 mL). Simultaneously adding 
dropwise, a concentrated solution of iodine in methanol (1.40g, 5.50 mmol) and a 10% sodium 
hydroxide solution over 30 min, with vigorous stirring. The solution was stirred overnight and 
quenched with 100 mL water upon which light yellow color precipitate formed. The filtered solid 
was washed with sodium bisulfite solution to deliver yellow powder of T7 (0.67g, 91%). M.P.: 
132-140ºC, 1H NMR (400MHz, DMSO-d6): 8.07(2H, d), 7.79(2H, d), 7.57(1H, s), 7.33(1H, s), 
5.44 (2H, s). 
 
3.2.1.2. Synthesis of 3-((4-(iodoethynyl)-1H-pyrazol-1-yl)methyl)benzamide (T8) 
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T2 (0.50g, 1.85 mmol) was dissolved in THF (50 mL). Then simultaneously adding dropwise, a 
concentrated solution of iodine in methanol (1.40g, 5.50 mmol) and a 10% sodium hydroxide 
solution over 30 min, with vigorous stirring. The solution was stirred overnight and quenched with 
100 mL water upon which light yellow color precipitate formed. The filtered solid was washed 
with sodium bisulfite solution to deliver pale powder of T8 (0.64g, 87%). M.P.: 133-135ºC, 1H 
NMR (400 MHz, CDCl3): 8.10(1H, s), 7.92(1H, d), 7.83(1H, t), 7.56(1H, d), 7.33(2H, s), 5.33 
(2H, s). 
 
3.2.1.3. Synthesis of 4-((4-(iodoethynyl)-3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzamide (T9) 
 
T3 (0.50g, 1.67 mmol) was dissolved in THF (50 mL). Simultaneously adding dropwise, a 
concentrated solution of iodine in methanol (1.40g, 5.50 mmol) and a 10% sodium hydroxide 
solution over 30 min, with vigorous stirring. The solution was stirred overnight and quenched with 
100 mL water upon which light yellow color precipitate formed. The filtered solid was washed 
with sodium bisulfite solution to deliver pale powder of T9 (0.57g, 80%). M.P.: 132-137ºC, 1H 
NMR (400 MHz, CDCl3): 9.40(2H, s), 7.78(2H, d), 7.12(2H, d), 5.31 (2H, s), 2.26(3H, s), 2.13(3H, 
s). 
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3.2.1.4. Synthesis of 3-((4-(iodoethynyl)-3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzamide (T10) 
 
T4 (0.50g, 1.67 mmol) was dissolved in THF (50 mL). Simultaneously adding dropwise, a 
concentrated solution of iodine in methanol (1.40g, 5.50 mmol) and a 10% sodium hydroxide 
solution over 30 min, with vigorous stirring. The solution was stirred overnight and quenched with 
100 mL water upon which light yellow color precipitate formed. The filtered solid was washed 
with sodium bisulfite solution to deliver pale powder of T10 (0.54g, 76%). M.P.: 131-134ºC, 1H 
NMR (400MHz, CDCl3): 7.77 (1H, s), 7.66 (1H, d), 7.46 (1H, d), 7.13 (1H, t), 5.25 (2H, s), 2.25 
(3H, s), 2.15 (3H, s). 
 
3.2.2. Calculation of molecular electrostatic potential surfaces 
 
MEPS were calculated for T1-T4 and T7-T10 and 25 co-formers implementing density functional 
theory using B3LYP and 6-311++G** basis set in vacuum. All calculations were executed with 
the Spartan’14 software. The compounds were sketched, and the geometries were optimized so 
that the calculation could be set up on the most stable geometry of the compound. A positive point 
in the vacuum is used as a probe against the surface of the molecules. The numbers are represented 
in kJ/ mol, which is the interaction energy between the positive probe and the surface of the 
molecule. The numbers indicate electrostatic potentials, where a negative number corresponds to 
an acceptor and positive number to a donor. 
 
3.2.3. Co-crystallization experiments 
 
The co-crystal screening of T1-T4 is described in section 2.2.3. T7-T10 targets were subjected to 
co-crystallization screening experiments with the 25 co-formers. See section 2.2.3 for detailed 
description on co-crystallization experiments. 
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3.3. Results 
 
3.3.1. Molecular electrostatic potential surface (MEPS) calculations 
 
The targets examined in this study T1-T4 and T7-T10 contain two acceptor sites carbonyl C=O 
& pyrazole-N, and two donor sites amide-NH & ethynyl-H/ iodo-ethynyl. The MEPS calculations 
for the targets are summarized in Figure 3.4. 
 
Figure 3.4. Calculated MEPS values for the targets (kJ/ mol). 
 
We ranked the acceptor and donor sites according to MEPS, where a higher positive potential 
indicates the best donor and the highest negative potential indicates the best acceptor. The MEPS 
data indicated carbonyl C=O as the best acceptor and amide N-H as the best donor which was 
consistent for all the targets. Hence MEPS predicted amide•••amide as the most likely homomeric 
interaction for all the targets, Figure 3.5. 
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Figure 3.5. The homomeric interactions predicted by MEPS (highlighted in blue). 
 
Similar MEPS calculations were carried out for the 25 co-formers to analyze the best donor and 
acceptor for the homomeric interaction in the co-former. Table 3.2 summarizes the electrostatic 
potentials of the best donor-acceptor for the co-formers (rounded to the nearest whole number). 
 
Table 3.2. Best donor-acceptor for the co-formers ranked using the MEPS data. 
Co-formers Best donor 
(kJ/ mol) 
Best acceptor (kJ/ mol) MEPS predicted 
Interaction 
2-Chloro-4-fluorobenzoic acid 154 -184  
2,4-Difluorobenzoic acid 201 -191 
2,6-Difluorobenzoic acid 191 -193 
2,6-Dimethylbenzoic acid 267 -187 
6-Methylnicotinamide 222 -184 
2,5-Dimethylbenzoic acid 253 -194 
Adipic acid 287 -189 
Azealic acid 284 -193 
Glutaric acid 296 -190 
Malonic acid 318 -171 
Oxalic acid 307 -147 
Pimelic acid 285 -192 
Sebacic acid 288 -194 
Suberic acid 288 -191 
T1-T4
T7-T10
Homomeric interactions
Groups 1&2 
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Succinic acid 314 -211 
2-Bromo-5-methylpyridine N/A -178  
2,5-Dibromopyridine N/A -152 
2,6-Dibromopyridine N/A -157 
2,6-Dichloropyridine N/A -157 
3-Benzoylpyridine N/A -165 
2-Amino-3,5-dibromopyridine 169 -206  
2-Amino-4-methoxy-6-methylpyridine 140 -255 
2-Amino-5-bromopyridine 173 -223 
2-Aminopyridine 155 -246 
2-Aminoterephthalic acid 275 -151 
 
3.3.2. Experimental co-crystal screening 
Formation of a co-crystal was established by carefully comparing the IR spectrum of the ground 
solid mixture with the IR spectra of the pure donor and the acceptor. The C=O, N-H, and CC 
bond stretch of the targets and co-formers were analyzed which if a new interaction is formed was 
directly affected. A shift greater than 3cm-1 corresponds to a successful co-crystal event. Table 3.3. 
summarizes the IR stretching frequencies of successful co-crystallization experiments. The IR 
stretching frequencies remained unchanged for the instances where the co-crystallization 
experiments failed.  
Table 3.3. IR stretching frequencies (cm-1) of the successful co-crystals experiment. 
 T1 T2 T3 T4 T7 T8 T9 T10 
Co-former 
CC 2359 
C=O 1711 
CC 2338 
C=O 1665 
CC 2335 
C=O 1665 
CC 2349 
C=O 1666 
CC 2222 
C=O 1648 
CC 2229 
C=O 1672 
CC 2226 
C=O 1654 
CC 2229 
C=O 1673 
2-Amino-3,5-
dibromopyridine 
Ground Mixture 
N-H 3463, 3270 
C=C 1623 
N-H 3350, 
3166 
CC 2359 
C=O 1716 
N-H 3369, 
3166 
CC 2338 
C=O 1667 
N-H 3362, 
3167 
CC 2333 
C=O 1666 
N-H 3352, 
3143 
CC 2350 
C=O 1666 
N-H 3406, 
3262 
CC 2223 
C=O 1650 
N-H 3452, 
3213 
CC 2223 
C=O 1670 
N-H 3457, 
3367 
CC 2223 
C=O 1654 
N-H 3320, 
3168 
CC 2223 
C=O 1669 
2-Amino-4-methoxy-
6-methylpyrimidine 
Ground Mixture 
N-H 3366, 3184 
C=C 1632 
N-H 3341, 
3164 
CC 2357 
C=O 1712 
N-H 3357, 
3181 
CC 2338 
C=O 1668 
N-H 3351, 
3169 
CC 2336 
C=O 1664 
N-H 3346, 
3159 
CC 2350 
C=O 1664 
N-H 3483, 
3396 
CC 2223 
C=O 1650 
N-H 3362, 
3180 
CC 2222 
C=O 1673 
N-H 3374 
3182 
CC 2229 
C=O 1658 
N-H 3483, 
3396 
CC 2223 
C=O 1671 
2-Amino-5-
bromopyridine 
Ground Mixture 
No 
conventional 
hydrogen-
bonds 
Group 3 
Group 4 
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N-H 3443, 3290 
C=C 1621 
N-H 3352, 
3166 
CC 2355 
C=O 1712 
N-H 3377, 
3170 
CC 2101 
C=O 1665 
N-H 3367, 
3189 
CC 2335 
C=O 1670 
N-H 3360, 
3148 
CC 2348 
C=O 1665 
N-H 3388, 
3374 
CC 2223 
C=O 1647 
N-H 3345, 
3155 
CC 2223 
C=O 1669 
N-H 3412, 
3216 
CC 2223 
C=O 1659 
N-H 3483, 
3345 
CC 2223 
C=O 1672 
2-Aminopyridine Ground Mixture 
N-H 3437, 3284 
C=C 1623 
N-H 3351, 
3169 
CC 2356 
C=O 1715 
N-H 3367, 
3180 
CC 2100 
C=O 1670 
N-H 3370, 
3187 
CC 2336 
C=O 1659 
N-H 3352, 
3153 
CC 2349 
C=O 1664 
N-H 3485, 
3216 
CC 2223 
C=O 1645 
N-H 3330, 
3171 
CC 2223 
C=O 1670 
N-H 3369, 
3250 
CC 2223 
C=O 1659 
N-H 3336, 
3246 
CC 2223 
C=O 1671 
2-Aminoterephthalic 
acid 
Ground Mixture 
N-H 3455, 3076 
C=C 1681 
N-H 3353, 
3171 
CC 2357 
C=O 1706 
N-H 3364, 
3144 
CC 2102 
C=O 1668 
N-H 3373, 
3178 
CC 2336 
C=O 1664 
N-H 3362, 
3189 
CC 2349 
C=O 1665 
N-H 3440, 
3398 
CC 2223 
C=O 1644 
N-H 
3341,3148 
CC 2226 
C=O 1674 
N-H 3339, 
3165 
CC 2223 
C=O 1654 
N-H 3475, 
3298 
CC 2223 
C=O 1669 
 
 
3.4. Discussions  
 
3.4.1. Using MEPS calculations for co-crystal screening 
 
Implementing MEPS to select the best donor-acceptor pair for the homomeric interaction for all 
the targets resulted in N-H as the best donor and O=C as the best acceptor. MEPS predicted similar 
homomeric interactions for all the targets. Although we were unable to obtain crystal structures 
either of T1-T4, we did obtain a crystal structure of T7, Figure 3.6. The observed homomeric 
synthon of the target matches the MEPS predicted amide•••amide interaction.  
 
Figure 3.6. Crystal structure of T7. 
 
There was only one combination for the most optimal homomeric interactions of co-formers which 
were correctly predicted by MEPS, Figure 3.7.  
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Figure 3.7. Crystal structure of glutaric acid (left), and aminopyridine (right)16,17. 
 
The targets in combination with co-formers of groups 1and 2, indicated OH of the acid as the best 
donor (highest positive potential), and comparable negative potential between acid C=O or target 
C=O. In instances where the target C=O was the best acceptor it corresponded to a heteromeric 
interaction, whereas in cases where the acid C=O was the best acceptor it was a homomeric 
interaction leading to recrystallization. Experimentally the C=O stretch in IR remain consistent for 
both acids and the targets demonstrating that no new interaction was formed. In addition, the CC 
stretch for both T1-T4 and T7-T10 remained consistent indicating CC does not participate in the 
assembly. The targets did not form co-crystals with either group1 or 2 co-formers, Scheme 3.3. 
 
Scheme 3.3. The observed homomeric and heteromeric interactions in targets with group1 and 2 
co-formers. 
Co-former group 1&2
Co-former group 4
Homomeric 
interactions
Heteromeric Interactions
T1-T4
Group 1&2
T7-T10
 64 
 
With group 3 co-formers, MEPS indicate amide N-H as the best donor. The choice of the best 
acceptor was either carbonyl C=O (-200 kJ/mol) of the target or pyridine-N (-157 kJ/mol). The 
best donor-acceptor pair according to MEPS was the amide•••amide interaction, Scheme 3.4. 
Experimentally we don’t see any change in the C=O or N-H stretch which suggests that no new 
interactions were formed. The heteromeric interactions in the majority of the reactions for co-
formers in groups 1-3 were not competitive enough to break the expected self-complementary 
interactions. Again, the CC stretch remained consistent indicating neither the ethynyl-H nor iodo-
ethynyl formed any new interaction. 
 
Scheme 3.4. The observed homomeric and heteromeric interactions in targets with group3 co-
formers. 
The combination of targets with the co-formers of group 4, followed the same trend where the 
amide N-H (except 2-aminoterephthalic acid) was the best donor. However, with this group of co-
formers the pyridine-N was found to be the best acceptor resulting in a “YES” to co-crystallization. 
Experimentally we did not observe any difference in the C=O stretches of the targets which in turn 
suggests that the amide•••amide interaction was still present. We observed a huge shift in the N-H 
amine stretch of the co-former which, suggest that the N-H•••pyridine-N interaction is broken to 
form a new interaction with N-H•••pyrazole leading to co-crystallization, Scheme 3.5. Although 
Homomeric 
interactions
Heteromeric Interactions
T1-T4
T7-T10
No conventional 
hydrogen-bonds
Group 3
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MEPS could not predict the synthons that drive the co-crystallization, it predicted the outcomes 
correctly. 
 
Scheme 3.5. The observed homomeric and heteromeric interactions in targets with group 4 co-
formers. 
Overall the amide N-H was the best donor according to MEPS in all the cases in combination with 
25 co-formers. Experimentally, the amide•••amide self-complementarity interaction was strong 
and could not be replaced with any new interaction. The IR spectra associated with the CC 
remained consistent in all the cases, which also proves that CC did not participate in these 
reactions. The MEPS for -CC-H and -CC-I show that both the positive potentials were 
comparable, where CC-H ranged from +134-135 kJ/ mol and CC-I were +154-160 kJ/ mol. 
Although the MEPS of CC-I was slightly higher than CC-H, overall, in the presence of other 
functional groups, it did not participate in any co-crystallization experiments. The results indicate 
that both hydrogen-bond and halogen-bond targets provide consistent interactions with all the 
different groups of co-formers.  
 
 
 
Homomeric interactions
Heteromeric Interactions
Predicted synthons Observed synthons
T1-T4
Group 4
T7-T10
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3.5. Conclusions 
 
1. The preferred homomeric interactions were amide N-H•••O=C interactions in both iodo-ethynyl   
    and ethynyl-H targets. The targets formed co-crystals only with group 4 co-formers, where in  
    addition to strong amide•••amide interaction a new heteromeric interaction was observed  
    between amine N-H•••pyrazole-N. This study also points out that, although the hydrogen and  
    iodine is far apart in the periodic table, if used in the same chemical environment that can mimic  
    each other. This structural similarity could be significant in biomedical areas as halogen bonds  
    are hydrophobic and lipophilic when compared to hydrogen bonds. 
 
2. MEPS could guide the structural preference for all homomeric interactions and failed co- 
    crystallization experiments. However, MEPS could not recognize the best donor-acceptor  
    synthon pair for heteromeric interactions of the targets with group 4 co-formers.  
 
3.6. References 
 
 (1)  Lehn, J.-M. From Supramolecular Chemistry towards Constitutional Dynamic Chemistry and 
Adaptive Chemistry. Chem. Soc. Rev. 2007, 36 (2), 151–160. 
https://doi.org/10.1039/B616752G. 
(2)  Benedict, J. B. Recent Advances in Crystallography; 2012. https://doi.org/10.5772/2711. 
(3)  Meyer, F.; Dubois, P. Halogen Bonding at Work: Recent Applications in Synthetic Chemistry 
and Materials Science. CrystEngComm 2013, 15 (16), 3058–3071. 
https://doi.org/10.1039/C2CE26150B. 
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Chapter 4 - Evaluating Hydrogen-Bond Propensity, Hydrogen-Bond 
Coordination and Hydrogen-Bond Energy as Tools for Predicting 
the Outcome of Attempted Co-crystallizations 
 
4.1. Introduction 
 
With the prevalence of co-crystals in pharmaceutics1,2,3,4,5,6,7,8,9,10,11,12 co-crystal prediction 
methodologies that could complement the experimental screening processes are becoming highly 
relevant 13,14,15,16,17,18,19,20,21,22,23,24,25,26. Despite reports of some predictive approaches27,28 there is 
a scarcity15 of systematic in-depth comparisons between different methods for co-crystal 
prediction. Therefore, in this study, we aim to remedy this problem in two ways. The first goal is 
to evaluate three predictive methodologies by comparing their outcomes with experimental co-
crystal screening results. The second goal is to predict which hydrogen-bond interactions are most 
likely to drive the synthesis of co-crystals, for cases where crystallographic data are available. We 
will examine two structure informatics models; hydrogen-bond propensity (HBP) and hydrogen-
bond coordination (HBC), and one approach based on calculated hydrogen-bond energies (HBE). 
In Chapter 2, we explored hydrogen-bond propensity as a predictive tool for 150 combinations of 
targets/ co-formers, which gave an accuracy of 92-95%. Other studies reported by Delori et al.29,30 
employed HBP on Pyrimethamine, an antimalarial drug against seven potential co-formers 
producing a minimum of 78% accuracy. Given the high reliability of HBP, it was selected as 
Methodology 1 in this study. 
The second method examined in this study is hydrogen-bond coordination (HBC)24. HBC is the 
probability of observing a 0,1,2 or 3 coordination number (CN) between a hydrogen-bond donor 
and an acceptor; contrary to HBP, which is the probability of formation of only one bond. Since, 
the chances of forming a co-crystal, are highly dependent on the presence of key hydrogen-bond 
donors and acceptors greater understanding of such interactions is essential for selecting co-
formers.   
Electrostatics play an integral part in hydrogen-bonding,31 and therefore, an electrostatic based 
method was used to obtain hydrogen-bond energy (HBE), as the third methodology. The maxima 
and minima of the molecular electrostatic potential surfaces (MEPS) were combined with Hunter’s 
parameters32,14 to determine HBE13,15 of key hydrogen-bond interactions. 
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The three methodologies were tested on Nevirapine and Diclofenac, two known drugs used as non-
nucleoside reverse transcriptase inhibitors, and nonsteroidal anti-inflammatory formulations, 
respectively33, 34. These active pharmaceutical ingredients (APIs) were selected because they are; 
(i) relatively small and, (ii) have limited conformational flexibility, Figure 4.1. We utilized 
previously published experimental data from systematic co-crystal screens of Nevirapine33 against 
fourteen co-formers and of Diclofenac34 against sixteen co-formers, Figure 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. (a) Nevirapine; (b) Diclofenac;  
c) co-formers screened against Nevirapine; and d) co-formers screened against Diclofenac.  
 
 
We used HBP, HBC, and HBE approaches to predict the co-crystallization outcomes followed by 
predicting which homomeric or heteromeric interactions will most likely prevail for Nevirapine 
and Diclofenac in combinations with 14 and 16 co-formers respectively. The predicted outcomes 
were compared with the experimental results to determine if one method is better than the other. 
Figure 4.2. summarizes the outline of this study.  
 
 
c) 
d) 
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Figure 4.2. Outline of this study. 
This study will address the following questions: 
1. Which method provides a better accuracy in predicting co-crystallization outcomes? 
2. Can the methods predict the primary hydrogen-bond interactions that drive the co-crystal  
    synthesis correctly?  
 
4.2. Prediction studies 
 
4.2.1. Hydrogen-bond propensity (HBP) 
 
The CSD contains a large amount of structural information which can be used in a statistical model 
to provide valuable insights about existing hydrogen-bond interactions. The hydrogen-bond 
propensity (HBP) is the probability of formation of an interaction based on defined functional 
groups and fitting data35,22,36,37,30,29.   
Figure 4.3 lists the defined functional groups of Nevirapine, and Diclofenac. All the calculations 
were done in Mercury 5.40, 2019 (updated on May 2019) 35,38,39,40. 
Figure 4.3. Functional groups defined for Nevirapine (left) and Diclofenac (right). 
 
Co-crystal 
Predictor
Structure 
informatics
Hydrogen-bond 
Propensity
Hydrogen-bond 
Coordination
Simple 
electrostatics 
model
Hydrogen-bond 
Energy
Validation 
studies  
Nevirapine Diclofenac 
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When the API and co-former are combined in a solution there will be a balance between 
homomeric interactions (intermolecular interactions between API•••API and co-former•••co-
former) and heteromeric interaction (API•••co-former).  Using HBP, we calculated a propensity to 
establish which interactions prevail. propensity  0 was deemed as a “YES” to co-crystallization (i.e. 
heteromeric hydrogen-bonds dominate); propensity <0 deemed as a “NO” to co-crystallization with 
homomeric hydrogen-bonds being more likely, Scheme 4.1. 
 
 
Scheme 4.1.  Approach for calculating HBP for Nevirapine and malonic acid. 
 
4.2.2. Hydrogen-bond coordination (HBC) 
 
Hydrogen-bond coordination (HBC) is the probability of observing a coordination number for any 
given hydrogen-bond donor and acceptor atom. The coordination number (CN) is defined as the 
number of interatomic hydrogen-bonds formed between a donor and an acceptor24. Contrary to 
HBP, which is the probability of formation of one bond, HBC gives the probability of formation 
of 0,1,2 and 3 CNs by a given donor/ acceptor. The CN with the highest probability corresponds 
to the most optimal hydrogen-bond interaction.  
Homomeric
interactions
Heteromeric
interactionsNevirapine
0.32
0.43
0.49
0.27
0.31
Dpropensity = (A-B)best –(A-A) best
= 0.49 – 0.43 = 0.06
Homomeric
interactions
Co-former
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HBC was calculated for each combination of an API and a co-former. The highest donor CN was 
matched with the highest acceptor CN between the similar molecules (API•••API and co-
former•••co-former) to select the most optimal homomeric interaction, Scheme 4.2 (highlighted in 
green). Using HBC to predict if a co-crystal was formed, the highest CN of a donor was paired 
with the highest CN of an acceptor between API and co-former, Scheme 4.2 (highlighted in red). 
If this donor-acceptor pair was heteromeric, it was assigned “YES” to co-crystallization, and if it 
was homomeric, then it was assigned as “NO” to co-crystallization.  
 
Homomeric interactions (API•••API) 
Atom (D/A) =0 =1 =2 =3 
N4 (D) 0.30 0.69 0.00 0.00 
N18 (A) 0.87 0.11 0.01 0.00 
N9 (A) 0.88 0.11 0.01 0.00 
O6 (A) 0.28 0.68 0.04 0.00 
Homomeric interactions (co-former•••co-former) 
O25 (D) 0.00 0.95 0.05 0.00 
O27 (D) 0.00 0.95 0.05 0.00 
O24 (A) 0.49 0.47 0.03 0.00 
O25 (A) 0.91 0.09 0.00 0.00 
O26 (A) 0.49 0.47 0.03 0.00 
O27 (A) 0.91 0.09 0.00 0.00 
 
Scheme 4.2. Approach for calculating HBC for Nevirapine and malonic acid. 
(D: hydrogen-bond donor, A: hydrogen-bond acceptor; green: homomeric interactions, red: 
heteromeric interaction) 
 
In Scheme 4.2, HBC predicted the most likely hydrogen-bond coordination between acceptor 
(O=C) of Nevirapine and donor (O-H) of malonic acid; therefore, it was assigned “YES” to co-
crystallization. 
 
 
 73 
 
4.2.3. Hydrogen-bond energy (HBE) 
 
HBE was calculated using molecular electrostatic potentials (MEPs) combined with Hunter’s 
parameters. MEPs were calculated using density functional theory (B3LYP 6-311++G** in 
vacuum) as implemented in Spartan’14 Version 1.1.041. The maxima of the MEPs13 were used to 
calculate (hydrogen-bond donor) following eq.4.1; similarly, eq.4.2 was applied to calculate 
(hydrogen-bond acceptor) using the minima in the MEPs. We calculated the interaction energy 
between the donor (highest ) and acceptor (highest ) implementing eq.4.3. Only conventional 
hydrogen-bonds donors (N-H, O-H) and acceptors (O=C, pyridine/pyrimidine/ pyrazole-N) were 
included.   
 
α = 0.0000162MEP max 2 + 0.00962MEP max            Equation 4.1 
  β = 0.000146MEP min 2 − 0.00930MEP min                   Equation 4.2. 
                     𝑬 = − ∑ 𝜶𝒊𝜷𝒋𝒊𝒋                                    Equation 4.3. 
 
The E was calculated by subtracting the homomeric interactions (API•••API and co-former•••co-
former) from the heteromeric interactions (API•••co-former). E  0 was assigned a “YES” to co-
crystallization (dominant heteromeric interactions); E <0 assigned a “NO” to co-crystallization 
(favoring homomeric interactions), Scheme 4.3.  
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Scheme 4.3. Approach for calculating HBE methodology for Nevirapine and malonic acid. 
(E and E in kJ/mol) 
 
4.3. Results 
 
4.3.1. Predictive outcomes of HBP, HBC, and HBE for Nevirapine 
 
Based on Scheme 4.1. the HBP values of homomeric, heteromeric and propensity values were 
calculated and summarized in Table 4.1. for Nevirapine and 14 co-formers. 
 
Table 4.1. Hydrogen-bond propensity (HBP) calculations of Nevirapine in combination with 14 
co-formers. 
Co-formers Homomeric interactions Heteromeric interactions = Hetero-Homo 
4-Hydroxybenzoic acid 0.28 0.43 0.15 
Benzoic acid 0.29 0.39 0.1 
Cinnamic acid 0.33 0.4 0.07 
Citric acid 0.32 0.44 0.12 
Ferulic acid 0.34 0.42 0.08 
Gallic acid 0.27 0.44 0.17 
Glutaric acid 0.37 0.48 0.11 
Hippuric acid 0.34 0.39 0.05 
Maleic acid 0.37 0.43 0.06 
Malonic acid 0.43 0.49 0.06 
Mandelic acid 0.29 0.4 0.11 
Heteromeric 
interactions
a= 2.81 b= 6.10
b= 5.68 b= 5.79
a= 3.58
b= 5.34
Homomeric
interactions
Homomeric
interactions
DE = Ecc– nE1-mE2   
DE = 59.65 – (36.14+17.19)  = 6.32 
Coformer
API
 75 
 
Oxalic acid 0.25 0.28 0.03 
Tartaric acid 0.37 0.44 0.07 
Urea 0.98 0.93 -0.05 
 
The HBC calculation is dependent on conventional hydrogen-bond donors and acceptors. 
Therefore, we divided the co-formers into two groups aliphatic and aromatics acids. Based on 
Scheme 4.2. the HBC values were calculated for Nevirapine and 14 co-formers.  
 
Table 4.2. Hydrogen-bond coordination (HBC) calculations of Nevirapine in combination with 14 
co-formers. 
Aromatic acids 
 
 
Homomeric interactions (APIAPI) 
Atom (D/A) =0 =1 =2 =3 
N4 (D) 0.51 0.49 0.00 0.00 
N18 (A) 0.90 0.09 0.01 0.00 
N9 (A) 0.90 0.09 0.01 0.00 
O6 (A) 0.29 0.67 0.04 0.00 
Homomeric interactions (co-formerco-former) 
O29 (D) 0.01 0.95 0.04 0.00 
O28 (A) 0.45 0.51 0.03 0.00 
O29 (A) 0.93 0.07 0.00 0.00 
 
Aliphatic acids 
 
Homomeric interactions (APIAPI) 
Atom (D/A) =0 =1 =2 =3 
N4 (D) 0.51 0.49 0.00 0.00 
N18 (A) 0.91 0.08 0.01 0.00 
N9 (A) 0.91 0.08 0.01 0.00 
O6 (A) 0.32 0.64 0.03 0.00 
Homomeric interactions (co-formerco-former) 
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O27 (D) 0.00 0.95 0.04 0.00 
O29 (D) 0.00 0.95 0.04 0.00 
O26 (A) 0.50 0.47 0.03 0.00 
O27 (A) 0.93 0.07 0.00 0.00 
O28 (A) 0.49 0.47 0.03 0.00 
O29 (A) 0.91 0.07 0.03 0.00 
 
Highlighted in green are the most optimal homomeric interactions predicted by HBC, in red are 
the most optimal heteromeric interactions. In both aliphatic and aromatic acids in combination 
with Nevirapine, donor (OH) of acid and acceptor (O=C) of Nevirapine was the most optimal 
interaction, which was deemed as a “YES” to co-crystallization.  
Table 4.3. summarizes the homomeric, heteromeric and E values of Nevirapine and 14 co-
formers. 
 
Table 4.3. Hydrogen-bond energy (HBE) calculations of Nevirapine in combination with 14 co-
formers. 
Co-formers Homomeric interactions Heteromeric interactions =Hetero-Homo (kJ/ mol) 
4-Hydroxybenzoic acid 28.29 28.64 0.35 
Benzoic acid 16.56 16.90 0.36 
Cinnamic acid 17.95 17.93 -0.02 
Citric acid 28.00 35.05 7.05 
Ferulic acid 21.97 27.00 5.03 
Gallic acid 28.07 38.60 10.53 
Glutaric acid 24.41 27.31 2.91 
Hippuric acid 30.91 33.09 2.18 
Maleic acid 18.69 21.56 2.87 
Malonic acid 24.23 29.19 4.96 
Mandelic acid 20.56 24.50 3.94 
Oxalic acid 19.63 30.98 11.35 
Tartaric acid 21.34 39.4 18.06 
Urea 32.51 48.47 15.96 
 
4.3.2. Predictive outcomes of HBP, HBC, and HBE for Diclofenac 
 
The HBP values of homomeric, heteromeric and propensity was calculated and summarized in Table 
4.4. for Diclofenac and 16 co-formers. 
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Table 4.4. Hydrogen-bond propensity (HBP) calculations of Diclofenac in combination with 16 
co-formers. 
Co-formers Homomeric 
interactions 
Heteromeric 
interactions 
=Hetero-
Homo 
2-Amino-3,5-dibromopyridine 0.73 0.82 0.09 
2-Amino-4-chloro-6-methylpyrimidine 0.82 0.82 0 
2-Amino-4-hydroxy-6-methylpyrimidine 0.81 0.83 0.02 
2-Amino-4,6-dimethylpyrimidine 0.76 0.81 0.05 
2-Amino-5-chloropyridine 0.69 0.81 0.12 
2-Aminopyridine 0.69 0.82 0.13 
2-Aminopyrimidine 0.82 0.71 -0.11 
2-Chloropyrimidine 0.51 0.55 0.04 
3-Aminopyridine 0.87 0.64 -0.23 
3-Hydroxypyridine 0.73 0.75 0.02 
3,5-Dimethyl-4-chloropyrazole 0.37 0.32 -0.05 
3,5-Dimethylpyrazole 0.36 0.3 -0.06 
4-Bromopyraole 0.52 0.45 -0.07 
4-Chloro-2,6-diaminopyrimidine 0.81 0.78 -0.03 
4-Iodo-3,5-dimethylpyrazole 0.41 0.32 -0.09 
4-Iodopyrazole 0.69 0.64 -0.05 
Pyrazole 0.56 0.53 -0.03 
 
Based on Scheme 4.2. the HBC values of Diclofenac were calculated. The co-formers for 
Diclofenac can be divided into three categories pyridine, pyrimidine and pyrazole. 
  
Table 4.5. Hydrogen-bond coordination (HBC) calculations of Diclofenac in combination with 16 
co-formers. 
Pyridine group of co-formers 
 
 
Homomeric interactions (API•••API) 
Atom (D/A) =0 =1 =2 =3 
N19 (D) 0.43 0.56 0.00 0.00 
O9 (D) 0.10 0.87 0.03 0.00 
N19 (A) 1.0 0.00 0.00 0.00 
O11 (A) 0.01 0.52 0.45 0.02 
O9 (A) 0.93 0.07 0.00 0.00 
Homomeric interactions (co-former—co-former) 
N8 (D) 0.02 0.30 0.60 0.08 
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N6 (A) 0.03 0.81 0.16 0.00 
N8 (A) 0.98 0.02 0.00 0.00 
 
Pyrimidine group of co-formers 
 
 
Homomeric interactions (API•••API) 
Atom (D/A) =0 =1 =2 =3 
N20 (D) 0.38 0.61 0.01 0.00 
O9 (D) 0.04 0.93 0.03 0.00 
N19 (A) 1.0 0.00 0.00 0.00 
O11 (A) 0.95 0.05 0.00 0.02 
O9 (A) 0.08 0.73 0.18 0.01 
Homomeric interactions (co-former—co-former) 
N9 (D) 0.01 0.19 0.73 0.07 
N6 (A) 0.17 0.79 0.03 0.00 
N9 (A) 0.98 0.02 0.03 0.00 
N2 (A) 0.16 0.80 0.03 0.00 
 
Pyrazole group of co-formers 
 
 
Homomeric interactions (API•••API) 
Atom (D/A) =0 =1 =2 =3 
N19 (D) 0.41 0.58 0.01 0.00 
O9 (D) 0.09 0.88 0.03 0.00 
N19 (A) 1.0 0.00 0.00 0.00 
O11 (A) 0.01 0.56 0.41 0.02 
O9 (A) 0.93 0.07 0.00 0.00 
Homomeric interactions (co-former—co-former) 
N1 (D) 0.01 0.82 0.16 0.00 
N2 (A) 0.09 0.91 0.00 0.00 
 
Highlighted in green are the most optimal homomeric interactions predicted by HBC, in red are 
the most optimal heteromeric interactions. In all instances, donor (OH) of Diclofenac and the 
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acceptor (pyridine/ pyrimidine/ pyrazole-N) of co-former was the most optimal interaction. Hence, 
HBC predicted Diclofenac to co-crystallize with all the 16 co-formers.  
Using Scheme 4.3. we calculated HBE values for Diclofenac, summarized in Table 4.6. 
 
Table 4.6. Hydrogen-bond energy (HBE) calculations of Diclofenac in combination with 16 co-
formers. 
Co-formers Homomeric 
interactions 
Heteromeric 
interactions 
=Hetero-
Homo 
KJ/ mol 
2-Amino-3,5-dibromopyridine 12.15 12.74 0.59 
2-Amino-4-chloro-6-methylpyrimidine 17.60 17.60 0.00 
2-Amino-4-hydroxy-6-methylpyrimidine 19.95 19.97 0.027 
2-Amino-4,6-dimethylpyrimidine 18.35 18.37 0.02 
2-Amino-5-chloropyridine 14.50 15.20 0.70 
2-Aminopyridine 16.18 17.57 1.39 
2-Aminopyrimidine 18.29 18.28 -0.01 
2-Chloropyrimidine 14.50 15.20 0.70 
3-Aminopyridine 19.73 22.07 2.34 
3-Hydroxypyridine 21.41 21.10 -0.31 
3,5-Dimethyl-4-chloropyrazole 20.67 21.83 1.17 
3,5-Dimethylpyrazole 20.67 21.83 1.17 
4-Bromopyraole 19.75 20.12 0.37 
4-Chloro-2,6-diaminopyrimidine 20.13 19.40 -0.72 
4-Iodo-3,5-dimethylpyrazole 20.67 21.83 1.17 
4-Iodopyrazole 19.75 20.12 0.37 
Pyrazole 19.75 20.12 0.37 
 
4.4. Discussions 
 
4.4.1. Experimental co-crystal screening results vs. prediction outcomes  
 
Table 4.7.  summarizes the results of the experimental co-crystal screen as well as the results from 
the three different methods that were employed in order to predict whether a co-crystal would form 
when Nevirapine33 was combined with fourteen co-formers. 
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Table 4.7. Experimental and HBP, HBC, and HBE data for attempted co-crystallizations targeting 
Nevirapine. 
Nevirapine Exp. HBP HBC HBE 
4-Hydroxybenzoic acid Yes Yes Yes Yes 
Benzoic acid Yes Yes Yes Yes 
Cinnamic acid Yes Yes Yes No 
Citric acid Yes Yes Yes Yes 
Ferulic acid Yes Yes Yes Yes 
Gallic acid Yes Yes Yes Yes 
Glutaric acid Yes Yes Yes Yes 
Hippuric acid Yes Yes Yes Yes 
Maleic acid Yes Yes Yes Yes 
Malonic aid Yes Yes Yes Yes 
Mandelic acid Yes Yes Yes Yes 
Oxalic acid Yes Yes Yes Yes 
Tartaric acid Yes Yes Yes Yes 
Urea Yes No No Yes 
Prediction match  13/14 13/14 13/14 
 
Nevirapine delivered 14/14 positive co-crystallization results. The success rate for predicting co-
crystallization in the case of Nevirapine with HBP, HBC, and HBE was 93%. This indicates that 
all three methods have high accuracy for predicting co-crystallization outcomes.  
Diclofenac, on the other hand, co-crystallized with 8/16 co-formers, 2/16 formed salts, and the 
rest, 6/16 did not react. A salt is formed when a proton migrates from an acidic -COOH to basic 
pyridine acceptor. Whereas in a co-crystal, the proton forms non-covalent interactions with the 
acceptor pyridine. However, in both cases, new, heteromeric interactions were formed. For the two 
salts observed in Diclofenac, we carried out the calculations with both neutral and charged species. 
Both the calculations yielded the same results, and therefore, a similar cut-off for salt and co-
crystal were employed29.  
 Table 4.8 summarizes the results of the experimental co-crystal screen and the results from the 
three different methods that were employed in order to predict whether a co-crystal would form 
when Diclofenac34 was combined with sixteen co-formers.   
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Table 4.8. Experimental and HBP, HBC, and HBE data for attempted co-crystallizations targeting 
Diclofenac. 
Diclofenac Exp. HBP HBC HBE 
2-Amino-3,5-dibromopyridine Yes Yes Yes Yes 
2-Amino-4-chloro-6-methylpyrimidine Yes Yes Yes No 
2-Amino-4-hydroxy-6-methylpyrimidine Yes Yes No Yes 
2-Amino-4,6-dimethylpyrimidine Yes Yes Yes Yes 
2-Amino-5-chloropyridine Yes Yes Yes Yes 
2-Aminopyridine salt Yes Yes Yes 
2-Aminopyrimidine Yes No Yes Yes 
3-Aminopyridine salt No Yes Yes 
3-Hydroxypyridine Yes Yes Yes No 
3,5-Dimethyl-4-chloropyrazole No No Yes No 
3,5-Dimethylpyrazole No No Yes Yes 
4-Bromopyrazole No No Yes Yes 
4-Chloro-2,6-diaminopyrimidine Yes No Yes No 
4-Iodo-3,5-dimethylprazole No No Yes Yes 
4-Iodopyrazole No No Yes Yes 
Pyrazole No No Yes Yes 
Prediction match  13/16= 81% 7/16= 44% 8/16= 50% 
 
Undoubtedly, HBP produced better predictive accuracies for Diclofenac in comparison to HBC 
and HBE. Although HBP predicted Nevirapine (93%) with higher accuracy than Diclofenac 
(81%). The prediction differences can be attributed to the fact that the CSD database consists of 
only positive co-crystallization results; hence, it was not surprising that the structure informatics 
methodologies have a lower success rate for instances where co-crystal was not formed.  
Calculating an overall success rate for both Nevirapine and Diclofenac yielded a success rate of 
87% (26/30) with HBP compared to 67% (20/30) for HBC and 70% (21/30) for the HBE. Clearly, 
among the three methodologies, HBP shows a higher accuracy for predicting co-crystallization, 
Figure 4.4.  
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Figure 4.4. Co-crystal prediction accuracy. 
 
4.4.2. Observed interactions in the crystal structures vs. prediction results 
 
We also analyzed the abilities of these methods to predict which specific hydrogen-bond 
interaction was likely to be present in the experimentally determined crystal structures (targets and 
co-crystals thereof). Nevirapine has two possible homomeric interactions, synthons I and II 
wherein only one of these interactions can exist at a time, Scheme 4.4. HBP calculations showed 
that there was a higher probability that synthon I will form. The co-formers examined in the case 
of Nevirapine were carboxylic acids (urea being the exception), and the most likely homomeric 
interaction was synthon III.  
 
Scheme 4.4. Postulated synthons of homomeric (left) and heteromeric (right) interactions and 
HBPs in Nevirapine and co-formers. 
 
87%
77%
73%
0%
20%
40%
60%
80%
100%
HBP HBE HBC
Co-crystal  predict ion accuracy
Synthon I Synthon II 
0.27 0.16 0.46 
Synthon III 
0.48 0.32 
Synthon IV Synthon V 
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In the crystal structure of Nevirapine synthon I was observed; and synthon III for co-formers, 
which match the predicted homomeric interactions by HBP, Figure 4.542.  
Figure 4.5. Crystal structure of nevirapine, glutaric acid (top) and co-crystals (bottom)42,43,44. 
 
To achieve co-crystals, either or both synthon(s) IV and V needs to be formed, Scheme 4.4. HBP 
predicts the formation of synthon IV (0.48) with a higher probability than synthon V (0.32). 
However, to satisfy the pyridine acceptor, either synthon II or V might form in addition to that of 
synthon IV. Between synthon II and V, HBP predicts the formation of synthon V. 
There were five reported co-crystal structures of Nevirapine. In four of these structures, both 
synthon IV and V were observed. The co-crystal structure of glutaric acid and Nevirapine was 
found to have only synthon IV44. The HBP predicted heteromeric (synthons IV and V, with a 
higher probability for synthon IV) and homomeric interaction (synthons I and III) match the 
experimentally observed interactions. HBP correctly predicts the synthons in 5/5 reported cases 
for Nevirapine. HBP fails to predict Nevirapine and urea accurately, where the homomeric 
interactions of urea were favored over heteromeric interactions. However, experimentally, a co-
crystal was formed.  
Implementing the HBC protocol, for predicting the most optimal homomeric interactions resulted 
in synthon I for Nevirapine and synthon III for the co-formers. The predicted heteromeric 
interactions correspond to synthon IV. HBC predicted interactions were consistent with the 
experimental observations, Figure 4.5. However, unlike HBP, HBC could not predict the presence 
Nevirapine, synthon I 
Glutaric acid, synthon III 
Co-crystal 
 2Nevirapine: Glutaric acid, synthon IV 
Co-crystal 
 Nevirapine: Citric acid, synthon IV & V 
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of synthon V in addition to that of synthon IV. HBC also fails to determine the correct outcome 
for urea.  
In the case of HBE, the predicted homomeric interactions for both Nevirapine and co-formers 
agree with the experimental outcomes. The predicted heteromeric interactions were synthons II, 
IV, and V; however, experimentally, we only see synthons IV and V in the crystal structures. 
Diclofenac has two possible homomeric interactions, synthon VII displaying a higher HBP than 
VI, Scheme 4.5. 
Scheme 4.5. Postulated synthons of homomeric (top) and heteromeric (bottom) interactions and 
HBPs in diclofenac and co-formers. 
 
The crystal structure of Diclofenac was found to have both synthon VI and VII, where the latter is 
an intramolecular interaction, Figure 4.6. The list of co-formers for Diclofenac can be divided into 
two groups pyridines and pyrimidines, and pyrazoles. The co-formers from the pyridine and 
pyrimidine groups experimentally formed co-crystal with Diclofenac. Synthon VIII (synthon IX 
in case of 3-hydroxy pyridine) depicts the homomeric interactions for this group of co-formers 
which, match the experimentally observed interaction.  
For a heteromeric interaction to occur with pyridines and pyrimidines, there were three 
possibilities, synthon XI, XII and XIII. HBP predicts the formation of synthon XII with a lower 
probability (0.31) when compared with the other synthons. We found only one reported co-crystal 
structure, wherein synthons XI and XIII were observed34, Figure 4.6.  
0.62 
  0.28 0.82   0.73   
0.66 
0.54 
0.31   0.29   0.57 
Synthon XI 
Synthon VII Synthon VIII Synthon IX Synthon X 
Synthon XV Synthon XII Synthon XIII Synthon XIV 
  0.94 
Synthon VI 
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Figure 4.6. Crystal structure of diclofenac, 2-aminopyridine (top) and co-crystal (bottom)45,46,47. 
 
The predicted homomeric interaction by HBP with the pyrazole group of co-formers was synthon 
X (0.66), and either synthon XIV (0.57) or XV (0.29) as the heteromeric interactions. Homomeric 
interactions were predicted to be more dominant than heteromeric interactions, which was 
consistent with the experimental observation of no reaction. 
In the case of HBC, homomeric interactions were correctly predicted for Diclofenac and pyridine 
& pyrimidine co-formers. The most optimal heteromeric interaction predicted with this group of 
co-formers was synthon XI. In the reported crystal structure, synthon XI was observed; however, 
unlike HBP, it fails to predict the presence of synthon XIII. For the pyrazole containing co-formers, 
synthon XV was found to be the most optimal interaction; although experimentally, it does not 
form a co-crystal. HBC fails to predict the correct interactions with the pyrazole groups of co-
formers. 
HBE could correctly predict the homomeric and heteromeric interactions for the co-formers 
containing pyridines and pyrimidines. However, for the group of co-formers containing pyrazoles, 
Diclofenac, synthons VI & VII 2-Aminopyridine, synthon VIII 
Co-crystal 
Diclofenac:2-Aminopyridine, synthons XI and XIII 
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HBE predicts to form synthon XV over X, which was not consistent with the experimentally 
observed outcomes. 
A comparison of the predicted interactions with the experimentally observed results is summarized 
in Table 4.9.  
 
Table 4.9. Predicted vs experimentally observed synthons (green: homomeric interactions, red: 
heteromeric interaction). 
 
HBP predicted interactions were consistent with the five reported crystal structures for Nevirapine 
and one reported structure for Diclofenac. HBC could not predict any of the combinations 
correctly, and finally, HBE could correctly predict the interactions only for Diclofenac. 
The HBP protocol was in good agreement with the co-crystallization screening outcomes, as well 
as the homomeric and heteromeric interactions involved during co-crystallization. Overall, HBP 
performs better than HBC and HBE protocols for Nevirapine and Diclofenac.  
The information provided by HBP can be essential in narrowing the co-formers and reducing the 
number of experiments. However, it is worth noting that HBP is only limited to reactions where 
direct interactions between hydrogen-bond donors and acceptors are involved.   
Although most studies reported to date employing HBP as a predictive methodology, examine 
targets/ APIs that are rigid and have molecular weight <300 g/mol. We believe that it would be of 
great interest to expand HBP tests on more flexible (rotatable bonds >3) and larger (molecular 
weight >300 g/mol) compounds that resemble most drug molecules closely. 
 
4.5. Conclusions 
 
1. Out of the three methodologies considered in this study for Nevirapine HBP, HBC and HBE all    
    produced a 93% success rate. However, for Diclofenac HBP results outperformed HBC and  
    HBE. The results from the three methodologies and their success rates are summarized in Table  
 Co-crystal Experimental HBP HBC HBE 
Nevirapine Yes IV and V IV and V IV II, IV and V 
Diclofenac 
(Pyridines/Pyrimidines) 
Yes VII, XI and XII VII, XI and XII XI VII, XI and XII 
Diclofenac  
(Pyrazoles) 
No X X XV  XV 
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    4.10. 
Table 4.10. Success rates for predicting the co-crystal formation of Nevirapine and Diclofenac. 
Compounds Methodology Success rate 
Nevirapine 
HBP 13/14= 93% 
HBC 13/14= 93% 
HBE 13/14= 93% 
Diclofenac 
HBP 13/16= 81% 
HBC 9/16= 56% 
HBE 10/16= 63% 
 
2. The homomeric and heteromeric interactions predicted by HBP matched the experimental   
    interactions in all the 6 cases; HBC could not correctly predict in any of the instances and HBE  
    prediction matched in only one case. 
 
The success of HBP in predicting co-crystallization and the most likely synthon formation 
outperforms the results obtained from HBC and HBE. The reliability of HBP is significant and 
critical in drug design as it requires minimum time and resources to complement the experimental 
trials3,23. 
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Chapter 5 – Evaluating the Predictive Abilities of Hydrogen-Bond 
Propensity, Molecular Complementarity, and Hydrogen-Bond 
Energy for Co-crystal Screening 
 
5.1. Introduction 
 
A cocrystal is composed of two (or more) different molecular entities, in the same crystal lattice 
which are held together by weak non-covalent interactions1,2,3. The design and synthesis of co-
crystals can be used as a modular approach to develop new materials with desirable properties in 
various fields4,5,6,7,8,9,10,11,12,13. Pharmaceutical co-crystals14,15 are of particular importance wherein 
the target compound, the active pharmaceutical ingredient (API), is combined with a ‘co-former’ 
that is intended to impart optimal physical properties without loss of biological activity. Although 
various promising strategies have been developed to synthesize co-crystals, many challenges still 
remain. The rational design of co-crystals have usually been based on supramolecular 
synthons16,17,18,19. Substantial experimental and theoretical studies have been conducted for 
relatively strong interactions, such as hydrogen bonding. However, recent studies by Kaźmierczak 
and Katrusiak20,21, found that there are ∼450 organic structures in the CSD that contain no 
intermolecular contact (shorter than the sum of vdw radii) so-called “loose” crystals.  
The question of what determines the packing of the molecules in a specific way in crystal structures 
is therefore of great research interest in co-crystallization. The “principle of close packing” 
pioneered by Kitaigorodsky22, recognizes that molecules are packed in such a way that there is 
minimum void between them where the "projections" of one molecule get into the "hollows" of 
adjacent molecules in a dovetail fashion, Figure 5.1.  
 
 
Figure 5.1. Close packing principle. 
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Applying Kitaigorodsky’s principle on a binary system to form a homogenous phase, both the 
components should have comparable size, shape, and charge distribution which would result in a 
dense structure with minimum volume. These characteristics were later referred to as molecular 
and crystal isostructurality.  
Hence the goal of this study is to evaluate Molecular Complementarity23 (MC) a shape and size 
dependent approach for predicting co-crystallization. Secondly, to bring forward MC in 
comparison24,25 to other approaches (based on hydrogen bonding) to identify the most reliable tool 
for predicting co-crystallization screening outcomes.  
MC is dependent on three shape descriptors and two polarity-based descriptors26. It is based on a 
box model of crystal packing, with three unequal dimensions where l > m > s in the model, Figure 
5.227. 
      
 
 
 
 
 
 
Figure 5.2. Box model with three unequal dimensions. 
 
In Chapter 3, we examined prediction accuracies of hydrogen-bond propensity (HBP), hydrogen-
bond coordination (HBC), and hydrogen-bond energy (HBE) for the co-crystal synthesis on small 
(molecular weight 180-300 g/mol) and rigid compounds. The results from the study ranked their 
predictive capabilities as HBP> HBE> HBC28,29,30,31. Therefore, in this study, we used HBP and 
HBE approaches in combination with MC.  
The three predictive methodologies were employed on seven APIs in combination with 42 co-
formers on the GRAS (generally regarded as safe)32 list, Table 5.1. The targets used in this study 
have a higher molecular weight (400-600 g/mol) and are more flexible (rotatable bonds greater 
than 3), compared to those that were examined in Chapters 2-4. Since the average molecular weight 
of organic structures reported in CSD is ~400 g/mol33 it will be interesting to investigate HBP and 
short axis (s) 
medium axis (m) 
large axis (l) 
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MC on compounds with a higher molecular weight. The APIs and are labeled T11- T17, Figure 
5.3. 
 
 
Figure 5.3. APIs of interest. 
 
Table 5.1.. Selected GRAS list co-formers. 
3-Hydroxy-2-naphthoic acid EDTA L-Proline Pamoic acid 
4-Hydroxybenzoic acid Folic acid L-Serine Phosphoric acid 
Adipic acid Fumaric acid L-Tartaric acid Piperazine 
Apigenin Glutaric acid Maleic acid Riboflavin 
Benzenesulfonic acid Glycine Malic acid Saccharin 
Benzoic acid Glycolic acid Malonic acid Salicylic acid 
Caffeine Hydrocinnamic acid Maltitol Sorbic acid 
Cholic acid Isonicotinamide Mannitol Succinic acid 
Citric acid L-Glutamic acid Nicotinamide Theophylline 
D-glucuronic acid L-Mandelic acid Oxalic acid Urea 
   Xanthine 
 
Figure 5.4 shows a road map of this study. The predictions were compared with the experimental 
data to determine the relative accuracies of the different models. 
 
 
 
 
 
T12
M.W= 441 g/ mol
T11
M.W= 412 g/mol
T14
M.W= 460 g/mol
T15
M.W= 451 g/mol
T16
M.W= 460 g/mol
T13
M.W=  605 g/mol
T17
M.W= 435 g/mol
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Figure 5.4. Road map of this study. 
 
This study is carried out to answer the following questions: 
1. Can HBP and HBE predict co-crystallization outcomes? 
2. Can MC predict co-crystallization outcomes? 
3. Will the individual or combination of the methodologies provide a better accuracy? 
 
5.2. Co-crystal screening 
 
GRAS list co-formers were purchased from Aldrich, Fischer, and Oakwood and was used as 
received. To measure the melting points, the Fischer-Johns melting point apparatus was used. FT-
IR spectra of the API, co-former, and potential co-crystals were analyzed using Nicolet 380 FT-
IR spectrometer applying an attenuated total reflection (ATR) technique and ZnSe as the crystal. 
 
5.2.1. Experimental co-crystal screening 
 
Liquid assisted grinding experiments were done with the APIs in combination with 42 GRAS list 
co-formers (294 co-crystal experiments). The target and co-former were added in a 1:1 molar ratio 
to a spotting plate with a few drops of methanol.  The mixture was ground for 30-40 seconds or 
until the solvent was completely evaporated, which resulted in a solid or a glue-like material. 
Eventually, IR spectroscopy was carried out to determine if the ground mixture consists of peaks 
from both the starting materials and consequently if there was any shift in the stretches. A shift 
greater than 3 cm-1 in the IR peaks was labeled as “YES” to co-crystallization, and consistent peaks 
were labeled as “NO” to co-crystallization34.  
 
Co-crystal 
Predictor
Hydrogen-bond 
approach
Hydrogen-Bond 
Propensity
Hydrogen-Bond 
Energy
Geometry based 
approach
Molecular 
complementarity
Individual 
Combined 
Overlapping 
region in Venn 
diagram 
Combined 
region in Venn 
Diagram 
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5.2.2. Predicting co-crystallization using hydrogen-bond propensity (HBP)  
 
When HBP is applied to an API and a co-former of interest,35,36,37,38,39 there are two possible 
outcomes; higher HBP value for a hydrogen-bond motif between a) API•••co-former, or b) 
API•••API and co-former•••co-former. To determine which motif will prevail, we calculated a 
HBP (HBPAPI•••co-former – HBP API•••API/ co-former•••co-former). If HBP  0, it was assigned as a “YES” to 
co-crystallization, and if HBP <0, it was assigned as a “NO” to co-crystallization.  
See section 2.2.3. for detailed description of hydrogen-bond propensity calculations. 
 
5.2.3. Predicting co-crystallization using hydrogen-bond energy (HBE) 
 
The same approach as HBP was applied, where we calculated a E (HBEAPI•••co-former – HBE 
API•••API/ co-former•••co-former). If E  0, it was assigned as a “YES” to co-crystallization and, if E <0, 
it was a “NO” to co-crystallization40. See section 4.2.3. for detailed description on hydrogen-bond 
energy calculations. 
 
5.2.4. Predicting co-crystallization using molecular complementarity (MC) 
 
MC is a knowledge-based predictive tool available in Mercury. In the default settings, MC is based 
on three shape descriptors (S-axis, S/L axis, and M/L axis) and two polarity descriptors (fraction 
of nitrogen and oxygen, and dipole moment)23. Each descriptor has a criterion to afford a “PASS/ 
FAIL.” A “PASS” corresponds to the formation of a co-crystal and “FAIL” means no 
reaction26,41,42. Overall it predicts the formation of a co-crystal if and only if all five descriptors 
exhibit a “PASS.” MC in default settings offered a reliability of 27-70%.  
Since the accuracy produced by default MC was very low, we investigated the descriptor 
relationships and their significance. Figure 5.5 shows the correlation coefficients of the descriptors, 
where a positive sign indicates a higher significance.26  Fábián23, proposed that although Fraction 
of polar volume (FPV) has a higher positive correlation coefficient than Fraction of nitrogen and 
oxygen (FNO), FPV could be replaced by FNO in the calculations as an easier alternative.  
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Figure 5.5. Molecular descriptors and their significance26. 
 
In order to investigate if the replacement of FPV with FNO affects the MC success rate, we 
included FPV in the calculations. Moreover, Polar Volume (PV) also displayed a positive 
correlation and was therefore, included as a descriptor in the updated/modified calculations.  
To calculate the “polar volume” and “fraction polar volume,” two different sources were used for 
the volume of the elements labeled as ‘source 1’43 and ‘source 2’44, respectively, Table 5.2. Both 
FPV and PV were calculated for 42 co-formers and seven APIs. The difference between source 1 
and 2 is that source 1 neglects hydrogen atoms, whereas, in source 2, the volume of the elements 
is dependent on the number of neighboring hydrogen atoms.  
Table 5.2. Numerical values of volumes of elements used in calculations from two different 
sources. 
Source 1 Atomic volume 
Volume of N 17.3 cm3 / mol 
Volume of O 14.0 cm3 / mol 
Volume of S 15.5 cm3 / mol 
Volume of C 4.58 cm3 / mol 
Volume of F 17.1 cm3 / mol 
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Source 2 
O (2,1) O (1,0) O(2,0) N(3,0) N(3,1) N(2,0) N(3,2)  
15.764 Å3 13.935Å3 12.512Å3 9.944Å3 18.148Å3 13.324Å3 24.643Å3  
C (3,0) C (4,1) C(4,3) C(4,2) C(3,1) C(4,0) S(4,0) P(4,0) 
12.119Å3 18.13Å3 33.468Å3 24.409Å3 21.02Å3 10.286Å3 17.531Å3 22.161Å3 
 
By carefully modifying the MC settings from five descriptors to seven descriptors, the accuracy 
range increased to 50-64% across the seven APIs, Table 5.3. The results from the modified settings 
were more consistent than the default for the APIs examined in this study. A total of 1050,000 data 
points was analyzed to introduce an updated and modified MC settings. A detailed instruction on 
how to implement the seven-descriptor settings for MC is provided in Appendix A.  
 
Table 5.3. Default vs. modified combinations of descriptor settings for MC calculations. 
Default Settings 
M/L axis ratio S/L axis ratio S-axis Dipole Moment Magnitude FNO 
Modified Settings 
M/L axis ratio S/L axis ratio S-axis Dipole Moment Magnitude FNO PV FPV 
 
 
5.3. Results 
 
5.3.1. Experimental co-crystallization 
 
The solvent assisted grinding experiments were analyzed using IR spectroscopy. See section 2.3.1 
for detailed description. Table 5.4. summarizes the experimental screening results.  
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Table 5.4. Experimental grinding results for seven targets against 42 potential co-formers. 
 T11 T12 T13 T14 T15 T16 T17 
IR data 2228,1774, 
1717, 1660 
1626, 1569, 
1452, 1434 
1771, 1680, 
1580, 1560 
1648, 1582, 
1482, 1441 
1665, 1588, 
1505, 1463 
1566, 1513, 
1480, 1422 
1702, 1685, 
1603, 1532 
Co-former Ground 
Mixture 
Ground 
Mixture 
Ground 
Mixture 
Ground 
Mixture 
Ground 
Mixture 
Ground 
Mixture 
Ground 
Mixture 
3-Hydroxy-2-naphthoic acid 
1655, 1626, 1597, 1513 
2228, 1763, 
1696, 1540 
Yes 
1646, 1619, 
1580, 1437 
Yes 
1770, 1679, 
1579, 1559 
No 
1658, 1581, 
1513, 1483 
Yes 
1666, 1589, 
1507, 1464 
No 
1573, 1514, 
1481, 1420 
Yes 
1701, 1685, 
1603, 1532 
No 
4-Hydroxybenzoic acid 
1667, 1605, 1592, 1509 
2228, 1775, 
1714, 1591 
No 
1668, 1630, 
1570, 1433 
No 
1760, 1679, 
1579, 1557 
Yes 
1650, 1581, 
1483, 1445 
No 
1666, 1588, 
1507, 1469 
No 
1565, 1513, 
1480, 1422 
No 
1700, 1684, 
1624, 1596 
No 
Adipic acid 
1683, 1461, 1426, 1407 
2228, 1785, 
1689, 1521 
Yes 
1701, 1641, 
1599, 1574 
Yes 
1763, 1680, 
1579, 1556 
Yes 
1645, 1565, 
1484, 1433 
Yes 
1667, 1588, 
1505, 1423 
No 
1579, 1553, 
1482, 1422 
Yes 
1700, 1684, 
1624, 1596 
No 
Apigenin 
1649, 1604, 1586, 1554 
2228, 1775, 
1714, 1591 
No 
1648, 1602, 
1555, 1491 
No 
1645, 1600, 
1573, 1553 
Yes 
1649, 1604, 
1575, 1554 
No 
1649, 1611, 
1589, 1577 
No 
1648, 1601, 
1553, 1498 
Yes 
1708, 1687, 
1650, 1605 
Yes 
Benzenesulfonic acid 
1663, 1445, 1092, 1031 
2222, 1776, 
1696, 1539 
Yes 
1640, 1577, 
1455, 1435 
Yes 
1786, 1637, 
1577, 1557 
Yes 
1658, 1566, 
1483, 1436 
Yes 
1666, 1588, 
1507, 1463 
Yes 
1619, 1566, 
1485, 1457 
Yes 
1710, 1660, 
1630, 1550 
Yes 
Benzoic acid 
1677, 1602, 1581, 1452 
1774, 1716, 
1623, 1601 
No 
1770, 1602, 
1596, 1450 
No 
1761, 1686, 
1578, 1502 
Yes 
1648, 1568, 
1484, 1445 
No 
1666, 1588, 
1504, 1426 
No 
1565, 1543, 
1515, 1482 
No 
1684, 1599, 
1532, 1467 
Yes 
Caffeine 
1694, 1639, 1545, 1454 
2227, 1775, 
1694, 1649 
No 
1694, 1648, 
1599, 1546 
No 
1693, 1651, 
1636, 1546 
Yes 
1692, 1659, 
1644, 1544 
No 
1698, 1675, 
1587, 1505 
Yes 
1697, 1652, 
1566, 1512 
Yes 
1696, 1655, 
1597, 1532 
No 
Cholic acid 
1712, 1247, 1090, 1077 
2228, 1774, 
1717, 1578 
No 
1716, 1630, 
1599, 1574 
No 
1770, 1683, 
1578, 1498 
No 
1648, 1583, 
1287, 1176 
No 
1666, 1587, 
1506, 1464 
No 
1562, 1511, 
1481, 1425 
No 
1701, 1685, 
1603, 1532 
No 
Citric acid 
1741, 1691, 1425, 1391 
2228, 1691, 
1539, 1392 
Yes 
1726, 1641, 
1623, 1600 
Yes 
1711, 1654, 
1579, 1559 
Yes 
1721, 1643, 
1558, 1485 
Yes 
1666, 1588, 
1505, 1463 
No 
1563, 1512, 
1480, 1421 
No 
1702, 1684, 
1602, 1531 
Yes 
D-Glucuronic acid 
1703, 1456, 1362, 1347 
1702, 1458, 
1346, 1254 
No 
1701, 1458, 
1363, 1346 
No 
1702, 1579, 
1489, 1460 
No 
1704, 1584, 
1446, 1341 
No 
1713, 1660, 
1587, 1507 
Yes 
1712, 1566, 
1513, 1481 
Yes 
1702, 1685, 
1603, 1532 
No 
EDTA 
1690, 1412, 1386, 1309 
1687, 1411, 
1388, 1341 
No 
1687, 1629, 
1440, 1407 
No 
1690, 1413, 
1385, 1310 
No 
1650, 1585, 
1440, 1412 
No 
1669, 1505, 
1410, 1310 
Yes 
1700, 1558, 
1513, 1480 
Yes 
1690, 1603, 
1533, 1468 
No 
Folic acid 
1688, 1602, 1481, 1451 
2228, 1706, 
1604, 1508 
Yes 
1668, 1629, 
1651, 1631 
Yes 
1681, 1606, 
1577, 1498 
Yes 
1678, 1649, 
1601, 1569 
Yes 
1666, 1590, 
1507, 1406 
Yes 
1694, 1565, 
1514, 1482 
Yes 
1701, 1686, 
1602, 1533 
No 
Fumaric acid 
1653, 1406, 1315, 1270 
2228, 164, 
1559, 1420 
No 
1630, 1570, 
1460, 1435 
No 
1770, 1682, 
1579, 1502 
No 
1650, 1405, 
1272, 1230 
No 
1666, 1589, 
1506, 1466 
No 
1695, 1584, 
1563, 1523 
Yes 
1701, 1685, 
1624, 1604 
No 
Gentisic acid 
1662, 1620, 1592, 1437 
2230, 1775, 
1697, 1612 
Yes 
1637, 1616, 
1603, 1575 
Yes 
1763, 1672, 
1579, 1500 
Yes 
1658, 1564, 
1482, 1438 
Yes 
1666, 1587, 
1573, 1506 
No 
1565, 1511, 
1482, 1418 
No 
1702, 1685, 
1602, 1532 
No 
Glutaric acid 
1682, 1466, 1430, 1406 
2228, 1695, 
1540, 1392 
Yes 
1706, 1642, 
1575, 1456 
Yes 
1762, 1700, 
1682, 1578 
Yes 
1706, 1644, 
1561, 1485 
Yes 
1694, 1667, 
1587, 1507 
No 
1561, 1514, 
1478, 1421 
No 
1685, 1603, 
1532, 1466 
No 
Glycine 
1607, 1577, 1500, 1441 
1577, 1502, 
1405, 1330 
No 
1610, 1572, 
1502, 1405 
No 
1579, 1497, 
1404, 1330 
No 
1577, 1580, 
1498, 1404 
No 
1682, 1667, 
1588, 1572 
No 
1563, 1510, 
1481, 1420 
No 
1702, 1686, 
1603, 1532 
No 
Glycolic acid 
1701, 1428, 1226, 1081 
2230, 1695, 
1538, 1488 
Yes 
1727, 1625, 
1577, 1434 
Yes 
1759, 1676, 
1578, 1560 
No 
1728, 1647, 
1565, 1484 
Yes 
1731, 1885, 
1587, 1505 
Yes 
1734, 1625, 
1565, 1512 
Yes 
1702, 1685, 
1603, 1532 
No 
Hydrocinnamic acid 
1692, 1426, 1406, 1299 
2228, 1772, 
1694, 1532 
No 
1693, 1639, 
1599, 1572 
No 
1766, 1703, 
1663, 1579 
Yes 
1649, 1583, 
1484, 1432 
No 
1666, 1588, 
1506, 1462 
No 
1707, 1565, 
1513, 1480 
Yes 
1701, 1684, 
1623, 1596 
No 
Isonicotinamide 
1653, 1621, 1594, 1546 
2228, 1778, 
1704, 1675 
1679, 1635, 
1596, 1570 
1763, 1676, 
1620, 1578 
1639, 1585, 
1553, 1403 
1665, 1588, 
1506, 1462 
1563, 1513, 
1480, 1421 
1704, 1684, 
1623, 1600 
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Yes Yes Yes Yes No No No 
L-Glutamic acid 
1641, 1499, 1407, 1350 
2228, 1775, 
1718, 1638 
Yes 
1640, 1572, 
1511, 1476 
Yes 
1643, 1500, 
1495, 1420 
No 
1650, 1581, 
1512, 1484 
Yes 
1666, 1506, 
1294, 1215 
No 
1574, 1562, 
1545, 1510 
Yes 
1703, 1685, 
1623, 1602 
No 
L-Mandelic acid 
1708, 1491, 1455, 1241 
1696, 1540, 
1361, 1286 
Yes 
1644, 1569, 
1552, 1494 
Yes 
1760, 1719, 
1679, 1577 
Yes 
1728, 1648, 
1565, 1484 
Yes 
1649, 1602, 
1578, 1555 
No 
1560, 1509, 
1480, 1425 
No 
1701, 1684, 
1602, 1531 
No 
L-Proline 
1608, 1565, 1541, 1473 
2227, 1700, 
1602, 1544 
Yes 
1620, 1557, 
1449, 1435 
Yes 
1753, 1672, 
1578, 1497 
Yes 
1653, 1565, 
1435, 1409 
Yes 
1666, 1653, 
1589, 1506 
No 
1566, 1512, 
1480, 1421 
Yes 
1702, 1685, 
1623, 1603 
No 
L-Serine 
1582, 1466, 1408, 1382 
2229, 1785, 
1718, 1590 
Yes 
1629, 1587, 
1466, 1410 
Yes 
1758, 1681, 
1578, 1557 
Yes 
1609, 1579, 
1468, 1410 
Yes 
1666, 1589, 
1506, 1467 
Yes 
1569, 1514, 
1480, 1421 
Yes 
1701, 1685, 
1626, 1595 
No 
L-Tartaric acid 
1732, 1706, 1442, 1251 
1732, 1706, 
1442, 1251 
No 
1732, 1706, 
1442, 1251 
No 
1650, 1589, 
1490, 1420 
Yes 
1732, 1706, 
1442, 1251 
No 
1666, 1588, 
1506, 1464 
No 
1666, 1588, 
1506, 1464 
No 
1701, 1686, 
1596, 1588 
No 
Maleic acid 
1703, 1558, 1458, 1428 
2228, 1754, 
1694, 1618 
Yes 
1646, 1554, 
1449, 1420 
Yes 
1764, 1677, 
1579, 1501 
Yes 
1708, 1646, 
1561, 1484 
Yes 
1667, 1588, 
1505, 1451 
No 
1569, 1543, 
1481, 1455 
No 
1702, 1685, 
1623, 1597 
No 
Malic acid 
1737, 1682, 1438, 1407 
2228, 1695, 
1539, 1392 
Yes 
1718, 1635, 
1599, 1575 
Yes 
1713, 1579, 
1558, 1509 
Yes 
1719, 1643, 
1558, 1485 
Yes 
1666, 1590, 
1506, 1293 
Yes 
1564, 1515, 
1482, 1437 
Yes 
1700, 1685, 
1623, 1597 
No 
Malonic acid 
1691, 1432, 1387, 1301 
2229, 1691, 
1538, 1375 
Yes 
1719, 1640, 
1619, 1575 
Yes 
1708, 1661, 
1578, 1505 
Yes 
1719, 1642, 
1560, 1484 
Yes 
1729, 1666, 
1641, 1588 
Yes 
1561, 1510, 
1480, 1435 
No 
1700, 1685, 
1602, 1532 
No 
Mannitol 
1712, 1538, 1455, 1415 
2229, 1702, 
1645, 1593 
Yes 
1700, 1416, 
1299, 1279 
Yes 
1691, 1577, 
1554, 1503 
Yes 
1656, 1646, 
1504, 1423 
Yes 
1667, 1588, 
1506, 1464 
Yes 
1565, 1516, 
1482, 1421 
No 
1702, 1685, 
1603, 1532 
Yes 
Methylparaben 
1676, 1605, 1584, 1559 
2229, 1774, 
1676, 1606 
No 
1677, 1630, 
1605, 1572 
No 
1761, 1681, 
1606, 1579 
Yes 
1649, 1605, 
1585, 1560 
No 
1666, 1588, 
1507, 1292 
No 
1568, 1556, 
1481, 1419 
Yes 
1677, 1604, 
1583, 1532 
Yes 
Nicotinamide 
1673, 1617, 1595, 1484 
2228, 1774, 
1716, 1523 
No 
1670, 1626, 
1572, 1455 
No 
1665, 1628, 
1617, 1576 
Yes 
1650, 1582, 
1552, 1484 
No 
1666, 1588, 
1506, 1464 
No 
1564, 1512, 
1479, 1437 
No 
1564, 1512, 
1479, 1437 
No 
Oxalic acid 
1677, 1161, 1128, 826 
2229, 1691, 
1539, 1455 
Yes 
1723, 1633, 
1576, 1434 
Yes 
1757, 1660, 
1579, 1554 
Yes 
1720, 1644, 
1484, 1442 
Yes 
1666, 1588, 
1507, 1465 
No 
1566, 1513, 
1481, 1420 
No 
1744, 1699, 
1682, 1622 
Yes 
Pamoic acid 
1649, 1452, 1428, 1308 
1646, 1450, 
1428, 1289 
No 
1649, 1452, 
1427, 1308 
No 
1646, 1500, 
1452, 1427 
No 
1648, 1452, 
1430, 1291 
No 
1653, 1507, 
1453, 1427 
No 
1649, 1566, 
1482, 1452 
Yes 
1685, 1649, 
1624, 1602 
Yes 
Phosphoric acid 
N/A 
1695, 1635, 
1122, 963 
Yes 
1695, 1635, 
1122, 963 
Yes 
1646, 1582, 
1241, 1118 
Yes 
1642, 1589, 
1147, 1062 
Yes 
1666, 1590, 
1507, 1412 
No 
1646, 1567, 
1120, 956 
Yes 
1564, 1512, 
1479, 1437 
No 
Piperazine 
1648, 1456, 1322, 1270 
2225, 1727, 
1665, 1600 
Yes 
1629, 1567, 
1449, 1430 
Yes 
1698, 1659, 
1558, 1493 
Yes 
1668, 1577, 
1400, 1316 
Yes 
1666, 1590, 
1507, 1412 
No 
1562, 1512, 
1479, 1421 
No 
1564, 1512, 
1479, 1437 
No 
Riboflavin 
1730, 1645, 1578, 1536 
1730,1644, 
1620, 1577 
No 
1730, 1643, 
1620, 1577 
No 
1729, 1646, 
1578, 1537 
No 
1730, 1645, 
1577, 1535 
No 
1730, 1645, 
1577, 1537 
No 
1731, 1645, 
1578, 1543 
No 
1725, 1713, 
1685, 1647 
Yes 
Saccharin 
1714, 1591, 1458, 1332 
2228, 1764, 
1697, 1617 
Yes 
1731, 1639, 
1600, 1576 
Yes 
1714, 1679, 
1578, 1556 
No 
1731, 1649, 
1578, 1484 
Yes 
1667, 1588, 
1506, 1464 
No 
1567, 1513, 
1481, 1422 
No 
1701, 1685, 
1604, 1533 
No 
Salicylic acid 
1652, 1608, 1480, 1440 
2229, 1774, 
1657, 1659 
No 
1630, 1570, 
1456, 1436 
No 
1762, 1669, 
1578, 1561 
Yes 
1665, 1654, 
1442, 1404 
No 
1666, 1588, 
1506, 1465 
No 
1565, 1512, 
1480, 1419 
No 
1699, 1684, 
1656, 1603 
No 
Sorbic acid 
1672, 1634, 1608, 1411 
2227, 1763, 
1683, 1609 
Yes 
1664, 1623, 
1585, 1485 
Yes 
1759, 1685, 
1616, 1577 
Yes 
1645, 1577, 
1483, 1432 
Yes 
1670, 1508, 
1493, 1459 
No 
1566, 1514, 
1480, 1423 
No 
1685, 1623, 
1604, 1532 
Yes 
Succinic acid 
1679, 1411, 1307, 1197 
2229, 1774, 
1715, 1701 
No 
1679, 1630, 
1600, 1574 
No 
1759, 1678, 
1578, 1557 
Yes 
1679, 1646, 
1566, 1484 
No 
1663, 1588, 
1507, 1461 
No 
1565, 1524, 
1483, 1457 
Yes 
1685, 1603, 
1532, 1410 
No 
Theophylline 
1700, 1659, 1555, 1481 
1715, 1656, 
1560, 1523 
1708, 1694, 
1647, 1564 
1702, 1659, 
1557, 1482 
1706, 1661, 
1559, 1486 
1664, 1587, 
1503, 1465 
1711, 1666, 
1562, 1513 
1702, 1685, 
1603, 1532 
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Yes Yes No Yes No Yes No 
Urea 
1674, 1590, 1550, 1454 
2228, 1775, 
1716, 1600 
No 
1630, 1571, 
1451, 1428 
No 
1684, 1578, 
1554, 1550 
Yes 
1650, 1577, 
1483, 1431 
No 
1666, 1588, 
1506, 1463 
No 
1560, 1513, 
1480, 1421 
No 
1685, 1623, 
1596, 1523 
No 
Xanthine 
1692, 1650, 1564, 1454 
1697,1656, 
1565, 1458 
No 
1690, 1654, 
1569, 1457 
No 
1656, 1569, 
1508, 1460 
No 
1695, 1648, 
1566, 1435 
No 
1697, 1666, 
1572, 1507 
Yes 
1705, 1654, 
1565, 1544 
Yes 
1685, 1624, 
1604, 1531 
No 
Experimental 
supramolecular yield 
55% 55% 69% 55% 24% 50% 24% 
 
5.3.2. HBP calculations 
 
The homomeric, heteromeric and propensity values were calculated and summarized in Table 5.5. 
for the 294 combinations of targets and co-formers. 
 
Table 5.5. HBP outcomes for seven targets against 42 potential co-formers. 
Co-former T11 T12 T13 T14 T15 T16 T17 
3-hydroxy-2naphthoic acid -0.1 0.48 -0.09 0.15 0.06 0.22 0.01 
4-hydroxybenzoic acid -0.05 0.47 -0.06 0.17 0.07 0.24 0.03 
Adipic acid -0.01 0.52 0.03 0.11 0.23 0.31 -0.08 
Apigenin -0.03 0.57 0.02 0.09 0.06 0.37 -0.05 
Benzenesulfonic acid 0.1 0.46 -0.02 0 0.24 0.26 0.03 
Benzoic acid -0.12 0.45 -0.07 0.14 0.17 0.26 0.04 
Caffeine 0.05 0.41 0.03 0.26 0.3 -0.11 0.41 
Cholic acid 0.09 0.49 -0.01 0.08 0.06 0.24 -0.17 
Citric acid -0.1 0.05 0.08 0.07 0.11 0.32 0.05 
D- Glucuronic acid -0.14 0.54 0.01 0.12 0.07 0.26 0.06 
EDTA -0.01 0.3 0.02 0.12 0.23 0.3 -0.09 
Folic acid 0.05 0.42 0.1 0.1 0.1 0.29 -0.26 
Fumaric acid -0.06 0.49 -0.03 0.08 0.17 0.26 -0.01 
Gentisic acid -0.11 0.53 -0.07 0.09 0.19 0.27 0.05 
Glutaric acid -0.02 0.1 0.03 0.1 0.24 0.31 -0.07 
Glycine -0.07 0.38 0.04 0.01 0.33 0.05 -0.1 
Glycolic acid 0.03 0.61 -0.01 0.06 0.17 0.27 -0.04 
Hydrocinnamic acid -0.07 0.3 0.01 0.24 0.23 0.34 -0.01 
Isonicotinamide -0.02 0.38 0.02 -0.05 -0.07 0.33 -0.12 
L-glutamic acid 0.07 0.6 0.08 0.12 0.36 0.13 -0.07 
L-Mandelic acid -0.02 0.29 0.03 0.31 0.24 0.48 0.03 
L-prolin 0.02 0.11 0.02 0 0.12 0.25 -0.07 
L-Serine 0.02 0.51 0.03 0.07 0.12 0.24 -0.07 
L-tartaric acid 0 0.43 0.05 0.21 0.2 0.36 -0.02 
Maleic acid -0.1 0.49 0 0.08 0.17 0.27 -0.05 
Malic acid 0.01 0.47 0.06 0.2 0.2 0.37 -0.03 
Malonic acid 0 0.15 0.04 0.1 0.25 0.24 -0.07 
Mannitol -0.06 0.43 -0.02 -0.04 0.02 0.33 0.03 
Methylparaben 0.11 0.66 -0.1 0.06 0.33 0.33 -0.02 
Nicotinamide -0.03 0.3 0.02 0.26 -0.07 0.31 -0.1 
Oxalic acid -0.03 0.54 -0.17 -0.04 0.02 0.09 -0.01 
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Pamoic acid -0.11 0.5 -0.09 -0.03 0.22 0.19 0.02 
Phosphoric acid -0.22 -0.02 -0.19 0.15 -0.31 0 -0.16 
Piperazine -0.02 0.29 0 0.12 0.03 0.33 -0.11 
Riboflavin 0.07 0.15 -0.02 0.01 -0.07 0.02 -0.01 
Saccharin 0.06 0.4 -0.01 -0.22 0.22 0.24 0.04 
Salicylic acid -0.1 0.49 -0.07 0.12 0.25 0.25 0.05 
Sorbic acid -0.1 0.44 -0.03 0.09 0.16 0.28 -0.01 
Succinic acid -0.01 0.52 0.04 0.09 0.24 0.29 -0.07 
Theophylline 0.1 0.47 -0.1 0.11 -0.03 0.08 0.08 
Urea -0.09 0.02 -0.02 -0.05 -0.04 0.03 -0.05 
Xanthine 0.05 0.33 0.05 -0.02 -0.13 0.26 0.01 
Predicted supramolecular yield 38% 98% 55% 83% 83% 97% 36% 
 
 
5.3.3. HBE calculations 
 
The homomeric, heteromeric and E values were calculated and summarized in Table 5.6. for the 
294 combinations of targets and co-formers. 
 
Table 5.6. HBE outcomes for seven targets against 42 potential co-formers. 
Co-former T11 T12 T13 T14 T15 T16 T17 
3-hydroxy-2naphthoic acid 4.17 13.8 1.82 6.32 3.73 11.58 5.17 
4-hydroxybenzoic acid 3.23 10 1.74 6.22 3.65 7.705 5.09 
Adipic acid 1.19 8.3 -0.4 7.68 4.14 5.947 4.81 
Apigenin 0.21 7.5 -1.4 8.18 3.22 5.058 3.9 
Benzenesulfonic acid 3.91 11 2.4 7.41 4.51 8.62 5.98 
Benzoic acid 2.14 9.5 0 2.97 1.3 7.578 2.65 
Caffeine -0.8 6.3 0.31 -5.88 -3.1 2.722 -3.2 
Cholic acid 2.14 10.8 0 2.97 1.3 9.846 2.66 
Citric acid 3.11 8.4 1.41 9.64 6.3 8.24 6.4 
D- Glucuronic acid 0.41 9.7 -1.6 0.1 -0.8 6.786 0.5 
EDTA 1.18 0.25 -0.7 12.4 4.7 6.838 5.49 
Folic acid -7.2 10.4 -5.1 3.13 -4.1 -2.217 -3.4 
Fumaric acid 3.12 14.2 0.88 4.59 2.48 8.317 3.87 
Gentisic acid 3.46 10.1 1.18 5.15 2.88 11.58 4.29 
Glutaric acid 2.7 9.8 0.5 3.9 1.97 8.124 3.35 
Glycine 2.58 14.1 0.39 3.69 1.82 7.76 3.2 
Glycolic acid 4.5 9.5 2.11 6.86 4.12 11.85 5.58 
Hydrocinnamic acid 1.53 6 -0.5 1.96 0.57 7.642 1.9 
Isonicotinamide 0.29 11.1 -1.7 -0.1 -0.9 4.363 0.36 
L-glutamic acid 3.21 11.1 0.95 4.73 2.57 9.028 3.98 
L-Mandelic acid 4.18 8.8 2.17 6.97 4.2 8.806 5.66 
L-prolin 1.53 10.7 -0.5 1.96 0.57 6.99 1.9 
L-Serine 3.78 15.6 1.47 5.68 3.26 8.495 4.69 
L-tartaric acid 6.66 10.5 4.04 10.4 6.7 12.94 8.25 
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Maleic acid 3.14 13.9 0.9 4.62 2.5 8.403 3.9 
Malic acid 5.5 12.1 3 8.51 5.31 11.4 6.81 
Malonic acid 3.65 3.7 1.35 5.47 3.11 9.93 4.53 
Mannitol -2.9 8.7 -2.1 5.89 3.03 6.6 4.45 
Methylparaben 2.36 9 0.88 5.36 3.57 6.817 5.01 
Nicotinamide 0.43 5.5 -1.3 6.11 -0.5 3.816 0.79 
Oxalic acid 6.47 14.6 4.54 0.48 7.36 11.93 8.94 
Pamoic acid 2.53 9.2 1.06 11.4 3.57 6.99 5.01 
Phosphoric acid 0 7.6 -1.7 6.11 3.13 5.044 3.84 
Piperazine -1.1 3 0 9.18 -3.4 0.553 -3.5 
Riboflavin -6 0.69 -3 -7.94 -3.3 -1.563 -2.6 
Saccharin 2.7 12.4 0.5 3.31 1.97 10.39 3.35 
Salicylic acid 3.4 14.1 1.12 3.9 2.8 11.49 4.21 
Sorbic acid 1.38 7 -0.4 5.04 0.79 5.11 2.13 
Succinic acid 1.29 8.4 -0.3 2.26 4.25 6.058 4.92 
Theophylline 1.97 8.5 0.52 7.74 3.26 6.35 4.69 
Urea -0.2 1.6 2.59 5.68 1.16 0 -0.2 
Xanthine 2.45 9.4 0.92 -0.29 4.2 13.03 5.66 
Predicted supramolecular yield 88% 100% 69% 90% 83% 95% 88% 
 
5.3.4. MC calculations 
 
The MC values were calculated using the updated seven descriptors for the 294 combinations of 
targets and co-formers and are summarized in Table 5.7.  
 
Table 5.7. MC outcomes for seven targets against 42 potential co-formers. 
Co-former T11 T12 T13 T14 T15 T16 T17 
3-hydroxy-2naphthoic acid 0 30 10 50 45 85 50 
4-hydroxybenzoic acid 0 0 0 100 0 20 0 
Adipic acid 0 0 0 100 0 96 16 
Apigenin 0 0 0 100 0 20 0 
Benzenesulfonic acid 0 0 0 100 0 60 0 
Benzoic acid 0 0 0 100 0 20 0 
Caffeine 0 0 0 0 0 80 0 
Cholic acid 0 0 0 100 0 80 0 
Citric acid 0 0 32 0 0 0 0 
D- Glucuronic acid 0 52 8 0 60 0 0 
EDTA 0 100 84 0 12 64 20 
Folic acid 72 0 72 20 96 100 92 
Fumaric acid 0 0 0 0 0 52 0 
Gentisic acid 0 0 0 33 0 80 0 
Glutaric acid 0 0 0 60 0 96 16 
Glycine 0 0 0 0 0 0 0 
Glycolic acid 0 40 0 0 0 0 0 
Hydrocinnamic acid 0 0 12 40 60 96 68 
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Isonicotinamide 0 16 0 100 0 20 0 
L-glutamic acid 0 40 4 0 16 100 48 
L-Mandelic acid 4 0 12 0 52 100 72 
L-prolin 0 0 20 0 0 0 0 
L-Serine 0 0 0 0 0 0 0 
L-tartaric acid 0 24 0 0 0 0 0 
Maleic acid 0 0 0 0 36 20 36 
Malic acid 0 0 0 0 0 0 0 
Malonic acid 0 40 0 0 0 0 0 
Mannitol 92 56 96 0 68 100 96 
Methylparaben 0 0 0 0 0 80 0 
Nicotinamide 0 0 0 100 0 20 0 
Oxalic acid 0 0 0 100 0 0 0 
Pamoic acid 100 100 100 0 44 100 48 
Phosphoric acid 0 0 0 20 0 0 0 
Piperazine 0 0 0 0 0 20 0 
Riboflavin 84 8 84 0 0 80 0 
Saccharin 0 0 0 20 0 80 0 
Salicylic acid 0 10 10 0 0 55 0 
Sorbic acid 0 0 0 25 0 80 0 
Succinic acid 0 0 0 100 0 96 16 
Theophylline 0 0 0 0 0 80 0 
Urea 0 0 0 0 0 0 0 
Xanthine 0 0 0 0 0 0 0 
Predicted supramolecular yield 64% 45% 71% 40% 43% 29% 50% 
 
 
5.4. Discussions 
 
5.4.1. Individual prediction outcomes vs. experimental results 
 
The accuracy of the methodologies was calculated by comparing the individual prediction results 
with the experimental co-crystallization outcomes. In order to ease the process of comparison, we 
calculated a success rate which is the number of predictions that match the experimental outcome 
divided by the total number of combinations (294). The success rates of the seven APIs are 
summarized in Table 5.8.  
 
Table 5.8. Success rates of HBP, HBE, and MC (* TP: true positive and TN: true negative). 
 
HBP HBE MC 
TP TN Overall TP TN Overall TP TN Overall 
T11 11/23=49% 14/19=74% 60% 21/23=91% 3/19=16% 57% 16/23=70% 8/19=42% 57% 
T12 22/23=96% 0/19=0% 52% 21/23=91% 0/19=0% 50% 10/23=43% 10/19=43% 50% 
T13 17/29=57% 8/13=62% 60% 19/29=66% 3/13=23% 52% 23/29=79% 5/13=38% 64% 
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T14 20/23=87% 4/19=21% 57% 21/23=91% 2/19=11% 55% 9/23=39% 11/19=58% 50% 
T15 9/10=90% 9/32=28% 43% 7/10=70% 4/32=13% 26% 6/10=60% 21/32=66% 64% 
T16 20/21=95% 1/21=5% 50% 20/21=95% 1/21=5% 50% 5/21=24% 14/21=67% 52% 
T17 4/10=40% 22/32=69% 62% 8/10=80% 4/32=13% 29% 8/10=80% 19/32=59% 64% 
Overall 
103/139 
=74% 
58/155 
=37% 
161/294 
=55% 
117/139 
=84% 
17/155 
=11% 
134/294 
=46% 
77/139 
=55% 
88/155 
=55% 
165/294 
=56% 
 
HBP across the seven compounds gave a success rate of 43%-62%. The true positives (TP, where 
the prediction matches the positive co-crystal experiment) and true negatives (TN, where the 
prediction matches the negative co-crystal experiments) were separately analyzed. An accuracy 
range of 40-96% was observed for TP and 0-74% for TN. The higher accuracy for TP than TN can 
be attributed to the fact that CSD only contains positive co-crystallization results. Therefore, it is 
not surprising that HBP was better at predicting TP than TN.  
HBE delivered success rates of 26-57%, with TP 66-95% and TN 0-23%. HBE offered the lowest 
accuracy for TN and highest for TP across all the methods. Although HBE performed better for 
smaller compounds in Chapter 4, it failed for larger compounds studied here. The HBE 
calculations were entirely based on electrostatics and any shape or geometry factors were not 
included. Due to this HBE produced more false positives than true negatives leading to lower TN 
success rates. This raises the question whether we can extrapolate the accuracy of predictive 
approaches to larger compounds?  
Finally, MC exhibited a prediction match of 50-64% for the seven compounds with TP 24-80% 
and TN and 38-67% success rates. Similar to any other methods, MC is built on a database of small 
molecules. Although, Fábián23 mentioned that the short and the long axes appear to be more 
influential than other frequently used size descriptors, such as molecular weight. The cut-off values 
of “l, m and s” tested on small compounds might not translate to larger compounds. 
We ranked the methodologies in decreasing order of their overall predictive accuracy for TP, 
which resulted in HBE (84%)> HBP (74%)> MC (55%); and for TN MC (55%)> HBP (37%)> 
HBE (11%). Additionally, if we combine TP and TN results, the predictive ability of MC (56%)> 
HBP (55%)> HBE (46%).  
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5.4.2. Using Venn diagram to interpret the predictive outcomes 
 
Since the average molecular weight of organic structures reported in CSD is ~400 g/mol33 
therefore,  individually the methods did not deliver a high accuracy, compared to 80-90% observed 
on small molecules in Chapter 431, Hence, we used Venn diagrams to apply a combination of the 
methods. The regions inside the circles of the Venn diagrams represent the outcomes that were 
correctly predicted by that particular methodology. For example, the co-formers which reside 
inside the HBP region of the Venn diagram was correctly predicted by HBP. Those co-formers 
that were present in the combined regions such as HBP&HBE; HBP&MC; HBE&MC denotes that 
both the methodologies correctly match the experimental results. Subsequently, the co-formers 
that were accurately predicted by all three methods occupy the region where all the methods 
overlap. Lastly, co-formers outside the Venn diagram (for example, xanthine, cholic acid, and 
methylparaben in case of T11) were not predicted correctly by any of the three methods. The co-
formers who experimentally formed co-crystals were represented in “green,” and those who did 
not form co-crystals in “red”, Figure 5.6.      
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T17 
 
Figure 5.6. Venn diagram representation for combination of methods. 
(*green & red represents experimentally obtained positive and negative co-crystals respectively) 
 
Two different approaches were employed to analyze the Venn diagram, Figure 5.7. Approach1, is 
only employing a fraction of the correctly predicted results from a particular method and requires 
two or more methods to provide similar prediction for it to be present in the overlapping region. 
The success rates of the overlapping region (approach 1) from the Venn diagrams are listed in 
Table 5.9. 
 
  
 
 
 
 
 
 
 
Figure 5.7. Approaches used to analyze the Venn diagrams. 
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Table 5.9. Success rates of the overlapping regions (* TP: true positive and TN: true negative). 
 
Overlapping regions 
TP TN Overall 
T11 20/23=87% 11/19=58% 31/42=74% 
T12 22/23=96% 1/19=5% 23/42=55% 
T13 20/29=69% 5/13=38% 25/42=60% 
T14 20/23=87% 3/19=16% 23/42=55% 
T15 10/10=100% 7/32=22% 17/42=40% 
T16 20/21=95% 2/21=10% 22/42=52% 
T17 8/10=80% 16/32=50% 24/42=57% 
Overall 120/139=86% 45/155=29% 165/294=56% 
 
Overall, the overlapping region displayed a 56% success rate, with a considerable imbalance 
between the TP and TN. The high accuracy for TP over TN corresponds to CSD consisting of only 
positive results.  Hence, it is not surprising that the TN does not exhibit similar accuracy. Clearly, 
this approach would not be useful as a co-crystal prediction tool.  
Consequently, we moved to approach 2 which includes the combined region of two methods at a 
time. There were three possible combinations, i.e., HBP & MC, HBP & HBE, and HBE & MC. 
The success rates from the combination methods are summarized in Table 5.10.  
 
Table 5.10. Success rates of the combined region (* TP: true positive and TN: true negative). 
 
HBP & MC HBP&HBE HBE&MC 
TP TN Overall TP TN Overall TP TN Overall 
T11 
12/23 
=52% 
13/19 
=68% 
25/42 
=60% 
13/23 
=57% 
6/19 
=32% 
29/42 
=69% 
15/23 
=65% 
7/19 
=37% 
22/42 
=52% 
T12 
22/23 
=96% 
10/19 
=53% 
32/42 
=76% 
23/23 
=100% 
0/19 
=0% 
23/42 
=55% 
23/23 
=100% 
10/19 
=53% 
33/42 
=79% 
T13 
27/29 
=93% 
11/13 
=85% 
38/42 
=90% 
26/29 
=90% 
10/13 
=77% 
36/42 
=86% 
25/29 
=86% 
8/13 
=62% 
33/42 
=79% 
T14 
21/23 
=91% 
12/19 
=63% 
33/42 
=79% 
22/23 
=96% 
5/19 
=26% 
27/42 
=64% 
23/23 
=100% 
10/19 
=53% 
33/42 
=79% 
T15 
10/10 
=100% 
22/32 
=69% 
32/42 
=76% 
10/10 
=100% 
7/32 
=22% 
17/42 
=40% 
10/10 
=100% 
22/32 
=69% 
32/42 
=76% 
T16 
21/21 
=100% 
14/21 
=67% 
35/42 
=83% 
21/21 
=100% 
2/21 
=10% 
23/42 
=55% 
20/21 
=95% 
14/21 
=67% 
34/42 
=81% 
T17 
9/10 
=90% 
27/32 
=84% 
36/43 
=86% 
9/10 
=90% 
23/32 
=72% 
32/42 
=76% 
10/10 
=100% 
20/32 
63% 
30/42 
=71% 
Overall 
122/139 
=88% 
109/155 
=70% 
231/294 
=79% 
124/139 
=89% 
53/155 
=33% 
177/294 
=60% 
126/139 
=91% 
91/155 
=59% 
217/294 
=74% 
 
We would assume that the region corresponding to HBP&MC would provide better accuracy since 
it is combination of the probability of hydrogen-bond formation with close packing principle. For 
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the seven compounds it provides an accuracy range of 60-90%. TP exhibited an accuracy greater 
than 90% in all cases (except 52% for T11). For TN, we observed 53-85% success rates. Both 
HBP and MC are based on CSD which includes only positive results hence, as expected TP 
performs better than TN. The results are however significantly higher than any other approach 
could demonstrate at this point. 
HBP&HBE region corresponds to hydrogen-bonding synthons hierarchy and does not include any 
geometric factors. This combination provided high false positive results comparable. Needless to 
say, this combination was not the best candidate.  
Finally, a combination of HBE&MC, similar to HBP&MC includes both hydrogen-bonding and 
geometry factors. Hence, one would anticipate similar reliability. The TP accuracy ranges from 
65-100% and TN 52-81%. As expected, the results were comparable to that of HBP&MC. 
Although if we include time as a factor, calculating HBP and MC is faster in comparison to HBE. 
Overall the combination of HBP&MC methods provided faster and reliable prediction for 
designing co-crystallization experiments. 
 
5.5. Conclusions 
 
1. HBP produces a success rate of 55% with 74% and 37% accuracies for TP and TN, respectively.  
    HBE delivered the highest TP results (84%) and lowest TN accuracy (11%). 
2. MC could predict the co-crystallization outcomes overall with 56% accuracy. In comparison to  
    other methods, MC produces the lowest TP (55%) and highest TN accuracies (55%).  
3. The combined region of HBP&MC in the Venn diagram produced the highest reliability of 79%  
    (TP accuracy was 88%, and TN was 70%). 
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Chapter 6 - CoForm: An Automatic Tool for Predicting Co-
crystallization 
 
6.1. Introduction 
 
In the previous chapters, we investigated predictive tools based on hydrogen-bond propensity1, 
hydrogen-bond coordination2, molecular complementarity3, and molecular electrostatic potential 
surface calculations4 in order to predict co-crystallization screening outcomes. These approaches 
were complex and required in-depth knowledge of either theoretical, quantum-mechanical, or 
statistical data analysis. With the growing demand of co-crystallization and co-crystallization-
based5 approaches to access new solid forms in various fields6,7,8 related to agrochemicals, 
energetics, and smart materials9,10,11,12,13,14,15,16,17,18,19, it is imperative that we develop cheaper, 
faster, and more reliable methods for predicting when a pair of molecules will co-crystallize and 
when they will not. In order to address these issues, we have developed CoForm, an automatic tool 
for predicting co-crystallization. A comparison between existing predictive tools and CoForm is 
given in Figure 6.1. 
 
Figure 6.1. Comparison between existing co-crystallization techniques and CoForm.  
 
CoForm is based on a mathematical model that compares the target of interest with a known set of 
targets. The known targets are associated with a list of co-formers that form co-crystals (positive 
partners), and a list of co-formers that do not form co-crystals (negative partners). The database 
for the known targets was created using approximately 2000 experimental data collected from past 
and present Aakeröy lab members over a period of 15 years. All experiments were done either by 
liquid assisted grinding (LAG) or melt co-crystallization. The experiments were analyzed using 
IR spectroscopy, where the fingerprint region was investigated for any potential shift in stretching 
1000s of experiment Existing theoretical 
predictions
CoForm
Ø Time consuming
Ø Very expensive
Have we done enough 
experiments?
How to choose a potential molecular partner “co-former” ?
Ø Complex
Ø Require in-depth knowledge
Ø Annual license ranges from 
2K- 20K
How accurate are 
these predictions?
Ø User-friendly
Ø Inexpensive
Ø Fast
How accurate are 
these predictions?
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frequency. Further analysis using melting points, differential scanning calorimetry (DSC), 
thermogravimetric analysis (TGA), and single-crystal analysis were also carried out.  
CoForm, utilizes 42 co-formers that are generally regarded as safe20 (GRAS) for pharmaceutical 
co-crystals and an additional 50 co-formers, which are conventionally used as co-formers in co-
crystallization experiments, Table 6.1. 
 
Table 6.1. List of co-formers.   
GRAS list co-formers Non GRAS list co-formers 
3-Hydroxy-2-naphthoic acid 1-Bromo-4- iodotetrafluorobenzene 
4-Hydroxybenzoic acid 1,2-Bis(4-pyridyl)ethane 
Adipic acid 1,2-Bis(4-pyridyl)ethylene 
Apigenin 1,4-Dihydroxybenzene 
Benzenesulfonic acid 1,4-Diiodobenzene 
Benzoic acid 1,4-Diiodotetrafluorobenzene 
Caffeine 2-Amino-3,5-dibromopyridine 
Cholic acid 2-Amino-3-hydroxypyridine 
Citric acid 2-Amino-4,6-dimethylpyrimidine 
D-glucuronic acid 2-Amino-4-chloro-6-methylpyrimidine 
EDTA 2-Amino-4-hydroxy-6-methylpyrimidine 
Folic acid 2-Amino-4-methylpyrimidine 
Fumaric acid 2-Amino-5-chloropyridine 
Glutaric acid 2-Aminopyridine 
Glycine 2-Aminopyrimidine 
Glycolic acid 2-Chlorocyanoxime 
Hydrocinnamic acid 2-Fluorocyanoxime 
Isonicotinamide 2,4,6-Triaminopyrimidine 
L-Glutamic acid 2,6-Diaminopyridine 
L-Mandelic acid 2,6-Difluorobenzoic acid 
L-Proline 3-Aminobenzoic acid 
L-Serine 3-Aminopyridine 
L-Tartaric acid 3-Benzoylpyridine 
Maleic acid 3-Hydroxypyridine 
Malic acid 3-Nitrobenzoic acid 
Malonic acid 3,4-Dichlorobenzoic acid 
Maltitol 3,5-Dinitrobenzoic acid 
Mannitol 4,4’-Bipyridine 
Nicotinamide 4-Aminobenzoic acid 
Oxalic acid 4-Aminopyridine 
Pamoic acid 4-Benzoylpyridine 
Phosphoric acid 4-Bromocyanoxime 
Piperazine 4-Bromotetrafluorobenzoic acid 
Riboflavin 4-Chloro-2_6-diaminopyrimidine 
Saccharin 4-Cyanobenzoic acid 
Salicylic acid 4-Fluorocyanoxime 
Sorbic acid 4-Hydroxybenzoic acid 
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Succinic acid 4-iodotetrafluorobenzoic acid 
Theophylline 4-Nitrobenzoic acid 
Urea 4-Phenylpyridine 
Xanthine 4,4-Bisphenol 
 4,4'-Dipyridyl 
 4,4'-Trimethylenedipyridine 
 Azelic acid 
 Cyanoxime 
 Dodecanedioic acid 
 Pentafluorobenzoic acid 
 Pimelic acid 
 Sebacic acid 
 Suberic acid 
 
CoForm is a data-driven analysis of already existing targets, which is similar to hydrogen-bond 
propensity (HBP) and molecular complementarity (MC) studied in Chapters 2-5. A comparison 
between CoForm and HBP/ MC methods is summarized in Table 6.2.  
 
Table 6.2. Comparison between HBP/ MC vs. CoForm.   
HBP/ MC CoForm 
 Based on cheminformatics of crystal 
structures present in CSD. 
 Select a sampling dataset which is 
comparable to the defined functional groups 
of the target and co-former. 
 Understand the descriptors on which the 
calculations are based. 
 Each calculation takes 15-20 mins, further 
calculations to find propensity is needed. 
 Based on cheminformatics of 
hydrogen-bond donors and 
hydrogen-bond acceptors. 
 Two inputs required: # of donors and 
# of acceptors. 
 It takes 10- 15 seconds to provide a 
list of co-formers which will likely or 
not likely to form co-crystal. 
 
 
In order to examine the accuracy of CoForm and its potential limitations in predicting co-
crystallization, we carried out a systematic study where we matched the predicted results with the 
experimental outcomes. Two known antihistamine drugs, loratadine, and desloratadine were used 
in this study to predict the co-crystal screening outcomes, Figure 6.2. These targets were chosen 
as they have similar molecular backbone but with different hydrogen-bond donor acceptor ratio. 
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Loratadine has zero hydrogen-bond donors and two acceptors. It does not have any conventional 
homomeric hydrogen-bond interaction. Whereas desloratadine has one donor and one acceptor.  
 
                                               
Figure 6.2. Targets used in this study, a) Loratadine and b) Desloratadine. 
 
The study is carried out to answer the following questions: 
1. Can CoForm predict the co-crystallization outcomes of loratadine and desloratadine? 
2. Can CoForm perform better than commercial and established HBP/ MC methods? 
 
6.2. Co-crystal screening 
 
6.2.1. Experimental co-crystal screening 
 
Loratadine and desloratadine were experimentally screened against 42 GRAS list co-formers. The 
co-former and target was combined in 1:1 stoichiometry with a drop of methanol in a spotting 
plate. The mixture was ground for 30-40 seconds or until the solvent evaporated. The mixture was 
then analyzed using IR spectroscopy. The IR spectra of the target, co-former and the mixtures were 
compared and shifts greater than 3 cm-1 in the C=O stretch was indicated as “YES” to co-
crystallization. The consistent peaks were labeled as “NO” to co-crystallization. 
 
6.2.2. Predicting co-crystal screening using CoForm 
 
The CoForm database, consists of approximately 2000 data points including, both positive and 
negative co-crystallization results. The predictions from CoForm are dependent on the compounds 
present in the database. It is designed as a user-specific tool and can include co-formers and 
interactions that the user is specifically interested in.  
a) 
b) 
 121 
 
CoForm is built using Groovy programming language. Groovy was chosen because it is platform-
independent and, therefore, CoForm can be used on all three major operating systems, i.e., 
Windows, Linux, and Mac OSX. Moreover, Groovy is a scripting language that allows quick 
prototyping of software21. Consequently, we were quickly able to translate our prediction model 
into a prototype. 
CoForm requires three inputs from the user: 
1. Name of the target for which co-crystals need to be predicted. 
2. Number of donors (donor: molecule or molecular fragment X-H in which X is an electronegative 
atom). 
3. Number of acceptors (acceptor: an electronegative element usually N, O, F, occasionally S). 
CoForm ranks the co-formers as highly likely, likely, and least likely to produce a co-crystal with 
a specific target. The output is in the form of tables that can be exported as .csv files, Figure 6.3. 
The most likely and least likely lists, as the name suggests corresponds to the co-formers with the 
highest and lowest probability to form a co-crystal, respectively. The likely lists consist of co-
formers which were found to form co-crystals in some cases and did not form in certain instances. 
This list corresponds to maybes, and hence the co-formers fall between the highly likely and least 
likely lists. Since the co-crystallization outcomes are binary hence, we used the likely list of co-
formers as a YES to co-crystallization. This will produce some false positives, which is a better 
alternative than false negatives.   
 
 
 
 
 
 
 
 
 
 
Figure 6.3. Implementing CoForm for predicting co-crystal outcomes. 
Inputs: 
1) Name of the target 
2) Number of donors 
3) Number of acceptors 
List of co-formers which will 
most likely form co-crystal 
List of co-formers which will 
least likely form co-crystal 
List of co-formers which will 
likely form co-crystal 
 122 
 
6.2.3. Co-crystal screening using hydrogen-bond propensity (HBP) 
 
The detailed description of HBP calculations22,23,24,25,26 was illustrated in section 3.2.1. The 
functional groups used to determine the HBP values for loratadine and desloratadine are listed in 
Figure 6.4. 
 
 
 
 
 
Figure 6.4. Functional groups used in the calculations. 
 
6.2.4. Co-crystal screening using molecular complementarity (MC) 
 
Five conformers of targets and co-formers were generated to conduct MC calculations. The 
detailed description of MC calculations27,28,29 was illustrated in Appendix A. 
 
6.3. Results 
 
6.3.1. Experimental co-crystallization outcomes 
 
Solvent assisted grinding experiments between loratadine and desloratadine and 42 co-formers 
were analyzed using IR spectroscopy, Table 6.3.  
 
Table 6.3. Grinding results of loratadine and desloratadine. 
IR data (cm-1) 
Loratadine Desloratadine 
1699, 1472, 1432, 1381, 1354, 1320, 1273 1584, 1477, 1434, 1419, 1176, 1100, 1085 
Co-former Ground mixture Results Ground mixture Results 
3-Hydroxy-2-naphthoic acid 
1655, 1626, 1597, 1513, 1463, 1439 
1683, 1632, 1591, 1474, 1422, 
1394, 1322, 1276, 1227, 1172 Yes 
1671, 1621, 1588, 1568, 1476, 
1436, 1418, 1384, 1243, 1114 Yes 
4-Hydroxybenzoic acid 
1667, 1605, 1592, 1509, 1445, 1411 
1676, 1600, 1582, 1452, 1420, 
1322, 1278, 1232, 1177, 1124 Yes 
1706, 1619, 1561, 1476, 1437, 
1415, 1383, 1275, 1170, 1097 
Yes 
Adipic acid 
1683, 1461, 1426, 1407, 1267, 1187 
1689, 1477, 1418, 1384, 1326, 
1301, 1277, 1220, 1175, 1112 Yes 
1588, 1566, 1480, 1454, 1376, 
1328, 1297, 1248, 1218, 1139 
Yes 
Apigenin 
1649, 1604, 1586, 1554, 1491, 1442 
1649, 1604, 1586, 1554, 1491, 
1442, 1351, 1267, 1241 No 
1706, 1582, 1567, 1476, 1424, 
1336, 1159, 1116, 1106 
Yes 
Loratadine Desloratadine 
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Benzenesulfonic acid 
1663, 1445, 1092, 1031, 1009, 986 
1730, 1689, 1646, 1578, 1503, 
1426, 1394, 1343, 1304, 1273 Yes 
1731, 1646, 1578, 1540, 1497, 
1455, 1394, 1343, 1246, 1225 
Yes 
Benzoic acid 
1677, 1602, 1581, 1452, 1419, 1323 
1700, 1471, 1430, 1226, 1218, 
1151, 1111, 1066, 1015, 992 Yes 
1425, 1328, 1147, 1100, 1091, 
1075, 1049, 1009, 968, 958 
Yes 
Caffeine 
1694, 1639, 1545, 1454, 1428, 1357 
1691, 1648, 1562, 1418, 1332, 
1220, 1205, 1152, 1112, 995 Yes 
1696, 1646, 1564, 1463, 1436, 
1416, 1332, 1258, 1202, 1150 
Yes 
Cholic acid 
1712, 1247, 1090, 1077, 1043, 979 
1691, 1643, 1425, 1276, 1222, 
1112, 995 Yes 
1621, 1590, 1542, 1507, 1475, 
1437, 1420, 1365, 1341, 1325 
Yes 
Citric acid 
1741, 1691, 1425, 1391, 1358, 1235 
1700, 1698, 1470, 1432, 1360, 
1349, 1278, 1259, 1221 Yes 
1642, 1586, 1566, 1475, 1435, 
1421, 1331, 1282, 1246, 1236 
Yes 
D-Glucuronic acid 
1703, 1456, 1362, 1347, 1249, 1224 
1700, 1430, 1382, 1280, 1227, 
1177, 1112, 1077, 1017, 993 No 
1426, 1280, 1259, 1075, 1018, 
950, 877, 864 
Yes 
EDTA 
1690, 1412, 1386, 1309, 1253, 1092 
1678, 1655, 1639, 1617, 1572, 
1559, 1476, 1445, 1429, 1399 Yes 
1705, 1616, 1576, 1474, 1450, 
1349, 1260, 1198, 1140, 1117 
Yes 
Folic acid 
1688, 1602, 1481, 1451, 1410, 1336 
1688, 1434, 1278, 1219, 1170, 
1097, 1086, 1056, 994 No 
1624, 1567, 1475, 1436, 1422, 
1318, 1081, 1039, 999, 952 
Yes 
Fumaric acid 
1653, 1406, 1315, 1270, 1226, 1172 
1692, 1663, 1642, 1561, 1476, 
1438, 1420, 1220, 1187, 1113 Yes 
1707, 1661, 1560, 1528, 1481, 
1436, 1311, 1282, 1239, 1223 
Yes 
Glutaric acid 
1682, 1466, 1430, 1406, 1301, 1264 
1693, 1559, 1470, 1431, 1321, 
1273, 1219, 1170, 1114, 1081 Yes 
1644, 1560, 1475, 1436, 1421, 
1366, 1270, 1246, 1173, 1083 
Yes 
Glycine 
1607, 1577, 1500, 1441, 1409, 1315 
1678, 1473, 1433, 1384, 1324, 
1277, 1227, 1170, 1094, 1022 No 
1711, 1574, 1476, 1438, 1422, 
1382, 1254, 1171, 1088 
Yes 
Glycolic acid 
1701, 1428, 1226, 1081, 925, 683 
1701, 1428, 1226, 1081, 925, 
683, 884, 850 No 
1655, 1627, 1608, 1578, 1514, 
1476, 1468, 1437, 1382 
Yes 
Hydrocinnamic acid 
1692, 1426, 1406, 1299, 1216, 927 
1695, 1509, 1472, 1430, 1304, 
1224, 1114, 995 Yes 
1581, 1555, 1518, 1477, 1434, 
1396, 1340, 1309, 1154, 1073 
Yes 
Isonicotinamide 
1653, 1621, 1594, 1546, 1388, 1290 
1690, 1635, 1602, 1480, 1417, 
1330, 1275, 1225, 1191, 1177 Yes 
1687, 1661, 1601, 1474, 1438, 
1401, 1332, 1178 
Yes 
L-Glutamic acid 
1641, 1499, 1407, 1350, 1302, 1251 
1689, 1482, 1463, 1381, 1354, 
1320, 1273 Yes 
1716, 1645, 1589, 1579, 1473, 
1421, 1359, 1340 
Yes 
L-Mandelic acid 
1708, 1491, 1455, 1241, 1187, 1096 
1693, 1684, 1638, 1473, 1429, 
1374, 1321, 1272, 1227, 1201 Yes 
1553, 1439, 1417, 1379, 1345, 
1309, 1293, 1264, 1239, 1182 
Yes 
L-Proline 
1608, 1565, 1541, 1473, 1447, 1374 
1649, 1604, 1586, 1554, 1491, 
1442, 1351, 1267, 1241 
 
No 
1554, 1476, 1436, 1421, 1394, 
1332, 1076, 1001, 973, 944 
Yes 
L-Serine 
1582, 1466, 1408, 1382, 1337, 1301 
1696, 1620, 1590, 1540, 1523, 
1508, 1413, 1394, 1383, 1333 
Yes 1585, 1563, 1519, 1506, 1476, 
1438, 1420, 1332, 1272 
Yes 
L-Tartaric acid 
1732, 1706, 1442, 1251, 1211, 1181 
1688, 1654, 1473, 1422, 1382, 
1321, 1275, 1224, 1114, 1084 
Yes 1707, 1561, 1551, 1477, 1439, 
1385, 1231, 1150, 1116 
Yes 
Maleic acid 
1703, 1558, 1458, 1428, 1257, 1216 
1664, 1605, 1586, 1475, 1436, 
1386, 1356, 1276, 1221, 1159 
Yes 1583, 1556,1458, 1440, 1364, 
1267, 1235, 1160 
No 
Malic acid 
1737, 1682, 1438, 1407, 1355, 1279 
1693, 1682, 1650, 1604, 1572, 
1556, 1472, 1421, 1351, 1267 
Yes 1646, 1603, 1571, 1549, 1515, 
1472, 1430, 1359, 1296, 1270 
Yes 
Malonic acid 
1691, 1432, 1387, 1301, 1214, 1163 
1667, 1647, 1420, 1386, 1273, 
1224, 1161, 1112, 1085, 995 
Yes 1703, 1692, 1631, 1577, 1560, 
1437, 1425, 1376, 1355, 1311 
Yes 
Maltitol 
1149, 1047, 1016, 992, 968, 903 
1695, 1472, 1432, 1381, 1354, 
1320, 1273 No 
1584, 1477, 1434, 1419, 1176, 
1100, 1083, 1006, 993 
No 
Mannitol 
1712, 1538, 1455, 1415, 1387, 1251 
1701, 1667, 1466, 1446, 1429, 
1375, 1360, 1222, 1203, 1156 
Yes 1712, 1538, 1455, 1415, 1387, 
1251 
No 
Nicotinamide 
1673, 1617, 1595, 1484, 1421, 1391 
1695, 1415, 1387, 1311, 1277, 
1212, 1166, 1107, 968, 862 
Yes 1882, 1645, 1633, 1579, 1564, 
1440, 1415, 1401, 1379, 1308 Yes 
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Oxalic acid 
1677, 1161, 1128, 826, 779 
1690, 1619, 1586, 1544, 1424, 
1386, 1320, 1276, 1218, 1170 
Yes 1587, 1475, 1434, 1419, 1176, 
1100, 1085 No 
Pamoic acid 
1649, 1452, 1428, 1308, 1290, 1204 
1691, 1652, 1596, 1552, 1473, 
1432, 1356, 1323, 1226 Yes 
1697, 1647, 1546, 1479, 1428, 
1357, 1284, 1237, 1087 Yes 
Phosphoric acid 
N/A 
 
1690, 1676, 1582, 1474, 1434, 
1383, 1278, 1226, 1178, 1112 
Yes 
1581, 1473, 1439, 1422, 1394, 
1369, 1356, 1310, 1272, 1185 
Yes 
Piperazine 
1648, 1456, 1322, 1270, 1127, 1084 
1698, 1645, 1456, 1426, 1383, 
1326, 1277, 1221, 1169 No 
1584, 1477, 1434, 1419, 1176, 
1100, 1085 
No 
Riboflavin 
1730, 1645, 1578, 1536, 1503, 1395 
1730, 1645, 1578, 1536, 1503, 
1395, 1343, 1241, 1178 No 
1730, 1645, 1578, 1536, 1503, 
1395, 1343, 1241, 1178 
No 
Saccharin 
1714, 1591, 1458, 1332, 1295, 1255 
1694, 1649, 1453, 1429, 1306, 
1293, 1206, 1171, 1112, 1093 
Yes 1650, 1639, 1625, 1608, 1579, 
1558, 1508, 1444, 1432, 1384 
Yes 
Salicylic acid 
1652, 1608, 1480, 1440, 1292, 1233 
1674, 1625, 1587, 1463, 1425, 
1384, 1324, 1276, 1219, 1171 
Yes 1682, 1625, 1599, 1560, 1540, 
1469, 1425, 1349, 1260, 1243 
Yes 
Sorbic acid 
1672, 1634, 1608, 1411, 1374, 1314 
1688, 1477, 1432, 1384, 1325, 
1277, 1222, 1173, 1115, 1025 
Yes 1730, 1707, 1654, 1576, 1555, 
1538, 1519, 1505, 1441, 1417 
Yes 
Succinic acid 
1679, 1411, 1307, 1197, 1156, 1131 
1688, 1627, 1579, 1512, 1431, 
1380, 1318, 1276, 1224, 1116 
Yes 1648, 1561, 1512, 1456, 1437, 
1399, 1366, 1314, 1271 
Yes 
Theophylline 
1700, 1659, 1555, 1481, 1441, 1313 
1679, 1624, 1600, 1554, 1475, 
1434, 1275, 1223, 1160, 1112 
Yes 1679, 1651, 1624, 1591, 1553, 
1476, 1436, 1411, 1398, 1364 
Yes 
Urea 
1674, 1590, 1550, 1454, 1148, 1118 
1695, 1670, 1470, 1434, 1226, 
1161, 1120, 1086 
No 1645, 1609, 1591, 1569, 1516, 
1478, 1443, 1388, 1213, 1162 
Yes 
Xanthine 
1692, 1650, 1564, 1454, 1436, 1415 
1695, 1433, 1280, 1225, 1196, 
1168, 1115, 995 
No 1694, 1669, 1615, 1570, 1559, 
1528, 1438, 1422, 1408 
No 
Experimental supramolecular yield  64%  83% 
 
6.3.2. CoForm prediction outcomes 
 
CoForm was used to predict the co-crystal screening outcome for Loratadine and Desloratadine, 
Table 6.4. 
Table 6.4. CoForm co-crystal screening outputs for loratadine and desloratadine. 
Co-former Loratadine Desloratadine 
3-Hydroxy-2-naphthoic acid Yes Yes 
4-Hydroxybenzoic acid Yes Yes 
Adipic acid No Yes 
Apigenin Yes Yes 
Benzenesulfonic acid Yes Yes 
Benzoic acid Yes Yes 
Caffeine Yes Yes 
Cholic acid Yes Yes 
Citric acid Yes Yes 
D-glucuronic acid No Yes 
EDTA Yes Yes 
Folic acid No No 
Fumaric acid No Yes 
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Glutaric acid Yes Yes 
Glycine Yes Yes 
Glycolic acid No No 
Hydrocinnamic acid Yes Yes 
Isonicotinamide Yes No 
L-glutamic acid Yes Yes 
L-mandelic acid No Yes 
L-proline No Yes 
L-serine Yes Yes 
L-tartaric acid Yes Yes 
Maleic acid Yes Yes 
Malic acid Yes Yes 
Malonic acid No Yes 
Maltitol No Yes 
Mannitol Yes Yes 
Nicotinamide Yes Yes 
Oxalic acid No Yes 
Pamoic acid Yes Yes 
Phosphoric acid Yes Yes 
Piperazine Yes Yes 
Riboflavin No Yes 
Saccharin Yes Yes 
Salicylic acid Yes Yes 
Sorbic acid Yes No 
Succinic acid No Yes 
Theophylline Yes Yes 
Urea No No 
Xanthine Yes Yes 
 
6.3.3. HBP prediction outcomes 
 
HBP was used to predict the co-crystal screening outcomes, Table 6.5. 
Table 6.5. Hydrogen-bond propensity (HBP) calculations for loratadine and desloratadine. 
Co-former Homomeric 
interactions 
Heteromeric 
interactions 
=Hetero-
Homo 
Homomeric 
interactions
Heteromeric 
interactions
=Hetero-
Homo
3-Hydroxy-2-
naphthoic acid 0.23 0.47 0.24 0.4 0.31 -0.09 
4-Hydroxybenzoic acid 0.28 0.51 0.23 0.35 0.41 0.06 
Adipic acid 0.42 0.66 0.24 0.45 0.45 0 
Apigenin 0.31 0.41 0.1 0.4 0.4 0 
Benzenesulfonic acid 0.47 0.59 0.12 0.47 0.47 0 
Benzoic acid 0.27 0.43 0.16 0.35 0.35 0 
Caffiene - - N/A 0.25 0.8 0.55 
Cholic acid 0.45 0.64 0.19 0.54 0.6 0.06 
Citric acid 0.33 0.53 0.2 0.37 0.52 0.15 
D-glucuronic acid 0.53 0.56 0.03 0.49 0.53 0.04 
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EDTA 0.4 0.67 0.27 0.42 0.45 0.03 
Folic acid 0.56 0.7 0.14 0.54 0.45 -0.09 
Fumaric acid 0.46 0.59 0.13 0.42 0.41 -0.01 
Glutaric acid 0.43 0.67 0.24 0.45 0.44 -0.01 
Glycine 0.64 0.72 0.08 0.67 0.53 -0.14 
Glycolic acid 0.53 0.6 0.07 0.54 0.6 0.06 
Hydrocinnamic acid 0.37 0.58 0.21 0.35 0.35 0 
Isonicotinamide 0.56 0.47 -0.09 0.58 0.4 -0.18 
L-glutamic acid 0.56 0.7 0.14 0.6 0.52 -0.08 
L-mandelic acid 0.34 0.58 0.24 0.44 0.51 0.07 
L-proline 0.49 0.59 0.1 0.45 0.47 0.02 
L-serine 0.62 0.62 0 0.61 0.61 0 
L-tartaric acid 0.42 0.61 0.19 0.45 0.54 0.09 
Maleic acid 0.45 0.59 0.14 0.42 0.41 -0.01 
Malic acid 0.45 0.62 0.17 0.48 0.55 0.07 
Malonic acid 0.5 0.67 0.17 0.5 0.44 -0.06 
Maltitol 0.74 0.68 -0.06 0.7 0.76 0.06 
Mannitol 0.36 0.48 0.12 0.38 0.59 0.21 
Nicotinamide 0.57 0.48 -0.09 0.58 0.4 -0.18 
Oxalic acid 0.17 0.21 0.04 0.41 0.28 -0.13 
Pamoic acid 0.22 0.48 0.26 0.43 0.33 -0.1 
Phosphoric acid 0.87 0.53 -0.34 0.86 0.82 -0.04 
Piperazine 0.62 0.58 -0.04 0.47 0.41 -0.06 
Riboflavin 0.66 0.5 -0.16 0.66 0.55 -0.11 
Saccharin 0.44 0.46 0.02 0.41 0.33 -0.08 
Salicylic acid 0.25 0.5 0.25 0.41 0.34 -0.07 
Sorbic acid 0.44 0.58 0.14 0.41 0.4 -0.01 
Succinic acid 0.44 0.67 0.23 0.46 0.42 -0.04 
Theophylline 0.26 0.32 0.06 0.33 0.49 0.16 
Urea 0.97 0.93 -0.04 0.97 0.84 -0.13 
Xanthine 0.67 0.5 -0.17 0.64 0.56 -0.08 
 
6.3.4. MC prediction outcomes 
 
MC was used to predict the co-crystal screening outcomes, Table 6.6. 
Table 6.6. Molecular Complementarity (MC) calculations for loratadine and desloratadine. 
Co-former Loratadine hit rate % Desloratadine hit rate % 
3-Hydroxy-2-naphthoic acid 50 50 
4-Hydroxybenzoic acid 0 0 
Adipic acid 84 0 
Apigenin 0 0 
Benzenesulfonic acid 0 0 
Benzoic acid 0 0 
Caffiene 20 0 
Cholic acid 60 0 
Citric acid 0 0 
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D-glucuronic acid 0 0 
EDTA 0 0 
Folic acid 100 0 
Fumaric acid 0 0 
Glutaric acid 67 67 
Glycine 0 0 
Glycolic acid 0 0 
Hydrocinnamic acid 0 0 
Isonicotinamide 84 60 
L-glutamic acid 0 0 
L-mandelic acid 0 0 
L-proline 100 100 
L-serine 60 100 
L-tartaric acid 0 0 
Maleic acid 0 0 
Malic acid 0 0 
Malonic acid 0 0 
Maltitol 0 0 
Mannitol 0 0 
Nicotinamide 20 0 
Oxalic acid 0 0 
Pamoic acid 0 0 
Phosphoric acid 100 100 
Piperazine 0 0 
Riboflavin 100 100 
Saccharin 64 90 
Salicylic acid 60 25 
Sorbic acid 50 50 
Succinic acid 20 0 
Theophylline 0 0 
Urea 0 0 
Xanthine 0 0 
Supramolecular yield 31% 21% 
 
6.4. Discussions 
 
6.4.1. Current stage of CoForm  
 
CoForm, HBP, and MC were used to predict the potential co-crystallizing partners for loratadine 
and desloratadine. The accuracy of the predicting approaches was determined by calculating a 
success rate, which is the number of predictions that match the experimental results over the total 
number of predictions. CoForm produced a prediction success rate of 80%, HBP predicted 76% of 
the co-crystallization outcomes correctly and, MC 39%.  The true positives and true negatives were 
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analyzed separately. We displayed the results in a confusion matrix, Figure 6.5. Each cell in the 
figure is defined as follows: 
True positive: Prediction and experiment agree on successful co-crystallization partners. 
True negative: Prediction and experiment agree on failed co-crystallization partners.  
False positive: Prediction and experiment do not agree on successful co-crystallization 
partners.  
False negative: Prediction and  experiment do not agree on failed co-crystallization partners. 
  
Figure 6.5. Correlation between the experimental and predicted outcomes for loratadine. 
 
CoForm exhibits 80% accuracy for true positives and 72% for true negatives. HBP delivered 86% 
correctness for true positives and 45% for true negatives. The true positive results by HBP are 
comparable to that of CoForm however, with a very low accuracy for true negatives. MC delivered 
very low accuracies of 26% for true positives and 63% for true negatives. The prediction success 
rates of HBP and MC followed similar trends as we observed in Chapter 4. Individually both the 
methods were not very reliable for co-crystallization screening experiments.  
Similar comparisons using confusion matrices were carried out for desloratadine, and the 
correlation between the prediction and experimental outcomes are listed in Figure 6.6. 
True Positive
24/30
False Negative
5
False Positive
4
True negative
8/11
True Positive
26/30
False Negative
3
False Positive
6
True negative
5/11
True Positive
8/30
False Negative
22
False Positive
4
True negative
7/11
CoForm
Hydrogen Bond Propensity Molecular Complementarity
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Figure 6.6. Correlation between the experimental and predicted outcomes for desloratadine. 
 
CoForm displays 89% accuracy for true positives but could not predict any true negatives 
correctly. For HBP, the correctness for true positive was 50% and for true negative 60%. Finally, 
MC gave a 16% success for true positive and 60% for true negative.  
Overall for both loratadine and desloratadine, CoForm produced higher success rates for true 
positives than true negatives. When we compared the ratio of true positives to true negatives in 
our database, we found that there is a total of 373 positive co-crystals and 119 negative co-crystals 
results. The positive partners accounts for 76% in comparison to 24% for the negative partners 
which accounts for the imbalance in the prediction outcomes. Unfortunately, at this point, we could 
not add more failed co-crystallization experiments in our database. 
Table 6.7. summarizes the overall prediction abilities of the three methods in comparison to 
experimental results.  
 
Table 6.7. Success rates for predicting the co-crystal formation. 
Compounds Method Success rate 
Loratadine 
CoForm 33/41= 80% 
HBP 31/41= 76% 
MC 16/41= 39% 
Desloratadine 
CoForm 33/41= 80% 
HBP 22/41= 54% 
MC 9/41= 22% 
 
 
True Positive
32/36
False Negative
5
False Positive
4
True negative
0/5
True Positive
18/36
False Negative
18
False Positive
2
True negative
3/5
True Positive
6/36
False Negative
30
False Positive
2
True negative
3/5
CoForm
Hydrogen Bond Propensity Molecular Complementarity
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6.4.2. Evolution of CoForm  
 
The CoForm database currently consists of 2000 data for small molecules and approximately 500 
data for co-formers from the GRAS list. For CoForm to deliver results with high accuracy, we 
need to add more co-crystallization results. Additionally, the database only consists of hydrogen-
bond driven target and co-former pairs. In order to make CoForm more versatile, we have to ensure 
that other non-covalent interactions (such as halogen and chalcogen bonds) that drive the co-
crystallization experiments are also added into the database. We also plan to incorporate machine 
learning approaches to further benefit the prediction abilities of CoForm.  
Having said that, CoForm is designed as a user-specific tool and will produce the most reliable 
outcomes, if the unknown target is a close match (similar molecular weight, rotatable bonds, 
functional groups) to the known targets in the database. Therefore, having a user-specific database 
could increase the accuracy of CoForm.  The user specificity of CoForm also extends its usability 
not only in pharmaceutics, agrochemicals, energetics, but any field where physical properties play 
an important role.   
 
6.5. Conclusions 
 
We attempted to develop a fast and user-friendly software application to facilitate co-
crystallization screening experiments. We hope this tool will be widely adopted and used by both 
academic and industrial scientists interested in the crystalline solid-state, especially in the context 
of improving physical properties. 
1. CoForm could predict the results with 80% accuracy for loratadine and 80% for desloratadine. 
2. HBP produced a success rate of 76% and 54% for loratadine and desloratadine, respectively;  
    whereas MC delivered a very low success of 39% and 22% each.  
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Chapter 7 – Molecular Recognition by Cavitands via Cavity 
Inclusion 
 
7.1. Introduction 
 
Supramolecular chemistry deals with the assembly of multifunctional molecules to form complex 
architectures through reversible non-covalent interactions1. Inspiration often comes from nature’s 
use of these interactions in molecular recognition for biological processes2,3. Supramolecular 
chemistry has advanced from small molecular building blocks to larger aggregates contributing in 
various fields such as nanotechnology, selective transport4, sensors, drug delivery5, selective 
separation6, etc. In the previous chapters we explored different strategies to form solid-state 
architectures using hydrogen and halogen bonds on small molecules (molecular weight 250-600 
g/mol). In this chapter we attempted to extend our understanding of such interactions on larger 
molecular hosts such as, cavitands (molecular weight 950-1150 g/mol). 
Cavitands are bowl shaped macromolecules introduced by Cram in 19827,8. Cram defined 
cavitands as “molecules that contained enforced cavities large enough to accommodate simple 
molecules or ions”. Resorcinarene based cavitands can act as versatile molecular containers9,10,11 
since the defined space, volume and functional groups can be modulated. These containers can 
encapsulate guests like cations12, anions, and solvents through a variety of intermolecular 
interactions. This has made cavitands useful receptors with particular attention in molecular 
catalysis9, molecular sensing13,14,15,16, stabilization of reaction intermediates17,18, gas capsulation19, 
and photosensitizers20,21. Furthermore, the “nanospace” with these cavitands have unique well-
defined size, volume and chemical characteristics that are well suited for incorporating 
complementary guest molecules inside.  
The structural framework of a cavitand can be divided into four different parts: feet, body, bridge 
and rim, Figure 7.1. The lower end of the cavitand, the “feet” mostly consists of carbon and 
hydrogen. Covalent modifications to the feet alter solubility22,23. The middle part of the cavitand, 
the body, which is electron rich,24,25 can encapsulate electron deficient guest molecules. The 
bridging group determines the width of the cavity26,27,28. Finally, the rim is the top part of the 
cavitand. A cavitand bears four positions on the rim which on functionalization can offer four 
binding sites to complementary guest molecules per one host molecule. 
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Figure 7.1. Structural framework of a cavitand. 
 
Cavitands are known as versatile hosts since each structural feature of the cavitand can deliver 
characteristic host-guest interactions. In this study we focus our efforts on investigating the cavity 
of the cavitand. Figure 7.2 illustrates different ways cavitand can interact with a guest molecule at 
the cavity. 
 
Figure 7.2. Cartoon representation of five possible guest binding modes to a cavitand. 
 
In order to explore binding capabilities of the cavity without involving the rim, we specifically 
designed cavitands where the rim does not participate in any conventional hydrogen/ halogen 
Path B Path C Path D Path EPath A
Bridging group 
Rim 
Body 
Feet 
Polar group 
Non-polar group 
 - cloud 
Bridging group 
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bonds. Therefore, for guest encapsulation to take place, complementarity between the host cavity 
and guest is crucial. The difference in the size, shape and dipole moment of the guest can possibly 
determine the selectivity.  
We selected a series of isostructural cavitands where the upper rim of the target cavitand T18 is 
bromo-functionalized and T19 is iodo-functionalized Scheme 7.1. Target cavitands T20- T23 are 
deeper cavitands29 in comparison to T18-T19 due to the presence of triple bonds on the rim.  
 
Scheme 7.1. Target cavitands (R=hexyl). 
 
A series of solvent molecules with varied dipole moment were selected as guests, in order to 
explore the binding ability of the cavitands., Table 7.1. We conducted selectivity studies to 
examine if the cavitands are particularly biased towards encapsulating any solvent.  
 
 
 
T11 T12
T13 T14 T15
T16
T18 T19
T20 21 22
T23
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Table 7.1. Solvents of choice. 
 
 
The study is done to answer the following questions: 
1. Will the solvent encapsulation by isostructural hosts, T18 and T19 remain consistent? 
2. Will the depth of the cavity effect where the solvent is encapsulated? 
3. Will the dipole moment effect the location of the solvent in the cavitand? 
 
7.2. Experimental  
 
All chemicals were purchased from Aldrich, Fischer, TCI America, Oakwood and Alfa Aesar and 
used without further purification unless otherwise mentioned. Column chromatography was 
carried out using silica gel (150 Å pore size) from Analtech, Inc. 1H and 13C NMR spectra were 
recorded on Varian Unity plus 400 MHz spectrometer in CDCl3 or DMSO. The NMR data is in 
parts per millions (ppm) with downfield shift from tetramethylsilane which is an internal reference. 
Nicolet 380 FT-IR was used for infrared spectroscopy and the data was analyzed using Omnic 8.0 
Thermo Fischer Scientific Inc. software. DSC and TGA analysis were done using TA instruments 
Q20 and Q50, respectively.  
 
 
 
 
 
 
 
 
Dipole moment 0.64            0.37             0.00 1.15 1.88 3.44 4.10
Xylenes Dichloromethane Ethyl acetate Acetonitrile Dimethyl sulfoxide
Debye 
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7.2.1. Syntheses 
 
7.2.1.1. Synthesis of C-hexylcalix[4]resorcinarene, 130 
 
 
To a solution of resorcinol (50.0 g, 450 mmol) dissolved in ethanol (500 mL), heptanal (45.5 g, 
450 mmol) was added. The mixture was cooled to 0 oC under dinitrogen atmosphere and conc. 
HCl (70 mL) was added dropwise over 15-20 mins. The mixture was refluxed at 70 oC for 16 - 24 
hrs. The reaction was monitored using thin layer chromatography (TLC). Upon completion, the 
reaction mixture was allowed to cool to room temperature and diluted with water (500- 700 mL) 
to obtain a dark brown/ orange precipitate. The precipitate was filtered using Buchner funnel and 
washed with hot water until a neutral pH was obtained. The product was air dried overnight and 
further dried in an oven set at 100 oC further for 24 hrs to yield 1 (75 g, 87% yield). 
M.P.: > 280 ºC. 1H NMR (400MHz, DMSO-d6): 8.84 (s, 8H), 7.11 (s, 4H), 6.12 (s, 4H), 4.19 (t, J 
= 7.6Hz, 4H), 2.49 (m, 8H), 1.97-1.19 (m, 24H), 0.84 (t, 12 H, J=6.4Hz). 
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7.2.1.2. Synthesis of C-hexyltetrabromocalix[4]resorcinarene, 231 
 
 
C-hexylcalix[4]resocinarene, 1 (50.0 g, 65.0 mmol) was added to the flask containing 2-butanone 
(400 mL) cooled to 0 oC and covered with aluminum foil. The solution was stirred for 10-15 mins 
under dinitrogen atmosphere. Under dark conditions, N-bromosuccinamide (69 g, 390 mmol) was 
slowly added in small portions for a period of 30 mins. The condenser was attached, and the 
reaction was stirred at room temperature for 16- 24 hrs. The reaction was monitored using TLC. 
The precipitate formed in the reaction was filtered using Buchner filtration and washed with cold 
2-butanone (3 X 50 mL), then with cold acetone (3 X 100 mL) to yield 2. Product 2 was air dried 
and then dried in an oven at 100 oC to produce white solid (52 g, 78% yield). 
M.P.: > 280 ºC. 1H NMR (400MHz, DMSO-d6): 9.07 (s, 8H), 7.32 (s, 4H), 4.33 (t, J = 6.4Hz, 4H), 
2.12 (m, 8H), 1.22 (m, 24H), 0.82 (t, J = 7.2Hz, 12H). 
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7.2.1.3. Synthesis of C-hexyltetrabromocavitand, T1832 
 
 
To a stirred solution of C-hexyltetrabromocalix[4]resorcinarene, 2 (40.0 g, 31.0 mmol) dissolved 
in DMF (500 mL), K2CO3 (60 g, 435 mmol) was added under dinitrogen atmosphere. 
Bromochloromethane (55 g, 415 mmol) was added to the reaction mixture after 20-30 mins. A 
condenser was added, and the solution was heated at 65 oC for 24 hrs. After 24 hrs an additional 
amount of bromochloromethane (7.00 g, 55.0 mmol) was added and the mixture was further stirred 
at 65 oC for 24 hrs. The reaction was monitored using TLC. After completion, the reaction was 
cooled to room temperature and poured slowly into an aqueous HCl solution (2%, 650 mL). The 
solid was filtered off and washed with water until neutral pH was obtained. Additionally, the water 
layer was extracted using dichloromethane and the solid obtained after rotavap was added to the 
solid filtrate. The combined solids were then purified using column chromatography using hexane: 
ethyl acetate 9:1 mixture as an eluent. The product T18 was isolated as a white solid (24 g, 77% 
yield). 
M.P.: > 280 ºC. 1H NMR (400MHz, CDCl3): 7.03 (s, 4H), 5.95 (d, J = 7.4Hz, 4H), 4.85 (t, J = 
7.6Hz, 4H), 4.38 (d, J = 7.2Hz, 4H), 2.21 (m, 8H), 1.29 (m, 24H), 0.90 (t, 12H).  
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7.2.1.4. Synthesis of C-hexyltetraiodocavitand, T19 
 
C-hexyltetrabromoresorcinarene, T18 (10.0 g, 31.0 mmol) was dissolved in dry THF (10 mL) and 
the solution was evaporated and dried at 80 oC for 2 hrs under dinitrogen atmosphere using the 
Schlenk line. This procedure was repeated twice. The resulting solid was dissolved in dry THF (60 
mL) and cooled to -78 oC (dry ice/ acetone bath) under dinitrogen atmosphere for 30 mins. To the 
solution n-BuLi (1.6 M in hexanes, 2.5 mL, 4.00 mmol) was added dropwise for 30 mins and 
additionally stirred for an hour. Iodine dissolved in methanol was added dropwise in excess to the 
solution until the solution turned light yellow. The solution was stirred additionally for 2 hours, 
and the dry ice/ acetone bath was removed for the reaction mixture to reach room temperature. 
Upon reaching room temperature, the reaction was quenched with saturated solution of sodium 
thiosulfate (100 mL). The mixture was extracted using dichloromethane three times which was 
filtered and brought to dryness using rotavap to yield white solid (9.50 g, 98% yield). 
M.P.: > 280 ºC. 1H NMR (400MHz, CDCl3): 7.06 (s, 4H), 5.96 (d, J = 7.4Hz, 4H), 4.85 (t, J = 
7.6Hz, 4H), 4.33 (d, J = 7.2Hz, 4H), 2.19 (m, 8H), 1.34 (m, 24H), 0.91 (t, 12H).  
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7.2.1.5. Synthesis of C-hexyltetra((trimethylsilyl)ethynyl)cavitand, T2033 
 
 
C-hexyltetraiodoresorcinarene, T19 (4.00 g, 3.55 mmol) was dissolved in triethylamine (TEA) and 
degassed by bubbling dinitrogen through the reaction mixture for 20-30 mins. TMS-acetylene 
(1.74 g, 17.80 mmol), PdCl2(PPh3)2 (0.20 g, 0.35 mmol) and CuI (0.13 g, 0.71 mmol) were added 
to the mixture. The resulting mixture was refluxed at 70- 80 oC overnight under dinitrogen 
atmosphere. The reaction was monitored using TLC. Upon completion the solvent was evaporated 
using rotavap and the residue was dissolved in diethyl ether and washed with brine solution (100- 
200 mL). The organic layer was extracted thrice and dried over anhydrous magnesium sulfate. The 
solvent was removed using rotavap and the residue was purified by column chromatography with 
hexane: ethyl acetate 9:1 mixture as eluant to obtain T20 (3.00 g, 77% yield), a light yellow solid.  
M.P.: > 280 ºC. 1H NMR (400MHz, CDCl3): 7.01 (s,4H), 5.94 (d, J= 7.2Hz, 4H), 4.83 (t, J = 
7.6Hz, 4H), 4.38 (d, J = 8.4Hz, 4H), 2.17 (m, 8H), 1.89 (m, 24H), 0.86 (t, 12H), 0.16 (s, 36H). 
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7.2.1.6. Synthesis of C-hexyltetra(ethynyl)cavitand, T2134 
 
 
C-hexyltetra((trimethylsilyl)ethynyl) cavitand, T20 (5.00 g, 4.45 mmol) and potassium carbonate 
(2.50 g, 18.00 mmol) were stirred in methanol at room temperature for 2- 4 hrs. Upon completion 
the solvent was removed by rotavap and the solid was dissolved in diethyl ether and washed with 
water. The organic layer was dried using anhydrous magnesium sulfate and the solvent was 
removed via rotavap to obtain the product T21 (3.2 g, 79% yield), a light yellow solid.  
M.P.: > 280 ºC. 1H NMR (400MHz, CDCl3): 7.03 (s, 4H), 5.95 (d, J = 6.8Hz, 4H), 4.85 (t, J = 
7.4Hz, 4H), 4.40 (d, J = 8.2Hz, 4H), 4.11 (s, 4H), 2.21 (m, 8H), 1.24 (m, 24H), 0.90 (t, 12H). 
 
7.2.1.7. Synthesis of C-hexyltetra(iodoethynyl)cavitand, T22 
 
 
To a solution of C-hexyltetra(ethynyl) cavitand T21 (1.00 g, 1.20 mmol) dissolved in methanol 
(50 mL), a concentrated solution of iodine in methanol (2.00 g, 7.87 mmol) was added dropwise; 
simultaneously followed by addition of 10% sodium hydroxide for 30 mins. The solution was 
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vigorously stirred and the NaOH was added until the final solution turned brown/ yellow. The 
solution was stirred overnight and quenched with 100 mL water upon which light yellow color 
precipitate was formed. The solid was filtered and washed with sodium bisulfite which afforded 
T22 (0.80 g, 75% yield). 
M.P.: > 280 ºC. 1H NMR (400MHz, CDCl3): 7.06 (s, 4H), 5.98 (d, J = 7.2Hz, 4H), 4.85 (t, J = 
7.4Hz, 4H), 4.32 (d, J = 7.2Hz, 4H), 2.17 (m, 8H), 1.55 (m, 24H), 0.89 (t, 12H). 
 
7.2.1.8. Synthesis of C- hexyltetraboronic acid dipinacolyl ester cavitand, T2335 
 
 
C-hexyltetrabromoresorcinarene, T18 (1.00 g, 0.09 mmol) was dissolved in dry THF (10 mL), the 
solution was evaporated and dried at 80 oC for 2 hrs under dinitrogen atmosphere using Schlenk 
line. This procedure was repeated twice. The resulting solid was dissolved in dry THF (60 mL) 
and cooled at -78 oC (dry ice/ acetone bath) under dinitrogen atmosphere for 30 mins. To the 
solution n-BuLi (1.6 M in hexanes, 2.5 mL, 4.00 mmol) was added dropwise for 30 mins and 
additionally stirred for an hour. Trimethoxyborane (0.60 mL, 5.30 mmol) was added dropwise 
over 10 mins and the resulting solution was stirred at -78 oC for an hour, after which the dry ice/ 
acetone bath was removed, and the solution was allowed to reach room temperature. Upon 
reaching the room temperature the mixture was quenched with 1M hydrochloric acid (HCl) and 
stirred for 30 mins. The mixture was extracted using dichloromethane (DCM) and the organic 
layer was dried over magnesium sulfate and the solvent removed using rotavap. The resulting 
residue was dissolved in DCM (100 mL), excess pinacol (750 mg, 6.30 mmol) and magnesium 
sulfate (3.00 g) was added and the mixture was stirred overnight. Upon completion the mixture 
was filtered, and the solvent was dried using rotavap. The resulting residue was dissolved in DCM 
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and added to a beaker of acetone to induce precipitation. The resulting solid was filtered resulting 
in pure T23, a white flaky solid (600 mg, 55% yield).  
M.P.: > 280 ºC. 1H NMR (400MHz, CDCl3): 7.10 (s, 4H), 5.57 (d, J = 6.8 Hz, 4H), 4.74 (t, J = 7.2 
Hz, 4H), 4.53 (d, J = 7.6 Hz, 4H), 2.17 (m, 8H), 1.56-1.31 (m, 72H ), 0.86 (m, 12H). 
 
7.2.2. Preparation of the host-guest complexes  
 
The host-guest encapsulations studies were carried out by dissolving the host in guest solvents. 
After which we attempted to grow single crystals, by slow evaporation technique. The single 
crystal was then analyzed using thermogravimetric analysis (TGA) followed by single crystal X-
ray diffraction, Scheme 7.2. 
 
Scheme 7.2. Schematic representation of the steps involved. 
 
7.2.3. Thermogravimetric analysis (TGA) of target cavitands recrystallized from the 
solvents 
 
TGA analysis of the recrystallized hosts were performed to confirm the presence or absence of 
solvent in the crystal lattice. A mass of a sample was measured over time with gradual increase in 
the temperature. The weight loss observed was compared with the weight of the solvent molecules, 
to find the number of solvents present in the crystal lattice.   
 
7.2.4. Single crystal X-ray crystallography 
 
The target cavitand was dissolved in a minimum amount of guest solvent in a 2-dram borosilicate 
vial for slow evaporation in order to obtain single crystals for X-ray diffraction. In cases were slow 
evaporation failed, vapor diffusion, and anti-solvent crystallization techniques were employed. 
Guest  
+
Crystal growth
Single crystal XRDThermal gravimetric analysis
Host
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The single crystal X-ray crystallographic data was collected for each instance. The detailed 
description is illustrated in section 2.2.4.  
 
7.3. Results  
 
7.3.1. Thermogravimetric analysis (TGA) of target cavitands recrystallized from the 
solvents  
 
Figure 7.3. illustrates TGA analysis of the target cavitand T18 recrystallized from ethyl acetate. 
The weight loss is 14% at around 300 oC, which suggests that the solvents are not loosely bound 
to the cavitand. Loss of one ethyl acetate corresponds to 7.4% weight loss indicating that in this 
instance there was loss of two solvent molecules. Since the experiments were not done in dry 
conditions, water molecule weight% was always considered in these calculations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3. TGA of T18 recrystallized from ethyl acetate. 
 
Similar TGA analysis was done for all the target cavitands recrystallized from solvents. Table 7.2. 
summarizes the number of solvent molecules encapsulated by the cavitands w.r.t the weight loss 
shown in the TGA. See Appendix C for all the TGA data. 
Theoretical calculations: 
One EtOAc molecule = 7.4% 
One water molecule= 1.5% 
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Table 7.2. TGA data analysis of the target cavitands recrystallized from solvents. 
 
7.3.2. Single crystal X-ray crystallography 
 
We were able to get 13 crystal structures out of 30 combinations of cavitands and solvents. The 
crystallographic tables are listed in Appendix E. We got crystal structures of T18 with all five 
solvents, Figure 7.4. In T18:xylene, xylene was not present in the cavity of the cavitand rather was 
present as a part of crystal packing, exocyclically. Recrystallizing T18 in DCM, we did not observe 
the presence of any solvent molecules and the host were absolutely vacant. With T18:(EtOAc)2 
we observed 1:2 stoichiometry between the host and solvent. The solvent molecules were located 
at the rim as well as around the feet of the cavitand. In T18:ACN, the ACN was present around 
the feet of cavitand. Finally, with DMSO T18 shows similar binding and stoichiometry as that of 
ACN. 
 Xylene DCM Ethyl acetate ACN DMSO Mixture of solvents 
T18 1 0 2 1 1 1 DMSO 
T19 1 0 2 1 1 1 DMSO 
T20 1 1 2 1 2 2 DMSO 
T21 1 1 2 1 2 2 DMSO 
T22 1 1 2 1 2 2 DMSO 
T23 1 1 2 1 2 2 DMSO 
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Figure 7.4. Crystal structures of T18 recrystallized from different solvents (color codes: red-
oxygen, mustard -bromine, violet-iodine, yellow-sulfur, grey-carbon, white-hydrogen). 
 
With T19 we were able to get three crystal structures. In T19:xylene, xylene was present around 
the feet of the cavitands. For T19 recrystallized from DCM we only obtained T19 by itself and no 
solvent in the cavity. For T19:DMSO, we observed 1:1 stoichiometry with DMSO located at the 
rim of the cavitand, Figure 7.5. 
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Figure 7.5. Crystal structures of T19 recrystallized from different solvents (color codes: red-
oxygen, mustard -bromine, violet-iodine, yellow-sulfur, grey-carbon, white-hydrogen). 
 
The isostructural deeper cavitands T20-T23, demonstrated similar stoichiometries between host 
and solvents according to TGA analysis. We were able to get one crystal structure of T21 with 
DMSO, where the solvent molecules were located both around the rim and feet, Figure 7.6. 
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Figure 7.6. Crystal structures of T20-T23 recrystallized from different solvents (color codes: 
red-oxygen, mustard -bromine, violet-iodine, yellow-sulfur, grey-carbon, white-hydrogen). 
 
7.4. Discussions  
 
7.4.1. Solvent-Xylene 
 
The solvent xylene was present as a mixture of ortho, meta, para isomer. TGA analysis of T18-
T23 in combination with xylene displays 1:1 stoichiometry. We obtained single crystals of T18 
and T19 with xylene, which also show a 1:1 stoichiometry. In T18, xylene was not present in the 
cavitand, rather it participates in the packing arrangement. T18 specifically encapsulates ortho-
xylene. For T19, xylene was present around the feet of the cavitand and specifically encapsulates 
meta-xylene, Figure 7.7.  
DCM EtOAcXylene
TGA analysis
T20-T23:Xylene
TGA analysis
T20-T23:DCM
TGA analysis
T20-T23:(EtOAc)2
T20-T23
ACN DMSO
TGA analysis
T20-T23:ACN
TGA analysis
T20-T23:(DMSO)2
I
T21:(DMSO)2
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Figure 7.7. Packing of T18 and T19 with xylene (color codes: red-cavitands, green-xylene). 
 
In T18 since xylene interacted exocyclically, we observed “foot-in-the-mouth” kind of packing 
where foot of one cavitand was present in the mouth of other cavitand in order to fill the empty 
cavity space, Figure 7.8. For T19:xylene, xylene was present around the feet with empty space 
around the rim which was fulfilled by the foot of the neighboring cavitand molecule, Figure 7.8.  
 
Figure 7.8. Packing of T18 and T19 with xylene (color codes: red-cavitands, green-xylene). 
 
To understand the difference of the guest encapsulation between T18:xylene and T19:xylene, we 
measured the cavity size and overlay the structures. The size of the cavity for T18 and T19 were 
consistent with a negligible difference of 0.004 Å, Figure 7.9. However, the structure overlay 
shows that, the feet of T18 has less space to accommodate xylene in comparison to T19, where 
T18:Xylene
Foot in the mouth
Foot in the mouth
T19:Xylene
Foot in the mouth
Foot in the mouth
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the feet curves out to make enough space for xylene encapsulation. Xylene is composed of carbon 
and hydrogen hence, it chooses to be around the feet, which is the non-polar part of the cavitand. 
TGA analysis of T20-T23 also shows 1:1 stoichiometry with xylene. Although, we were unable 
to obtain single crystals, we assume that the structures will be similar to T19:xylene.  
 
 
Figure 7.9. a) Top and bottom view of T18; b) Top and bottom view of T19; c) structure overlay 
of T18 and T19 (color codes: red-oxygen, yellowish green-boron, grey-carbon, white-hydrogen). 
 
7.4.2. Solvent-dichloromethane (DCM) 
 
TGA analysis of T18 and T19 with DCM shows no solvents in the cavitand, whereas with T20-
T23 gave 1:1 stoichiometry. We received crystal structures of T18 and T19 recrystallized from 
DCM. In both cases, the cavitands were vacant. The “foot-in-the-mouth” kind of packing remained 
consistent as we observed in T18/T19:xylene. For T18, the body was oriented at 180o to each 
other, whereas for T19 the body was at 90o, Figure 7.10. The arrows at the bottom of the Figure 
7.10, indicate the packing pattern observed in the crystal lattice. The arrowhead corresponds to the 
rim of the cavitand. 
Top
Top
Bottom
Bottom
7.648
7.689
5.238
5.295
T18:Xylene
T19:Xylene
T18 and T19 structure overlay
Yellow T18 and Green T19 
a)
b)
c)
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Figure 7.10. Packing of T18:DCM and T19:DCM (color codes: red-oxygen, brown-bromine, 
violet-iodine grey-carbon, white-hydrogen). 
 
For the deeper cavitands, T20-T23 we saw a 1:1 stoichiometry with DCM as indicated by TGA 
analysis. To examine the difference in the depth of the cavitands, we measured diagonally from 
top of the rim to the bottom of the body i.e. hydrogen on the aromatic ring, Figure 7.11. The 
difference between the depth of the T18 and T21 cavitands was around 2Å; for T18 and T20 was 
2.06 Å; for T21 and T20 was same with negligible difference of 0.07 Å. Since the deeper cavitands 
has more rim space, we assume that in these cases, the solvent will most likely be located around 
the rim.  
 
Figure 7.11. Difference in the depth of the cavitands T18, T21 and T20 (color codes: red-
oxygen, brown-bromine, yellowish green-boron grey-carbon, white-hydrogen). 
T18:DCM
T19:DCM
T18
T21
10.718.75
T20
10.77
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7.4.3. Solvent-ethyl acetate (EtOAc) 
 
TGA analysis of T18-T23 with EtOAc, shows 1:2 stoichiometry. The single crystal structure of 
T18:(EtOAc)2 shows presence of two solvent molecules, one at the top of rim and the other at the 
feet of the cavitand. Since the rim of the cavitand was occupied by ethyl acetate, the molecular 
packing arrangement no longer follows “foot-in-the-mouth” kind of packing. The body is oriented 
at 180o from each other, Figure 7.12. For all other combinations of cavitand and ethyl acetate, we 
were not able to get crystal structures. TGA analysis of T19-T23 with EtOAc demonstrates 1:2 
stoichiometry. In order to accommodate two EtOAc in the cavity it has to follow similar solvent 
encapsulation as we observed for T18.  
 
Figure 7.12. Packing of T18:(EtOAc)2 (color codes: red-oxygen, brown-bromine, grey-carbon, 
white-hydrogen, green-EtOAc). 
 
7.4.4. Solvent -acetonitrile (ACN) 
 
TGA analysis of T18-T23 with ACN indicates 1:1 stoichiometry. We obtained a crystal structure 
of T18 recrystallized from ACN, Figure 7.7. In T18:ACN, the ACN was located around the feet 
of the cavitand. It formed CH(feet)•••N(ACN) interactions with the feet of the cavitand. It also 
forms a CH(ACN)•••O(rim) interaction with the rim of the neighboring cavitand. These 
interactions are commonly known as non-conventional hydrogen bonds.36,37,38 The molecular 
packing still follows “foot-in-the-mouth” kind of packing. Although the packing is different from 
what we observed for T18:(EtOAc)2, Figure 7.13. 
T18:Ethyl acetate
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Figure 7.13. Packing of T18:ACN (color codes: red-oxygen, brown-bromine, grey-carbon, 
white-hydrogen, green-ACN). 
 
7.4.5. Solvent -dimethyl sulfoxide (DMSO) 
 
TGA analysis indicates 1:1 stoichiometry of T18-T19 in combination with DMSO. With deeper 
cavitands T20-T23, we got 1:2 stoichiometry. Crystal structure of T18:DMSO shows DMSO 
encapsulation around the feet of the cavitand; T19 encapsulates DMSO at the rim of the cavitand; 
and T21 consists of two DMSO molecules located at the rim and feet of the cavitand, Figure 7.8. 
The molecular arrangement of T18:DMSO does not follow “foot-in-the-mouth” packing, although 
the rim was completely empty. We also observed a CH•••O non-conventional hydrogen-bond 
interaction between DMSO and T18, Figure 7.14.  
 
T18:ACN
CH•••N 
interaction
CH•••O 
interaction
CH•••O 
interaction
CH•••N 
interaction
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Figure 7.14. Packing of T18:DMSO, T19:DMSO, and T21:DMSO (color codes: red-oxygen, 
brown-bromine, violet-iodine, grey-carbon, white-hydrogen, green-DMSO). 
 
In T19:DMSO, the solvent was located at the rim that interacts with another DMSO molecule, 
present at the feet of the cavitand, forming a parallel and anti-parallel chained pattern, Figure 7.15. 
With T21, we observed the presence of DMSO molecules both at the rim and feet of the cavitand. 
 
Figure 7.15. Packing of T19:DMSO (color codes: red-oxygen, violet-iodine, grey-carbon, white-
hydrogen, green-ACN). 
 
T18:DMSO T19:DMSO T21:DMSO
T19:DMSO
 157 
 
7.4.6. Solvent selectivity 
 
We conducted selectivity studies by recrystallizing the cavitands from an equimolar mixture of 
solvents. We allowed crystal growth by slow evaporation technique followed by TGA and single 
crystal analysis. Among all the solvents, xylene/ DCM had the lowest dipole moment, and DMSO 
had the highest. Both xylene and DCM were not encapsulated in T18.  For T19, xylene was present 
in 1:1 stoichiometry, but DCM was not encapsulated. Deeper cavitands T20-T23 showed 1:1 
stoichiometry with both xylene and DCM. EtOAc is present in the center of the dipole moment 
chart and showed 1:2 stoichiometry with all the cavitands. In T18-T23, ACN was present in 1:1 
stoichiometry. Finally, DMSO exhibited 1:1 stoichiometry with T18-T19 and 1:2 with T20-T23. 
T18-T23 when subjected to a mixture of solvents, displayed a higher selectivity for DMSO as 
observed by TGA analysis and single crystal characterization. We also observed that the “foot-in-
the-mouth” packing was found only with lower dipole moment solvents. With the increasing 
dipole moment other weak interactions such as CH•••O/ N stabilized the solvent encapsulation by 
the cavitand. 
 
7.5. Conclusions 
 
1. Overall the isostructural hosts showed similar stoichiometry for a given solvent. Although since  
    the cavitands did not have a strong non-covalent interaction the location of the solvents within  
    the cavitand were random, Figure 7.16. 
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Figure 7.16. Comparison between T18 and T19 solvent encapsulation. 
 
2. The difference in the depth of T20-T23 displayed 1:1 stoichiometry with DCM and  
    1:2 with DMSO in comparison to no solvent molecules observed between T18-T19 with DCM   
    and 1:1 with DMSO. 
 
3. DMSO had the highest dipole moment and was most selective in comparison to other solvent  
    molecules, Figure 7.17.  
 
Figure 7.17. Selectivity between the solvent molecules. 
b)
a)
Recrystallized from Xylene
Recrystallized from DCM
Recrystallized from DMSO
T18 T19
+
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Chapter 8 –Cavitands as Molecular Containers 
 
8.1. Introduction 
 
8.1.1. Background 
 
Cavitands are organic macromolecules with bowl-shaped cavities capable of encapsulating 
cations, anions and solvents through a variety of intermolecular interactions1,2,3,4. There are various 
applications of cavitands as a molecular host5,6,7,8,9,10,11,12 that are characteristic of the defined 
space, volume and functional groups13,14,15,16,17. The structural framework of the cavitands enables 
them to act as versatile molecular hosts where a large variation can be achieved without altering 
the integrity of the cavitand framework. In previous chapters, we used reversible non-covalent 
intermolecular interactions as tool18 for exploring diversity in supramolecular assemblies. In this 
chapter we extend our understanding to hydrogen-bonding in cavitands, tailored towards 
molecular recognition19 events for a wide range of guests. We focus our efforts on cavitands with 
two possible modes of host-guest binding, Figure 8.1. 
 
Figure 8.1. Cartoon representation of possible guest binding modes to the rim of a cavitand. 
 
Guest 1 Guest 2
Path A 
Path B 
Solvent
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A major challenge in supramolecular chemistry is predicting the stoichiometry of host-guest 
interactions. Solid state techniques such as FTIR can provide proof for host-guest interactions but 
not the stoichiometry. Ideally analysis of the single crystal X-ray diffraction is the best possible 
route however, growing crystals of such large systems is rather difficult. The most common answer 
to this problem is by conducting NMR titrations20. In titration method, one component (i.e. guest) 
is incrementally titrated into the other component (i.e. host), by carefully monitoring the change 
in the chemical shift. The data acquired from the titration is fit into non-linear binding curves to 
obtain the value of association constant Ka which is the basic parameter for evaluating the host-
guest recognition process. In addition, free energy, ΔG can be calculated as expressing the 
favorability of the complexation and also the stoichiometry of the binding event can be determined 
by means of a Jobs plot21,22.  
 
8.1.2. Choice of host and guest molecules 
 
8.1.2.1. Fragrant compounds as guests 
 
Fragrant compounds are organic compounds with characteristic strong odors that find applications 
in perfumes and perfumed products. The smell of fragrance compounds is often related to their 
highly volatility23,24. Therefore, molecular mass of these compounds is an important factor. The 
molecular mass of commonly used fragrant compounds range between 200 – 300 g/ mol. In this 
study we use three aliphatic carboxylic acid and two cyclic hydroxyl fragrant compounds 
frequently used as fragrant compounds, Figure 8.2.  
 
 
 
 
 
Figure 8.2. Fragrant compounds of choice. 
 
The goal of this study is to use cavitands as a molecular container for fragrant compounds. The 
host-guest interactions between cavitands and guests will most likely change the volatility of the 
latter. In order to facilitate host-guest interactions we choose hydrogen-bond acceptor cavitands, 
Menthol Isoborneol 2-Methylbutyric acid 2-Methylhexanoic acid 2-Methylpentanoic acid 
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since all the guests have hydrogen-bond donor sites. We used three hydrogen-bond acceptor 
cavitands, where T24 and T25 are structural isomers Figure 8.3.  T26 had very similar molecular 
electrostatic potential surfaces (MEPS) as that of T24 and T25.  
 
 
Figure 8.3. Choice of cavitands. 
 
8.1.2.2. Heterocyclic N-oxides as guest 
 
Heterocyclic-N-oxides were perceived as side products historically, of hepatic metabolism of N-
heterocyclic therapeutic compounds25. Heterocyclic-N-oxides became a mainstream drug, during 
1960s due to unusual discovery of antihypertensive and anti-alopecia agent Minoxidil by Upjohn26. 
Since then it has found various applications in anticancer, antiviral, anti-protozoal, and anti-fungal 
drug products in advanced discovery stage. Additionally, numerous heterocyclic-N-oxide 
compounds have found its applications in agrochemicals and cosmetics industry. In this study we 
use a series of N-oxides to study their binding ability with cavitands, Figure 8.4. The choice of 
hosts was hydrogen-bond donor cavitands since all the guests have hydrogen-bond acceptor sites. 
Hydrogen-bond acceptor cavitands
R=hexylT17 T18 T19
Molecular electrostatic potentials:
Pyridine- N = -(180-230) Kj/mol
Molecular electrostatic potentials:
Pyrazole-N = -(150-185) Kj/mol
Molecular electrostatic potentials:
Pyridine- N = -(180-230) Kj/mol
T24
T25 T26
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Figure 8.4. a) Heterocyclic-N-oxide guests of choice, b) Hydrogen-bond donor cavitand. 
 
8.1.3. Goals 
 
We will synthesize three hydrogen-bond acceptor and one hydrogen-bond donor cavitands to 
examine host-guest interactions via NMR titrations with fragrant compounds and heterocyclic-N-
oxides. We will use TGA analysis in addition to NMR titrations, in order to analyze the resulting 
host-guest interactions. Hydrogen-bond propensity (HBP) calculations will be implemented to 
examine if host-guest interactions can be predicted for cavitands and guest compounds. We chose 
HBP, since it produced the highest reliability in comparison to other commercially available 
predictive methods, Chapter 4-5.  
The study is done to answer the following questions: 
1. Can HBP correctly predict the host-guest interactions? 
2. Will the guests interact with the cavitands and if yes what will be the stoichiometry?  
 
8.2. Experimental  
 
All chemicals were purchased from Aldrich, Fischer, TCI America, Oakwood and Alfa Aesar 
which were used without further purification unless otherwise mentioned. Column 
chromatography was carried out using silica gel (150 Å pore size) from Analtech, Inc. 1H and 13C 
NMR spectra were recorded on Varian Unity plus 400 MHz spectrometer in CDCl3 or DMSO. 
b) Hydrogen-bond donor cavitand
R=hexyl
3-Picoline-N-oxide 4-Picoline-N-oxide Pyrazine-N-oxide4-Pyridine-N-oxide
a) Heterocyclic-N-oxides
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The NMR data is in parts per million (ppm) with downfield shift from tetramethylsilane which is 
an internal reference. Nicolet 380 FT-IR was used for infrared spectroscopy and the data was 
analyzed using Omnic 8.0 Thermo Fischer Scientific Inc. software. DSC and TGA analysis were 
done using TA instruments Q20 and Q50, respectively. 
 
8.2.1. Synthesis of hosts 
 
8.2.1.2. Synthesis of C-hexyltetra(3-pyridyl) cavitand, T24 
 
 
A mixture of C- hexyltetraboronic acid dipinacolyl ester cavitand, T23 (2.0 g, 1.77 mmol) and 
tetrakistriphenylphosphine palladium (0) (420 mg, 0.362 mmol) were placed in a round bottom 
flask under a stream of dinitrogen. To this was added a mixture of toluene (30 mL), ethanol (20 
mL) and aqueous sodium bicarbonate (100 mg, 5 mL) purged with dinitrogen. Then 3-iodopyridyl 
(4.60g, 22.8 mmol) was added to the reaction mixture and refluxed for 72 hours under dinitrogen. 
Upon completion the reaction was cooled to room temperature and diluted with water (100 mL). 
The aqueous phase was washed with dichloromethane (3 x 100 mL) and dried with anhydrous 
magnesium sulfate. The solvent was removed on a rotary evaporator and the residue purified by 
column chromatography using an ethanol/ethyl acetate (1:2) mixture as the eluant. The product 
T24 was isolated as a white crystalline solid, (1.44 g, 72%).  
M.P.: > 280 ºC. 1H NMR (400MHz, CDCl3): 8.47 (d, 4H), 8.27 (s, 4H), 7.50 (d, 4H), 7.43 (s, 4H), 
7.36 (s, 4H), 5.28 (d, J = 6.8 Hz, 4H), 4.95 (t, J = 7.2 Hz, 4H), 4.26 (d, J = 7.6 Hz, 4H), 2.34 (m, 
8H), 1.43-1.35 (m, 72H ), 0.93 (m, 12H). 
T25T 24 
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8.2.1.1. Synthesis of C-hexyltetra(4-pyridyl) cavitand, T25 
 
 
A mixture of C- hexyltetraboronic acid dipinacolyl ester cavitand, T23 (2.00 g, 1.77 mmol) and 
tetrakistriphenylphosphine palladium (0) (420 mg, 0.362 mmol) were placed in a round bottom 
flask under a stream of dinitrogen. To this was added a mixture of toluene (30 mL), ethanol (20 
mL) and aqueous sodium bicarbonate (100 mg, 5 mL) purged with dinitrogen. Then 4-iodopyridyl 
(4.60g, 22.8 mmol) was added to the reaction mixture and refluxed for 72 hours under dinitrogen. 
Upon completion the reaction was cooled to room temperature and diluted with water (100 mL). 
The aqueous phase was washed with dichloromethane (3 x 100 mL) and dried with anhydrous 
magnesium sulfate. The solvent was removed on a rotary evaporator and the residue purified by 
column chromatography using an ethanol/ethyl acetate (1:2) mixture as the eluant. The product 
T25 was isolated as a white crystalline solid, (1.53 g, 73%).  
M.P.: > 280 ºC. 1H NMR (400MHz, CDCl3): 8.63 (d, 8H), 7.31 (s, 4H), 6.47 (d, 8H), 5.50 (d, J = 
6.8 Hz, 4H), 5.23 (t, J = 7.2 Hz, 4H), 4.80 (d, J = 7.6 Hz, 4H), 2.30 (m, 8H), 1.36 (m, 72H ), 0.93 
(m, 12H). 
 
 
T24T 25 
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8.2.1.3. Synthesis of C-hexyltetra(3-pyrazole) cavitand, T26 
 
 
A mixture of C- hexyltetraboronic acid dipinacolyl ester cavitand, T23 (2.00 g, 1.77 mmol) and 
tetrakistriphenylphosphine palladium (0) (420 mg, 0.362 mmol) were placed in a round bottom 
flask under a stream of dinitrogen. To this was added a mixture of toluene (30 mL), ethanol (20 
mL) and aqueous sodium bicarbonate (100 mg, 5 mL) purged with dinitrogen. Then 3-
iodopyrazole (4.44g, 22.8 mmol) was added to the reaction mixture and refluxed for 72 hours 
under a dinitrogen atmosphere. Upon completion the reaction was cooled to room temperature and 
diluted with water (100 mL). The aqueous phase was washed with dichloromethane (3 x 100 mL) 
and dried with anhydrous magnesium sulfate. The solvent was removed on a rotary evaporator and 
the residue purified by column chromatography using an ethanol/ethyl acetate (1:2) mixture as the 
eluant. The product T26 was isolated as a white crystalline solid, (0.98 g, 54%).  
M.P.: > 280 ºC. 1H NMR (400MHz, CDCl3): 7.43 (d, 4H), 7.33 (s, 4H), 7.04 (s, 4H), 5.97 (d, J = 
6.8 Hz, 4H), 4.85 (t, J = 7.2 Hz, 4H), 4.38 (d, J = 7.6 Hz, 4H), 2.21 (m, 8H), 1.44-1.31 (m, 72H ), 
0.90 (m, 12H). 
 
 
 
 
 
 
 
 
T26
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8.2.1.4. Synthesis of C-hexyltetracarboxylic cavitand, T27 
 
 
 
 
Dry freshly distilled tetrahydrofuran (20 mL) was added to C-hexyltetrabromocavitand, T18 (2.16 
g, 1.91 mmol), and then the solution was evaporated and dried at 80 °C (0.1 mmHg) for 2 h under 
a nitrogen atmosphere to get a rigorously dry solid. This procedure was repeated twice. At the end 
of the drying procedure, the solid, T18 was dissolved in dry tetrahydrofuran (200 mL) and cooled 
to -78 °C using dry ice/ acetone bath under dinitrogen for 10 minutes. N- butyllithium (1.6 M in 
hexanes) (5.96 mL, 9.55 mmol) was slowly added dropwise to this solution upon which a milky 
solution begins to appear. After addition, the reaction mixture was stirred for 2 hours under 
nitrogen. Then the solution was added to a mixture of dry ice and diethyl ether. The reaction was 
left until it reached room temperature. Upon completion, a NaOH (1 M) aqueous solution (100 
mL) was added to the reaction mixture at room temperature. THF was then removed under vacuum 
and the aqueous layer was washed with Et2O (100 mL × 3), followed by acidifying with 
concentrated HCl at 0 °C. The resulted white solid of the product, T27 was then extracted with 
Et2O (100 mL × 3). The organic layer washed with water and brine, dried over anhydrous MgSO4 
and solvent removed under vacuum to yield T27 as white solid (1.32 g, 74%). M.P. > 280 ̊C; 1H 
NMR (δH; 400 MHz, CDCl3): 7.18 (s, 4H), 5.75 (d, J = 8.4Hz, 4H), 4.74 (t, J = 6.2Hz, 4H), 4.50 
(d, J = 7.2Hz, 4H), 2.19 (m, 8H), 1.30 (m, 24H), 0.90 (t, 12H); IR: 3530, 3224, 2929, 2846, 1715, 
1586, 1452, 1277, 1085, cm-1.  
8.2.2. Hydrogen bond propensity (HBP) calculations 
 
The hydrogen-bond propensity27,28,29,30,31 model was used to predict the host-guest interactions 
between the cavitands and guests molecules. A detailed description of HBP calculations is given 
T27 
R= (CH
2
)
5
CH
3
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in section 2.2.3. We excluded the feet of the cavitands while performing HBP calculations, Figure 
8.5.  
 
 
Figure 8.5. Schematic representation of the steps involved in HBP calculations. 
 
8.2.3. Preparation of the host-guest complexes  
 
The host-guest samples were prepared by dissolving the host and guest in 1:1 stoichiometry in a 
solvent. We used CDCl3 as the solvent and kept it constant for all host-guest samples. The mixture 
was then heated, and the solvent was allowed to evaporate. The leftover solid residue was used for 
thermogravimetric analysis (TGA). 
 
8.2.4. Thermogravimetric analysis (TGA) of target cavitands and guest molecules  
 
TGA analysis of the host-guests complexes were performed to confirm the presence or absence of 
guest in the crystal lattice. Early weight loss (below 100 oC) suggests the presence of loosely bound 
guest molecules in the crystal lattice whereas, weight loss at a higher temperature corresponds to 
the presence of strong host-guest interaction. Figure 8.6. illustrates TGA analysis of T24 with the 
aliphatic guests. The % weight loss in TGA corresponds to the number of guest molecules that are 
lost. This weight loss in TGA was compared with the NMR titration to examine if they display 
similar stoichiometry.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Define the functional 
groups
Generating a fitting data
Probability of formation of 
hydrogen-bond interaction
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Figure 8.6. TGA analysis of T25 with aliphatic guest and their corresponding weight losses. 
 
8.2.5. NMR titration experiment 
 
8.2.5.1. Preparation of the solutions 
 
 The host (cavitand) concentration [H] was kept constant throughout the titration while the guest 
(active ingredients) concentration [G] was varied gradually. A stock solution of the host cavitand 
was prepared from which a constant amount was added to each NMR sample. The concentration 
of each final sample was kept at 1.6 mM. A stock solution of the guest was prepared from which 
successive volumes were added into the host during the titration. The concentrations of the guest 
[G] in the final solution ranged between 0.25-12 mM, Table 8.1.  
 
 
T24:(2-Methylbutyric acid)2 + 2CDCl3 
T24:( 2-Methylpentanoic acid)2 + 2CDCl3 
T24:( 2-Methylhexanoic acid)2 + 2CDCl3 
T24 + 2CDCl3 
10.62% = 110g (T24:2CDCl3) 
19.64% = 205g [T24: (2-Methylbutyric acid) 2] 
26.84% = 282g [T24: (2-Methylpentanoic acid) 2] 
27.58% = 288g [T24: (2-Methylhexanoic acid) 2] 
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Table 8.1. Host-guest concentrations used in this study. 
 
8.2.5.2. Binding constant determination 
 
A solution of known concentration of the guest was successively added to the host until an 
equilibrium was reached in the host-guest binding event which is indicated by a constant value of 
the chemical shift in the NMR spectrum. All the spectra were run at 298 K in CDCl3 unless 
otherwise noted. A series of 9-10 data points were recorded for each titration experiment. The 
changes in the chemical shifts acquired from the titrations were graphed against the guest 
concentration with non-linear mathematical approach based on Benesi-Hildebrand32 analysis using 
Origin 8.1 software. The equation used for curve fitting is given below,  
 
 𝑯 + 𝑮 → 𝑯𝑮  
𝐾𝑎 =  
[𝐻𝐺]
[𝐻] [𝐺]
 
∆𝜹 =  
∆𝜹𝒔𝒂𝒕
𝟐
[(
[𝑮]𝟎
[𝑯]𝟎
+ 𝟏 + 
𝟏
𝑲𝒂[𝑮]𝟎
) − √(
[𝑮]𝟎
[𝑯]𝟎
+ 𝟏 + 
𝟏
𝑲𝒂[𝑯]𝟎
)
𝟐
− 𝟒
[𝑮]𝟎
[𝑯]𝟎
]   Equation 8.1.  
 
                                      [H]0 is the host concentration 
                                      [G]0 is the total guest concentration (bound and unbound) 
                                       Ka is the association constant 
is the change in the chemical shift 
 
 
 
Host Guest 
conc. 
mM 
moles mmol Volume conc. mM moles mmol Volume Solvent Equivalence 
1.6 0.0032 0.4 0.8 0.0016 0.1 1.5 0.5 
1.6 0.0032 0.4 1.6 0.0032 0.2 1.4 1 
1.6 0.0032 0.4 2.4 0.0048 0.3 1.3 1.5 
1.6 0.0032 0.4 3.2 0.0064 0.4 1.2 2 
1.6 0.0032 0.4 4.8 0.0096 0.6 1 3 
1.6 0.0032 0.4 6.4 0.0128 0.8 0.8 4 
1.6 0.0032 0.4 8 0.016 1 0.6 5 
1.6 0.0032 0.4 9.6 0.0192 1.2 0.4 6 
1.6 0.0032 0.4 12.8 0.0256 1.6 0 8 
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8.3. Results 
 
8.3.1. Hydrogen-bond propensity calculations 
 
Following the scheme 2.2.3, hydrogen-bond propensity calculations was carried out for each host-
guest pair. Table 8.2 summarizes the HBP values. A positive number indicates potential host-guest 
interactions and a negative HBP value suggests no host-guest interaction. T24 and T25 both 
consist of “pyridine” as the functional group in combination with OH. Hence all the HBP values 
are the same for both hosts. 
 
Table 8.2. HBP values of cavitands and guest molecules. 
Compounds HBP= Heteromeric-Homomeric 
T24/T25 + 2-Methylbutyric acid 0.73-0.21 = 0.52 
T24/T25 + 2-Methylpentanoic acid 0.73-0.21 = 0.52 
T24/T25 + 2-Methylhexanoic acid 0.73-0.21 = 0.52 
T24/T25 + Menthol 0.55-0.26= 0.29 
T24/T25 + Isoborneol 0.55-0.26= 0.29 
T26 + 2-Methylbutyric acid 0.55-0.59 = -0.04 
T26 + 2-Methylpentanoic acid 0.55-0.59 = -0.04 
T26 + 2-Methylhexanoic acid 0.55-0.59 = -0.04 
T26 + Menthol 0.61-0.67= -0.06 
T26 + Isoborneol 0.61-0.67= -0.06 
T27 + 3-Picoline-N-oxide 0.72-0.29= 0.43 
T27 + 4-Picoline-N-oxide 0.72-0.29= 0.43 
T27 + Pyridine-N-oxide 0.72-0.29= 0.43 
T27 + Pyrazine-N-oxide 0.72-0.29= 0.43 
 
 
8.3.2. Thermogravimetric analysis (TGA) of target cavitands and guest molecules 
 
Table 8.3. summarizes the weight loss in TGA analysis and corresponding stoichiometry of the 
cavitands with the guests. T24 and T27 interacts with all the guests, T25 shows host-guest 
interactions with only cyclic rigid guests, and T26 does not interact with any of the guests. In all 
the instances, two solvent molecules (CDCl3) were present. 
 
 175 
 
Table 8.3. Host-guest stoichiometry from weight loss in TGA analysis. 
Guest 
2-methylbutyric 
acid 
2-methylpentanoic 
acid 
2-methylhexanoic 
acid 
Isoborneol Menthol 
T24 
21.88% =  
2guests  
26.89% =  
2guests 
29.74%=  
2guests 
27.67%= 
2guests 
28.73%= 
2guests 
T25 
11.37% = 
2CDCl3 
14.76% =  
2CDCl3 
15.03% =  
2CDCl3 
24.65%= 
2guests 
26.58%= 
2guests 
T26 
15.32%= 
2CDCl3 
14.54%= 
2CDCl3 
14.63%= 
2CDCl3 
15.64%= 
2CDCl3 
15.42%= 
2CDCl3 
 
 
Guest 3-Picoline-N-oxide 4-Picoline-N-oxide Pyridine-N-oxide Pyrazine-N-oxide 
T27 
17.32% = 
2guests 
19.27%=  
2guests 
18.26% =  
2guests 
17.56%=  
2guests 
 
 
8.3.3. NMR titrations 
 
The binding affinity of the hosts, towards the guest were evaluated in solution using 1H NMR 
spectroscopy. We expected an O-H•••N interaction to form in solution between the cavitands and 
guests. We focused our work on 1H NMR titration as a way of quantifying this binding event, 
where the binding of the hydrogen-bond donor and acceptor was monitored by changes in the 
chemical shifts of the hydrogen atoms. An example of a positive and negative host-guest 
interaction is illustrated in Figure 8.7.  
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Figure 8.7. An example of positive (top) and negative (bottom) host-guest interactions. 
 
The changes in δ ppm values (δbound host – δfree host) obtained by titrating the guest (2-methylbutyric 
acid) with the host T24 were plotted against the guest concentration and by non-linear curve fitting 
into equation 8.1 afforded Ka = 1412 M-1, Figure 8.8. Jobs plot analysis of the results revealed 1:2 
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complexation which was consistent with TGA in the solid state. Similar analysis was done for all 
host-guest pairs and the results are summarized in Table 8.4. 
 
   
Figure 8.8. Titration curve of 2-methylbutyric acid into T24 in CDCl3 at 25 °C (left); Jobs plot 
of [T24: (2-Methylbutyric acid)2] pair at 25 °C (right). 
 
Table 8.4. Summary of host-guest interactions for T24-T27. 
Guest T24 T25 T26 
 Stoichiometry Binding 
constant 
Stoichiometry Binding 
constant 
Stoichiometry Binding 
constant 
2-Methylbutyric acid 1:2 1412 M-1 No interaction - No interaction - 
2-Methylpentanoic 
acid 
1:2 1552 M-1 No interaction - No interaction - 
2-Methylhexanoic 
acid 
1:2 1732 M-1 No interaction - No interaction - 
Menthol 1:2 1638 M-1 1:2 1680 M-1 No interaction - 
Isoborneol 1:2 1750 M-1 1:2 1786 M-1 No interaction - 
Guest T27 
 Stoichiometry Binding constant 
3-Picoline-N-oxide 1:2 2156 M-1 
4-Picoline-N-oxide 1:2 2765 M-1 
Pyridine-N-oxide 1:2 2635M-1 
Pyrazine-N-oxide 1:2 2743 M-1 
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8.4. Discussions  
 
8.4.1. Fragrant compounds 
 
T24-T26 have similar MEPS for the acceptor-N site which suggests that they would demonstrate 
comparable host-guest interactions. The HBP calculations for T24-T25 in combination with the 
fragrant compounds exhibit a positive value and for T26 a negative value, Table 8.2. HBP is 
dependent on the statistical analysis of the defined functional groups of the host and guest present 
in the Cambridge Structural Database (CSD). The defined functional groups of T24-T25 are 
pyridine-N and that of the guests are carboxylic acid-COOH/ alcohol-OH therefore, we observe 
same HBP results for all T24-T25 combinations. 
 
8.4.1.1. Host-guest interactions with T24  
 
The TGA analysis for T24 in combination with the guests indicates a consistent weight loss of 
~21-29%. The weight loss corresponds to two guest molecules and two solvent molecules 
(2CDCl3). Although T24 had four arms where it could interact with the guests exhibiting a 1:4 
stoichiometry. Due to the presence of steric cloud on the upper rim of the cavitands T24 displays 
a 1:2 stoichiometry with the guests. In case of [T24:(2-Methyl butyric acid)2] the weight loss in 
the TGA analysis starts at ~176 0C and is completed at 400 0C. The weight loss corresponds to 2 
guest molecules, and the temperature at which the weight loss starts is the boiling point of the 
guest. The fact that it takes over 200 0C to completely loose the guest, suggests a strong host-guest 
binding. A similar trend was observed for T24 and other fragrant molecules. 
The NMR titrations for T24 in combination with guests was varied from 1:0.5 to 1:8 stoichiometry. 
The host concentration was kept constant and we increased the guest concentration. With the 
increasing guest concentration, the (δbound host – δfree host) value kept decreasing due to OH•••N 
interaction between host-guest. After a point the (δbound host – δfree host) became constant, since host 
has completely reacted with the guest and any more addition of guest is extra unreacted guest. 
Hence the (δbound host – δfree host) becomes constant, Figure 8.8. We plotted a Jobs plot which 
indicated a 1:2 stoichiometry for the T24 combined with guest, Table 8.4. Additionally, we 
calculated the binding constants for all the combinations with T24 and the results ranged between 
1412-1750 M-1.  
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Based on the TGA, 1H NMR titrations and Job’s plot, guest binding takes place on the upper rim 
of the cavitand via OH···N hydrogen bonds and one cavitand was capable of binding to two guest 
molecules.  
8.4.1.2. Host-guest interactions with T25  
TGA analysis for T25 in combination with aliphatic guests demonstrates a weight loss of 11-15%. 
This weight loss corresponds to the presence of two solvent molecules (2CDCl3). The temperature 
at which the weight loss starts is below 100 oC and is completed by 200 oC which was much below 
than what we observed for T24 and guest compounds (~200-400 oC), Figure 8.9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.9. TGA analysis of T25 with aliphatic guest and their corresponding weight losses. 
 
For menthol and isoborneol the TGA weight loss was 24-26% at 200-400 oC, which is equivalent 
to two guest and two solvent molecules. The stoichiometry observed with menthol and isoborneol 
was 1:2. T24 and T25 are structural isomers. However, we see a difference in the host-guest 
interactions between them. 
2-Methylbutyric acid 
2-Methylpentanoic acid 
2-Methylhexanoic acid 
T25+2CDCl3 
No host-guest interactions 
10.59% = 110g (T25+2CDCl3) 
10.52% = 110g (T25+2CDCl3)  
8.7% = 110g (T25+2CDCl3) 
11.56% = 110g (T25+2CDCl3) 
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To further investigate the selectivity of T25 towards rigid guests, we conducted experiments where 
T25 was subjected to a mixture of aliphatic and cyclic guests. We prepared six different 
combinations of mixtures and analyzed them according to TGA weight loss. In each case the 
weight loss in TGA corresponded to cyclic guests and solvent molecules, Table 8.5. 
 
Table 8.5. Summary of the selectivity outcome for T25. 
Guest mixtures TGA data analysis 
2-Methylbutyric acid + Isoborneol 2Isborneol  
2-Methylbutyric acid +Menthol 2Menthol 
2-Methylpentanoic acid + Isoborneol 2Isborneol  
2-Methylpentanoic acid + Menthol 2Menthol  
2-Methylhexanoic acid + Isoborneol 2Isborneol  
2-Methylhexanoic acid + Menthol 2Menthol  
 
The NMR titrations for T25 in combination with guests was also varied from 1:0.5 to 1:8 
stoichiometry. With aliphatic guests, T25 did not show any change in the 1H NMR chemical shift. 
No change in the chemical shift corresponds to no formation of OH•••N interactions. However, 
T25 in combination with isoborneol and menthol displays a 1:2 stoichiometry with binding 
constants of 1680 and 1786 M-1 respectively.  The binding constants of T25 with isoborneol and 
menthol is comparable to that of T24. The TGA analysis and NMR titrations display similar 
results.  
The selectivity of the aliphatic guests to bind specifically with T24 can be rationalized based on 
the following hypothesis: 
a) We calculated the most stable structure of T24 and T25 using DFT calculations and basis set 
B3LYP and 6-31++G** (calculations were done excluding the hexyl feet), Figure 8.10. The 
calculations show that in T24 the pyridine-N are facing away from each other and in T25 the 
pyridine-N are facing upwards. Hence, in T24 the pyridine-N have sufficient space for flexible 
aliphatic acids to make OH•••N interaction. In case of T25 the pyridine-N available for binding 
are facing upwards which leads to steric hindrance between the non-bonding parts, hence these 
flexible guests cannot form any host-guest interactions.  
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Figure 8.10. Most stable geometry of T24 (left) and T25 (right). 
 
b) Our second hypothesis is that the cavitands are arranged in “foot in the mouth” type of packing 
which adds to the steric hindrance in the upper rim of the cavitands. Although we don’t have a 
crystal structure at this point. However, based on the other existing crystal structures of cavitands 
in Chapter 7, where the upper rim does not participate in any interactions, such arrangements are 
frequently observed. Figure 8.11 illustrates an example of “foot in the mouth” type of packing. 
 
Figure 8.11. An example of T11 with “foot in the mouth” packing. 
 
c) Menthol and Isoborneol mimics the host-interaction in T24 and T25 because they are rigid and 
small. Hence, the donor OH can interact with pyridine-N even in the presence of the steric cloud. 
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A control experiment was conducted with T24 and T25 in combination with benzoic acid to 
confirm the formation of OH•••N interactions with rigid guests. We observed that benzoic acid 
interacts with both T24 and T25 in 1:2 stoichiometry and binding constants of 1856 M-1, Table 
8.6.  
Table 8.6. Summary of host-guest interactions for T24-T25 with benzoic acid. 
Guest T24 T25 
 Stoichiometry Binding 
constant 
Stoichiometry Binding 
constant 
Benzoic acid 1:2 1856 M-1 1:2 1856 M-1 
 
8.4.1.3. Host-guest interactions with T26  
 
The NMR titrations and TGA analysis indicate that T26 does not interact with any of the guests. 
This can be attributed to stronger homomeric interactions of pyrazole N-H•••N in T26 than the 
heteromeric interaction O-H•••N. The HBP calculations attempted on T26, in combination with 
the guests, predicts that the homomeric interactions were preferred over heteromeric interactions, 
Table 8.2.  
8.4.1.4. Improved stability of the fragrant compounds 
 
The aliphatic guests used in this study are liquid at room temperature. Successful host-guest 
interactions resulted the final product as solid-glue like material. One of the goals of this study 
was to examine if we can improve the volatility of the fragrant compounds via host-guest 
interactions. Qualitative study was performed to test if the volatility of the compounds had 
improved. For the fragrant compounds by itself, it took 5-10 mins for a drop of guests to 
completely evaporate at room temperature. We followed that same process for cavitands 
containing guests, where the resulting solids were kept on a slide at room temperature. We 
performed NMR of the resulting solid every 6-7 days to check for the presence of guest peaks. We 
observed guest peaks in the NMR for 30 days after which we did not test it further. This analysis 
suggests that the volatility of the fragrant compounds was improved from 5-10mins to over a 
month. 
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8.4.2. Heterocyclic-N-oxides 
 
HBP calculations predicted formation of a host-guest interaction between T27 in combination with 
the guest compounds.  TGA analysis and NMR titrations were carried out with T27 in combination 
with heterocyclic-N-oxides. TGA analysis indicate a weight loss which corresponds to two guest 
molecules and presence of two solvent molecules, Table 8.3. The presence of two solvent 
molecules was consistent in all the host-guest interactions.  
NMR titrations conducted with T27 and N-oxide guests were varied from 1:0.5 stoichiometry to 
1:8. The Job’s plot calculations indicate a 1:2 stoichiometry in all the cases. A Job’s plot of 
[T27:(Pyrazine-N-oxide)2] is illustrated in Figure 8.12. 
 
 
Figure 8.12. Jobs plot of [T27: (Pyrazine-N-oxide)2] pair at 25 °C (right). 
 
The binding constants of T27 with guest compounds were observed between 2156-2743 M-1, 
which is significantly higher than what we obtained for T24-T25. The HBP values for T27 were 
also significantly higher than T24-T25. The difference in the binding constants can be attributed 
to stronger OH•••O interaction than OH•••N. Since, oxygen is negatively charged in N-oxides and 
is a better Lewis base than pyridine-N contributing to higher binding constants. 
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 8.5. Conclusions  
 
1. HBP correctly predicted the host-guest interactions for T24, T26 and T27. However, it fails to  
   predict the selectivity of T25 for rigid cyclic guests over aliphatic guests. 
2. T24 interacts in 1:2 stoichiometry with all fragrant guest compounds, T25 interacts selectively  
   with cyclic guest compounds in 1:2 stoichiometry, and T26 does not participate in any host- 
   guest interactions. Hydrogen-bond donor cavitand T27 interacts with heterocyclic-N-oxides in  
   1:2 stoichiometry.  
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Chapter 9  – Summary 
 
In our first study we examined, six different target molecules in combination with 25 possible co-
formers and used the hydrogen-bond propensity (HBP) protocol for predicting if a co-crystal 
would form or not. The correct outcome was successfully predicated 92-95% of the time which 
indicates that for this series of small molecules, HBP is a very reliable indicator for determining if 
a co-crystal will form between a target molecule and a particular co-former, Figure 9.1.  
 
 
Figure 9.1. Validation study for HBP in predicting co-crystallization outcomes. 
 
In our second study we used molecular electrostatic potential surfaces (MEPS) to rank the best 
donor-acceptor pair for predicting the most likely synthon formation, Figure 9.2. This study shows 
that, although hydrogen and iodine are far apart in the periodic table, if used in the same chemical 
environment then can mimic each other. This structural similarity could be significant in 
biomedical areas as halogen bonds are hydrophobic and lipophilic when compared to hydrogen 
bonds. 
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Figure 9.2. Validation study for MEPS in predicting co-crystallization outcomes. 
 
Next, the predictive abilities of three different approaches were compared for predicting co-
crystallization outcomes for two known drug molecules, Nevirapine and Diclofenac, and a series 
of potential co-formers.  The hydrogen-bond propensity (HBP) tool gave the correct result in 26 
out of 30 cases, whereas a hydrogen-bond coordination (HBC) method predicted the correct 
outcome in 22 out of 30 cases.  Finally, calculated hydrogen-bond energies (HBE) using a simple 
electrostatic model, gave the correct result in 23 out of 30 experiments.  In cases, where the crystal 
structure of a co-crystal of either Nevirapine or Diclofenac was known, we also examined how 
well the three methods predicted which primary hydrogen-bond interactions were present in the 
crystal structure.  HBP correctly predicted 6 out of 6 cases, HBC could not predict any of the 
synthon formations correctly, and HBE successfully predicted 1 out of 6 cases, Figure 9.3.  
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Figure 9.3. Validation study for HBP, HBE, and HBC in predicting co-crystallization outcomes 
(top) and synthon formations (bottom). 
 
Although there is an abundance of studies reported on small and rigid targets, there is scarcity of 
reports based on large and flexible compounds for predicting co-crystallization screening 
experiments. Hence, in this study three predictive methods HBP, HBE, and molecular 
complementarity (MC) were employed on seven APIs in combination with 42 co-formers on the 
generally regarded as safe (GRAS) list. The targets used in this study have a molecular weight of 
400-600 g/mol and have more than three rotatable bonds. The validation studies indicated that a 
combination of HBP and MC yielded the best results with an overall accuracy of 79%, Figure 9.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.4. Strategies to predict co-crystallization outcomes. 
 
The predictive approaches investigated thus far were complex and required in-depth knowledge of 
either theoretical, quantum-mechanical, or statistical data analysis. In order to address the growing 
demand of co-crystallization and co-crystallization-based approaches to access new solid forms in 
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various fields, we developed CoForm which is cheaper, faster, and more reliable for predicting the 
outcome of co-crystallization experiments, Figure 9.5. 
 
 
Figure 9.5. Validation study for CoForm in comparison to HBP and MC in predicting co-
crystallization outcomes. 
 
In order to investigate guest encapsulation via cavity inclusion we synthesized six cavitands where 
the rim did not participate in any conventional hydrogen/ halogen bonding. Five solvents (xylene, 
dichloromethane, ethyl acetate, acetonitrile, and dimethyl sulfoxide) with varied dipole moment 
were selected as guests. We found that cavitands encapsulated guests in a variety of arrangements 
with different stoichiometries as illustrated in Figure 9.6. In addition, selectivity study of 
equimolar mixtures of solvents suggested that the cavitands were selective towards dimethyl 
sulfoxide which had the highest dipole moment.  
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Figure 9.6. Cartoon representation of observed solvent binding modes to a cavitand. 
 
Finally, we examined cavitands as molecular containers, for storage of volatile fragrant 
compounds and heterocyclic-N-oxides. The cavitands interacted with the fragrant compounds in 
1:2 stoichiometry which was established by NMR titrations and TGA analysis. We found that the 
host-guest interactions improved the volatility of the fragrant compounds from 5-10 mins to over 
a month. The heterocyclic N-oxides was also observed to interact in 1:2 stoichiometry. The binding 
preferences of the guests are illustrated in Figure 9.7. 
 
Figure 9.7. Cartoon representation of observed host-guest binding.  
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Appendix A – Design, develop and evaluate molecular 
complementarity as a predictive tool for co-crystal design. 
 
A.1. Rationale 
 
MC in the default setting, uses five descriptors, Scheme A.1. Each descriptor has a criterion to 
afford a “PASS” when it is predicted to form a co-crystal or a “FAIL” when it predicts not to form 
a co-crystal. For MC to predict a co-crystal formation, an overall “five PASS” from all the five 
descriptors is required. 
 
 
Scheme A.1. Default descriptor setting for molecular complementarity. 
 
The compounds examined in this study are flexible. Therefore, it might exist in different 
conformations. To factor in the conformational insights, the five most stable conformations of both 
APIs and co-formers were incorporated in MC. The conformers were generated using Mercury 
and then passed through the five descriptors to afford a “PASS/ FAIL,” Scheme A.1. 
Complementary shaped conformers of the API and co-former provided a “PASS,” and the rest 
resulted in a “FAIL.” Finally, the 125 (25 conformations X 5 descriptors) “PASS/ FAIL” 
combinations, contributed to yield a hit rate %. Hit rate% is the number of “PASS” over the total 
number of conformer combinations. If the hit rate 40%, it was assigned a “YES” to co-
crystallization, and if hit rate <40%, it was designated as “NO” to co-crystallization.    
Similar calculations were repeated, using the conformers generated using Spartan’14 Version 
1.1.0, implementing molecular mechanics (conformer distribution in vacuum). The difference 
between the Spartan and Mercury conformer calculations is that the former calculates the 
conformers based on relative low energy, and the latter uses structure informatics. Subsequently, 
a comparison study employing both methods was investigated to comprehend the differences 
between them.  
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Seven APIs were used, Figure A.1, to explore the reliability of MC for predicting co-crystallization 
outcomes. We attempted co-crystal experiments on the seven APIs with 42 GRAS36 list co-
formers, Table A.1. 
 
 
Figure A.1. Seven APIs of interest. 
 
Table A.1. Selected potential co-formers. 
 
Xanthine Theophylline Benzenesulfonic acid Caffeine 
Riboflavin Piperazine Methylparaben Mannitol 
Maltitol Malic acid L-tartaric acid Glycolic acid 
L-glutamic acid Cholic acid Glycine D-Glucuronic acid 
Folic acid Hydro cinnamic acid Apigenin L-serine 
EDTA 4-hydroxybenzoic acid L-mandelic acid Benzoic acid 
Pamoic acid Fumaric acid Adipic acid Glutaric acid 
Citric acid L-proline Gentisic acid Malonic acid 
Isonicotinamide Oxalic acid Maleic acid Sorbic acid 
Nicotinamide Urea Saccharin Phosphoric acid 
Succinic acid 3-hydroxy-2-naphthoic acid   
Salicylic acid    
 
 
A.2. Predicting co-crystallization using MC 
 
The first step to MC calculations is generating conformers of the APIs and co-formers. All the 
APIs and co-formers were sketched and auto edited individually. Under CSD materials, 
“conformer generator” was used to generate a maximum of five conformations for each of them. 
T12
M.W= 441 g/ mol
T11
M.W= 412 g/mol
T14
M.W= 460 g/mol
T15
M.W= 451 g/mol
T16
M.W= 460 g/mol
T13
M.W=  605 g/mol
T17
M.W= 435 g/mol
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Next, we selected co-crystal design followed by MC, under CSD materials to choose one target at 
a time (with its five conformations) against the 42 co-formers (each with five conformations). In 
the end, a table is generated with a hit rate% for each co-former and the defined API.  
The calculations were repeated with the conformers generated using Spartan. The first step to 
calculate the conformers in Spartan is to sketch the API of interest. After that, energy minimization 
was done to obtain the lowest energy (most stable) conformation of the compound. We then 
applied molecular mechanics as implemented in Spartan 14 Version 1.1.0, to generate five 
conformers. These steps were repeated for each API and the 42 co-formers. 
The first column in Table A.2, corresponds to default mercury settings with five conformations of 
API and that of co-formers generated using Mercury. The second column represents five 
conformations of both API and co-formers from Spartan. Third and fourth column is a mixture of 
Spartan and Mercury generated conformers. In the third column, API conformations were 
generated using Mercury, while the co-former conformations were calculated using Spartan. The 
fourth column corresponds to API conformations generated by Spartan and co-formers 
conformations generated from Mercury.  
Accuracy of MC methodology was examined by calculating a success rate, which is the number 
of predictions match the experiments divided by the total number of experiments. The results of 
the success rates are summarized in Table A.2.  
 
Table A.2. Success rates for MC-based predictions with default descriptor settings. 
 
 
Success Rate% 
Default-Mercury 
Success Rate% 
Spartan 
Success Rate% 
API mercury 
Success Rate% 
API spartan 
T11 43 40.5 38.1 45.2 
T12 27 24.4 26.8 22.0 
T13 25 N/A N/A N/A 
T14 41 41.4 51.2 46.3 
T15 57 41.5 41.5 48.8 
T16 62 65.8 55.3 52.6 
T17 70 65.9 73.2 68.3 
 
 
A.3. Discussions 
 
Firstly, the default descriptor settings for MC calculations resulted in poor success rates for T11-
T14 (success rates 25-43%) in Table A.2. Secondly, the results obtained from Spartan generated 
conformers were comparable to that of Mercury. The similarity in the Mercury and Spartan 
 196 
 
calculations indicate that there is no significant difference between the conformers generated by 
both the methods. Hence, the lower accuracies for the co-crystal predictions could most likely be 
due to the descriptor settings. Taking a closer look into the descriptors of the default settings, we 
observed at first that, S-axis descriptor individually failed in almost all of the instances. S-axis is 
the short axis, which, by default, has a cut-off of < 3.23Å for a “PASS.” This cut-off “failed” in 
almost all the cases for the compounds examined in this study. To change most of the “FAIL” by 
this descriptor to a combination of both “PASS and FAIL,” we varied the cut-off for S axis from 
(< 3.23-4.50) Å. To find out if this modification would result in enhanced predictability of co-
crystal formation, the success rates were calculated and are listed in Table A.3.  
 
Table A.3. Success rate for S-axis with varied cut-off for co-crystal formation. 
 S axis (Å)  < 3.23 Å S axis (Å)  < 4.0 Å S axis (Å) < 4.5 Å 
T11 45% 55% 57% 
T12 50% 62% 71% 
T13 31% 45% 57% 
T14 55% 62% 64% 
T15 64% 52% 50% 
T16 59% 59% 59% 
T17 52% 40% 38% 
Average 51% 54% 57% 
 
To select the best S-axis cut-off, an average of the success rates across the seven compounds were 
calculated. The cut-off with 4.5 Å had the highest average success rate. Individually, this cut-off 
increased the prediction accuracies for five of the APIs (except for T15andT17). Since < 4.5 Å 
gave better results than the default; hence, all the further calculations were done using the new cut-
off.  
Additionally, to make effective and meaningful changes to the descriptor settings, we investigated 
the descriptor relationships and their significance. Figure A.2 shows the correlation coefficients of 
the descriptors, where a positive sign indicates a higher significance.21 Fábián et al.,  proposed that 
although Fraction of polar volume (FPV) has a higher positive correlation coefficient than 
Fraction of nitrogen and oxygen (FNO), FPV could be replaced by FNO in the calculations as an 
easier alternative.  
 
 197 
 
 
 
Figure A.2. Molecular descriptors and their significance21. 
 
In order to investigate if the replacement of FPV with FNO affects the MC success rate, we 
included FPV in the calculations. Moreover, Polar Volume (PV) also displayed a positive 
correlation and was, therefore, included as a descriptor in the updated/modified calculations.  
To calculate the “polar volume” and “fraction polar volume,” two different sources were used for 
the volume of the elements labeled as ‘source 1’38 and ‘source 2’39, respectively, Table A.4. Both 
FPV and PV were calculated for 42 co-formers and seven APIs. The difference between source 1 
and 2 is that source 1 neglects hydrogen atom, whereas, in source 2, the volume of the elements is 
dependent on the number of neighboring hydrogen atoms.  
 
Table A.4. Numerical values of volumes of elements used in calculations from two different 
sources. 
Source 1 Atomic volume 
Volume of N 17.3 cm3 / mol 
Volume of O 14.0 cm3 / mol 
Volume of S 15.5 cm3 / mol 
Volume of C 4.58 cm3 / mol 
Volume of F 17.1 cm3 / mol 
Source 2 
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O (2,1) O (1,0) O(2,0) N(3,0) N(3,1) N(2,0) N(3,2)  
15.764 Å3 13.935Å3 12.512Å3 9.944Å3 18.148Å3 13.324Å3 24.643Å3  
C (3,0) C (4,1) C(4,3) C(4,2) C(3,1) C(4,0) S(4,0) P(4,0) 
12.119Å3 18.13Å3 33.468Å3 24.409Å3 21.02Å3 10.286Å3 17.531Å3 22.161Å3 
 
 
All possible combinations of the descriptor settings were applied and tested against the 
experimental results. The different descriptor combinations were labeled as Data 1-5, Table A.5. 
Data-1 is the default five descriptor settings of MC with updated S-axis; Data-2 includes all the 
seven descriptors which were found to have positive correlations, Figure 2; Data-3 replaces FNO 
with FPV; Data-4 replaces FNO with PV; and finally Data-5 includes both FPV and PV as 
descriptors, replacing FNO. Data 2-5 were calculated using volumes from both sources. All the 
different combinations of the descriptors were examined to get the highest possible accuracy for 
MC prediction.  
 
Table A.5. Different combinations of descriptor settings for MC calculations. 
Data-1 
M/L axis ratio S/L axis ratio S-axis Dipole Moment Magnitude FNO 
Data-2 
M/L axis ratio S/L axis ratio S-axis Dipole Moment Magnitude FNO PV FPV 
Data-3 
M/L axis ratio S/L axis ratio S-axis Dipole Moment Magnitude FPV 
Data-4 
M/L axis ratio S/L axis ratio S-axis Dipole Moment Magnitude PV 
Data-5 
M/L axis ratio S/L axis ratio S-axis Dipole Moment Magnitude PV FPV 
 
 
In addition to the descriptor settings, the requirement that an overall pass, requires 5pass/5 
descriptors in the default settings seemed to us to be overly harsh. We, therefore, decided to explore 
if the match between prediction and experiment could benefit from introducing slightly less rigid 
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pass requirements. Hence, several “PASS/FAIL” criteria were also included in the updated 
calculations to identify the best possible combinations.  
Once all the predictive calculations were done using the modified MC settings, the results were 
compared with the experimental outcomes. A success rate was calculated for all the different 
combinations, Table 6. An algorithm was designed and implemented (in groovy) to analyze a total 
of 1050,000 data points in this process to select the best combinations. 
In order to select the best updated MC settings, we focused on combinations with the fewest 
number of poor performances (below 40%) or where the results were consistently above 40% 
throughout the seven APIs. This process of elimination allowed us to rule out Data-3, which had 
at least one API in each “PASS/FAIL” column where the success rate is below 40%. It gave the 
worst prediction match in comparison to other settings. Although, except for T15 and T17, the 
accuracies of the other five APIs were increased in comparison to the default settings. These 
increased accuracies can be attributed to the fact that FPV had a higher positive correlation than 
FNO.  
PV and FPV calculated from two separate sources (1and2) also affected the calculations, as we 
observed differences in the success rates. However, the observed differences were within the range 
of 2-4%. Despite that a winner between the source 1and2 was picked following similar guidelines, 
i.e., the results remain consistently above 40% for all the APIs.  
The next step was to bring forward each descriptor settings with the most consistent (above 40%) 
“PASS/FAIL” criteria across the seven APIs to analyze the quality of the predictions between the 
different settings.  
It was observed that the best success rates were achieved across the seven APIs with the following 
combinations, Table A.6.: 
Data-1 with 3pass/ 5 descriptors;  
Data-2 with 5 pass/7 descriptors calculated using source 2;  
Data-4 with 3pass/5 descriptors calculated using source 1 and  
Data-5 with 4 pass 6 descriptors settings calculated using source 2.  
Table A.6. Comparison of prediction quality with different combinations of descriptors. 
 
Data-1 
 
5 Pass/5 descriptors 
 Pass fail criteria  
(5X5) 
 Complementarity Success rate 
4 Pass/5 descriptors 
 Pass fail criteria  
(5X5) 
 Complementarity Success rate 
3 Pass/5 descriptors 
 Pass fail criteria  
(5X5) 
 Complementarity Success rate 
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T11 55% 55% 45% 
T12 55% 43% 50% 
T13 69% 67% 50% 
T14 55% 53% 50% 
T15 21% 34% 64% 
T16 52% 52% 52% 
T17 24% 43% 60% 
 
 
Data-2 
7 Pass/7 descriptors 
Pass fail criteria 
(5X5) 
Complementarity 
Success rate 
6 Pass/7 descriptors 
Pass fail criteria 
(5X5) 
Complementarity 
Success rate 
5 Pass/7 descriptors 
Pass fail criteria 
(5X5) 
Complementarity 
Success rate 
4 Pass/7 descriptors 
Pass fail criteria 
(5X5) 
Complementarity 
Success rate 
   Source 1 Source 2 Source 1 Source 2 Source 1 Source 2 
T11 57% 55% 57% 57% 55% 57% 48% 45% 
T12 55% 52% 55% 52% 50% 50% 55% 45% 
T13 74% 69% 74% 69% 62% 64% 43% 45% 
T14 55% 52% 53% 50% 50% 50% 40% 40% 
T15 21% 29% 19% 21% 43% 64% 69% 74% 
T16 52% 52% 52% 55% 55% 52% 50% 55% 
T17 31% 38% 31% 40% 64% 64% 86% 81% 
 
 
Data-3 
5 Pass/5 descriptors 
 Pass fail criteria  
(5X5) 
Complementarity Success 
rate 
4 Pass/5 descriptors 
 Pass fail criteria  
(5X5) 
 Complementarity Success 
rate 
3 Pass/5 descriptors 
 Pass fail criteria  
(5X5) 
 Complementarity Success 
rate 
 Source 1 Source 2 Source 1 Source 2 Source 1 Source 2 
T11 55% 55% 57% 57% 38% 48% 
T12 55% 55% 52% 52% 45% 55% 
T13 71% 74% 71% 74% 50% 62% 
T14 55% 55% 50% 52% 50% 50% 
T15 52% 23% 52% 21% 52% 38% 
T16 52% 52% 52% 48% 50% 52% 
T17 24% 24% 24% 29% 57% 48% 
 
 
Data-4 
5 Pass/5 descriptors 
Pass fail criteria 
(5X5) 
Complementarity Success 
rate 
4 Pass/5 descriptors 
Pass fail criteria 
(5X5) 
Complementarity Success 
rate 
3 Pass/5 descriptors 
Pass fail criteria 
(5X5) 
Complementarity Success 
rate 
 Source 1 Source 2 Source 1 Source 2 Source 1 Source 2 
T11 55% 57% 50% 55% 45% 45% 
T12 55% 57% 50% 55% 52% 55% 
T13 71% 71% 52% 57% 40% 45% 
T14 55% 57% 52% 52% 50% 57% 
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T15 24% 24% 48% 38% 77% 69% 
T16 52% 52% 48% 48% 60% 48% 
T17 24% 24% 50% 43% 74% 60% 
 
 
Data-5 
6 Pass/6 descriptors 
Pass fail criteria 
(5X5) 
Complementarity Success rate 
5 Pass/6 descriptors 
Pass fail criteria 
(5X5) 
Complementarity Success rate 
4 Pass/6 descriptors 
Pass fail criteria 
(5X5) 
Complementarity Success rate 
 Source 1 Source 2 Source 1 Source 2 Source 1 Source 2 
T11 55% 55% 52% 55% 45% 43% 
T12 55% 48% 57% 50% 53% 52% 
T13 71% 74% 71% 74% 50% 60% 
T14 55% 54% 57% 54% 45% 55% 
T15 24% 29% 24% 26% 45% 59% 
T16 52% 52% 52% 52% 48% 50% 
T17 24% 21% 24% 23% 55% 45% 
 
 
Table A.7. Comparing the prediction using different descriptor combinations with the 
experimental outcomes. 
 
 
Data-1 
3 Pass/5 descriptors 
Data-2 
5 Pass/7 descriptors 
(Source 2) 
Data-4 
3 Pass/5 descriptors 
(Source 1) 
Data-5 
4 Pass/6 descriptors 
(Source 2) 
T11 45% 57% 45% 43% 
T12 50% 50% 52% 52% 
T13 50% 64% 40% 60% 
T14 50% 50% 50% 55% 
T15 64% 64% 77% 59% 
T16 52% 52% 60% 50% 
T17 60% 64% 74% 45% 
Average 53% 57% 56% 52% 
 
 
We identified that Data-2 with 5pass/ 7descriptors offered marginally better results than the other 
three combinations. Table A8 exhibits a comparison between the success rate obtained from the 
new and default settings.   
 
Table A.8. Comparison between the default and modified MC settings with the experimental 
outcomes for co-crystal formation.  
 
Where we started 
(Default) 
New setting 
Data-2 
T11 43% 57% 
T12 27% 50% 
T13 25% 64% 
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T14 41% 50% 
T15 57% 57% 
T16 62% 52% 
T17 70% 64% 
 
 
By carefully modifying the default setting of the MC calculations, we were able to improve the 
prediction success for four APIs, one remained the same and decreased the accuracy for two of 
them. The efficiency improved from 27% to 50% for T12 and 25% to 64% for T13 in comparison 
to the decrease from 62% to 52% for T16 and 70% to 64% for T17. Overall the accuracy of MC 
increases many fold times when the default settings are adjusted to the new settings. Although the 
reliability of MC, when compared to other predictive studies reported27 is low, however, there are 
very few significant studies reported on large and flexible compounds. Furthermore, the average 
molecular weight of organic structures reported in CSD is ~400 g/mol.40 Hence, the structure 
informatics studies for compounds with a molecular weight greater than 400 g/mol might not 
reflect the same high accuracies as that of small compounds. Nonetheless, it opens a whole new 
area for studying APIs, which might not be restricted to small and rigid compounds.   
It is worth noting that structure-informatics methods such as HBP and HBC27,25 predict the co-
crystallization outcomes based on hydrogen bonds, whereas MC is dependent on shape and 
polarity factors. Therefore, it will be interesting to compare and combine the different 
methodologies, which might provide significant insight into the predictive methods and its 
reliability. 
 
A.4. Conclusions 
 
We attempted to predict co-crystallization for seven APIs against 42 potential co-formers using 
MC. The predicted outcomes were compared with the experimental results. The seven APIs 
investigated in this study were significantly larger (molecular weight 400 - 600 g/ mol) and flexible 
(rotatable bonds > 3) than the compounds reported in CSD (average molecular weight ~400 g/ 
mol). The default MC settings in Mercury afforded a success rate ranging from 27-70%.  
A total of 1050,000 data points was analyzed to introduce updated and modified MC settings, 
which concluded that Data-2 with 5pass/ 7descriptors (using source 2) increases the overall 
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accuracy. The reliability of the updated MC ranges from 50-64%, which was found to be more 
consistent across the seven APIs than the default settings.  
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Appendix B – NMR of synthetized compounds 
 
B.1. Synthesis of 4-((4-bromo-1H-pyrazol-1-yl)methyl)benzonitrile (T5) 
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B.2. Synthesis of 4-((3-bromocyclopenta-2,4-dien-1-yl)methyl)benzamide 
 
 
 
 207 
 
B.3. Synthesis of 4-((4-((trimethylsilyl)ethynyl)-1H-pyrazol-1-yl)methyl)benzamide 
 
 
B.4. Synthesis of 4-((4-ethynyl-1H-pyrazol-1-yl)methyl)benzamide (T1) 
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B.5. Synthesis of 3-((4-bromo-1H-pyrazol-1-yl)methyl)benzonitrile (T6) 
17-043-5DMP
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B.6. Synthesis of 3-((3-bromocyclopenta-2,4-dien-1-yl)methyl)benzamide 
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B.7. Synthesis of 3-((3-((trimethylsilyl)ethynyl)cyclopenta-2,4-dien-1-yl)methyl)benzamide 
 
 
B.8. Synthesis of 3-((3-ethynylcyclopenta-2,4-dien-1-yl)methyl)benzamide (T2) 
40-3-4-april
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B.9. Synthesis of 4-((4-bromo-1H-pyrazol-1-yl)methyl)benzonitrile 
 
 
B.10. Synthesis of 4-((3-bromocyclopenta-2,4-dien-1-yl)methyl)benzamide 
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B.11. Synthesis of 4-((3,5-dimethyl-4-((trimethylsilyl)ethynyl)-1H-pyrazol-1-
yl)methyl)benzamide 
 
 
 
B.12. Synthesis of 4-((3-ethynyl-2,4-dimethylcyclopenta-2,4-dien-1-yl)methyl)benzamide (T3) 
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B.13. Synthesis of 3-((4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzonitrile 
 
 
B.14. Synthesis of 3-((3-bromo-2,4-dimethylcyclopenta-2,4-dien-1-yl)methyl)benzamide 
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B.15. Synthesis of 3-((3,5-dimethyl-4-((trimethylsilyl)ethynyl)-1H-pyrazol-1-
yl)methyl)benzamide 
 
 
B.16. Synthesis of 3-((3-ethynyl-2,4-dimethylcyclopenta-2,4-dien-1-yl)methyl)benzamide (T4) 
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B.17. Synthesis of 4-((4-(iodoethynyl)-1H-pyrazol-1-yl)methyl)benzamide (T7) 
 
 
B.18. Synthesis of 3-((4-(iodoethynyl)-1H-pyrazol-1-yl)methyl)benzamide (T8) 
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B.19. Synthesis of 4-((4-(iodoethynyl)-3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzamide (T9) 
B4.ESP
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B.20. Synthesis of 3-((4-(iodoethynyl)-3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzamide (T10) 
 
 
B.21. Synthesis of C-hexylcalix[4]resorcinarene, 1 
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B.22. Synthesis of C-hexyltetrabromocalix[4]resorcinarene, 2 
 
 
B.23. Synthesis of C-hexyltetrabromocavitand, T18 
 
 
 217 
 
 
 
B.24. Synthesis of C-hexyltetraiodocavitand, T19 
 
 
B.25. Synthesis of C-hexyltetra((trimethylsilyl)ethynyl)cavitand, T20 
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B.26. Synthesis of C-hexyltetra(ethynyl)cavitand, T21 
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B.27. Synthesis of C-hexyltetra(iodoethynyl)cavitand, T22 
 
 
B.28. Synthesis of C-hexyltetra(iodoethynyl)cavitand, T22 
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B.29. Synthesis of C- hexyltetraboronic acid dipinacolyl ester cavitand, T23 
 
 
B.30. Synthesis of C-hexyltetra(3-pyridyl) cavitand, T24 
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B.31. Synthesis of C-hexyltetra(4-pyridyl) cavitand, T25 
 
 
B.32. Synthesis of C-hexyltetra(3-pyrazole) cavitand, T26 
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B.33. Synthesis of C-hexyltetracarboxylic cavitand, T27 
 
 
B.34. Synthesis of C-hexyltetracarboxylic cavitand, T27 
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Appendix C – TGA analysis 
 
C1. T18 recrystallized from xylene 
 
 
 
C.2. T18 recrystallized from dichloromethane (DCM) 
 
 
 
One xylene molecule= 11% 
One water molecule= 1.5% 
One DCM molecule= 6% 
One water molecule= 1.3% 
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C3. T18 recrystallized from ethyl acetate (EtOAc) 
 
 
C4. T18 recrystallized from acetonitrile (ACN) 
 
 
 
 
One EtOAc molecule= 7.4% 
One water molecule= 1.3% 
One ACN molecule= 3.4% 
One water molecule= 1.3% 
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C5. T18 recrystallized from dimethyl sulfoxide (DMSO) 
 
 
C6. T18 recrystallized from equimolar mixture of solvents 
 
 
 
One DMSO molecule= 6.1% 
One water molecule= 1.5% 
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C7. T19 recrystallized from xylene 
 
 
 
C8. T19 recrystallized from dichloromethane (DCM) 
 
 
 
One xylene molecule= 10.2% 
One water molecule= 1.5% 
One DCM molecule= 7.3% 
One water molecule= 1.5% 
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C9. T19 recrystallized from ethyl acetate (EtOAc) 
 
 
C10. T19 recrystallized from acetonitrile (ACN) 
 
 
 
One EtOAc molecule= 7.3% 
One water molecule= 1.5% 
One ACN molecule= 3.4% 
One water molecule= 1.5% 
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C11. T19 recrystallized from dimethyl sulfoxide (DMSO) 
 
 
C12. T19 recrystallized from equimolar mixture of solvents 
 
 
 
 
 
One DMSO molecule= 6.7% 
One water molecule= 1.5% 
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C13. T20 recrystallized from xylene 
 
 
C14. T20 recrystallized from dichloromethane (DCM) 
 
 
 
One xylene molecule= 11% 
One water molecule= 1.5% 
One DCM molecule= 6% 
One water molecule= 1.3% 
 230 
 
C15. T20 recrystallized from ethyl acetate (EtOAc) 
 
 
 
C16. T20 recrystallized from acetonitrile (ACN) 
 
 
 
 
One EtOAc molecule= 7.4% 
One water molecule= 1.3% 
One ACN molecule= 3.8% 
One water molecule= 1.3% 
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C17. T20 recrystallized from dimethyl sulfoxide (DMSO) 
 
 
C18. T20 recrystallized from equimolar mixture of solvents 
 
 
 
One DMSO molecule= 6.1% 
One water molecule= 1.5% 
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C19. T21 recrystallized from xylene 
 
 
C20. T21 recrystallized from dichloromethane (DCM) 
 
 
 
 
One xylene molecule= 13.8% 
One water molecule= 2.3% 
One DCM molecule= 11% 
One water molecule= 2.3% 
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C21. T21 recrystallized from ethyl acetate (EtOAc) 
 
 
C22. T21 recrystallized from acetonitrile (ACN) 
 
 
 
 
One EtOAc molecule= 7.4% 
One water molecule= 2.3% 
One ACN molecule= 5.3% 
One water molecule= 2.3% 
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C23. T21 recrystallized from dimethyl sulfoxide (DMSO) 
 
 
C24. T21 recrystallized from equimolar mixture of solvents 
 
 
One DMSO molecule= 20% 
One water molecule= 2.3% 
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C25. T22 recrystallized from xylene 
 
 
C26. T22 recrystallized from dichloromethane (DCM) 
 
 
One xylene molecule= 8.3% 
One water molecule= 1.4% 
One DCM molecule= 6.7% 
One water molecule= 1.34% 
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C27. T22 recrystallized from ethyl acetate (EtOAc) 
 
 
C28. T22 recrystallized from acetonitrile (ACN) 
 
 
 
One EtOAc molecule= 7.4% 
One water molecule= 1.4% 
One ACN molecule= 3.2% 
One water molecule= 1.4% 
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C29. T22 recrystallized from dimethyl sulfoxide (DMSO) 
 
 
C30. T22 recrystallized from equimolar mixture of solvents 
 
 
 
One DMSO molecule= 6.1% 
One water molecule= 1.4% 
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C31. T23 recrystallized from xylene 
 
 
C32. T23 recrystallized from dichloromethane (DCM) 
 
 
 
 
One xylene molecule= 10.5% 
One water molecule= 1.8% 
One DCM molecule= 8.4% 
One water molecule= 1.8% 
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C33. T23 recrystallized from ethyl acetate (EtOAc) 
 
 
C34. T23 recrystallized from acetonitrile (ACN) 
 
 
 
One ACN molecule= 4.1% 
One water molecule= 1.8% 
One EtOAc molecule= 8.7% 
One water molecule= 1.8% 
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C35. T23 recrystallized from dimethyl sulfoxide (DMSO) 
 
 
C36. T23 recrystallized from equimolar mixture of solvents 
 
 
 
 
One DMSO molecule= 15.4% 
One water molecule= 1.8% 
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C37. T24 with Isoborneol 
 
 
C38. T24 with Menthol 
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C39. T25 with Isoborneol 
 
 
C40. T25 with Menthol 
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C41. Selectivity of T25 between Menthol and 2-Methylbutyric acid 
 
 
C42. Selectivity of T25 between Menthol and 2-Methylpentanoic acid 
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C43. Selectivity of T25 between Menthol and 2-Methylhexanoic acid 
 
 
C44. Selectivity of T25 between Isoborneol and 2-Methylbutyric acid 
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C45. T27 with 3-Picoline-N-oxide 
 
 
C46. T27 with 4-Picoline-N-oxide 
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C47. T27 with Pyridine-N-oxide 
 
 
C48. T27 with Pyrazine-N-oxide 
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Appendix D – Jobs Plot 
 
 
D1. T24 in combination with 2-Methylbutyric acid. 
 
1:2 host-guest stoichiometry
 
 
 
 
D2. T24 in combination with 2-Methylpentanoic acid. 
 
1:2 host-guest stoichiometry 
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D3. T24 in combination with 2-Methylhexanoic acid. 
 
1:2 host-guest stoichiometry 
 
 
 
 
D4. T24 in combination with Menthol. 
 
1:2 host-guest stoichiometry 
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D5. T24 in combination with Isoborneol. 
 
1:2 host-guest stoichiometry 
 
 
 
 
D6. T24 in combination with Benzoic acid. 
 
1:2 host-guest stoichiometry 
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D7. T25 in combination with Menthol. 
 
1:2 host-guest stoichiometry 
 
 
 
 
D8. T25 in combination with Benzoic acid. 
 
1:2 host-guest stoichiometry 
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D9. T27 in combination with 3-Picoline-N-oxide. 
 
1:2 host-guest stoichiometry 
 
 
 
D10. T27 in combination with 4-Picoline-N-oxide. 
 
1:2 host-guest stoichiometry 
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D11. T27 in combination with 4-Pyridine-N-oxide. 
 
1:2 host-guest stoichiometry 
 
 
 
D12. T27 in combination with 4-Pyrazine-N-oxide. 
 
1:2 host-guest stoichiometry 
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Appendix E – Crystallography Table 
 
 
Code T18:xylene T18 T18:(EtOAc)2 T18:ACN T18:DMSO 
Formula moiety C56H68Br4O8, 
C8H10 
C56H68Br4O8 (C64H84Br4O12) 
(C4H8O2)0.5 
C56H68Br4O8, 
C2H3N 
C56H68Br4O8, 
C2H6OS 
Empirical formula C64H78Br4O8 C56H68Br4O8 C64H84Br4O12 C58H71Br4NO8 C56H68Br4O8 
Molecular weight 1294.90 1188.74 1364.95 1229.79 1266.87 
Color, Habit Colorless,  
Rectangular 
Colorless, 
Needles 
Colorless, Plates Colorless,  
Rectangular 
Colorless,  
Rectangular 
Crystal system Monoclinic Orthorhombic Monoclinic Monoclinic Monoclinic 
Space group, Z P121/n1, 4 Pbca, 4 P121/c1, 4 P121/c1,4  P121/c1,4 
a, Å 11.9255(7) 29.4357(12) 15.5083(4) 18.2598(7) 18.730(2) 
b, Å 17.9854(10) 17.4607(7) 23.6111(6 17.4497(7) 25.524(3) 
c, Å 27.7020(16) 61.265(3) 18.3214(5) 18.8784(7) 12.8330(14) 
α, º 90 90 90 90 90 
β, º 94.3430(10) 90 107.8770(10) 111.954(2) 91.112(6) 
γ, º 90 90 90 90 90 
Volume, Å3 5924.6(6) 31488(2) 6384.8(3) 5579.0(4) 6133.9(12) 
Density, g/cm3 1.452 1.505 1.420 1.464 1.372 
T, ºK 199.99   199.99 273.(2) 296.(2) 296.15 
Crystal size, min x 
mid x max 
0.28 x 0.24 x 
0.13 
0.48 x 0.19 x 
0.09 
0.325 x 0.105 x 
0.070 
0.390 x 0.100 x 
0.090 
0.23 x 0.12 x 
0.10 
X-ray wavelength, 
Å 
1.54178  1.54178 1.54178 1.54178  1.54178 
µ, mm-1 3.743 4.170 3.549 3.948 3.924 
Trans min / max 0.7531 / 
0.6098 
0.239 / 0.705 0.639/ 0.79 0.39/ 0.72 0.466/ 0.695 
θmin, º 2.932 2.081 2.99 2.61 2.359 
θmax, º 68.210 68.251 69.97 69.92 67.586 
Reflections      
collected 53980 169575  62416 70021 35608 
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independent 10556 28264 11530 10015  9931 
observed 10300 24204 10627 9306 7916 
Rint 0.0284 0.0571 0.0480 0.1295 0.0516 
Threshold 
expression 
> 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) 
No. parameters 679 1849 730 645 655 
No. restraints 7 0 0 0 0 
R1 (observed) 0.0372 0.0756 0.0558 0.0634 0.2405 
wR2 (all) 0.0957 0.1860 0.1435 0.1664 0.6116 
Goodness of fit 
(all) 
1.065 1.141  1.085 1.040 3.107 
ρmax, ρmin, e Å−3 1.066, -0.801 0.002, 0.000  1.411, -1.566 1.637, -1.761  3.242, -2.130 
Completeness to 
2θ limit 
0.974 0.981 0.952 0.949 0.896 
 
 
Code T19:xylene T19 T19:DMSO T21:DMSO 
Formula moiety C56H68I4O8, 
C8H8 
C56H68I4O8 C56H68I4O8 
2(C2H6OS) 
C64H72Br4O8, 
2(C2H6OS) 
Empirical formula  C56H68I4O8 C56H68I4O8  C56H68I4O8  C64H72Br4O8 
Molecular weight  1472.78  1376.70   1532.96  1125.47 
Color, Habit Colorless,  
Rectangular 
Colorless, Needles Colorless, 
Rectangular 
Colorless,  
Rectangular 
Crystal system Monoclinic Monoclinic Monoclinic Monoclinic 
Space group, Z  C12/c1, 4  P 21/c1, 4  P121/c, 4 P121/c1,4  
a, Å  36.3616(16)  18.8079(14)  19.9328(5)  18.9835(6) 
b, Å  14.9480(7)   16.3640(11)  12.3491(3)  25.5744(8) 
c, Å  23.2062(10) 18.9127(13)  26.6063(6)  12.7022(4) 
α, º 90 90 90 90 
β, º  101.6480(10) 109.738(2)  105.2720(10)  92.5190(10 
γ, º 90 90 90 90 
Volume, Å3   12353.6(10)  5478.8(7)  6317.9(3)  6160.9(3) 
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Density, g/cm3 1.584 1.669  1.612 1.213 
T, ºK 199.99   199.99  199.99 199.99 
Crystal size, min x 
mid x max 
0.22 x 0.19 x 
0.17 
0.33 x 0.17 x 0.075 0.125 x 0.06 x 0.05 0.55 x 0.17 x 0.07 
X-ray wavelength, Å  1.54178  1.54178 1.54178 1.54178 
µ, mm-1  16.256 18.275 16.539 1.243 
Trans min / max  0.7530 / 0.6150 0.065/ 0.341 0.1766/ 0.5685  0.7531/ 0.5181 
θmin, º   3.206 2.496 2.298 2.330 
θmax, º 68.506 68.545 70.046 68.386 
Reflections     
collected  35657 26870 31840 45296 
independent  11003 9473 11437 11002 
observed 9731 7255 9768 8929 
Rint  0.0361 0.0892 0.0690 0.0362 
Threshold expression > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) 
No. parameters  686 617 703  807 
No. restraints 9 4 2 108 
R1 (observed) 0.1054 0.1572 0.0742 0.0554 
wR2 (all)   0.3157 0.4267 0.1903 0.1556 
Goodness of fit (all)   2.675 1.750 1.069 1.025 
ρmax, ρmin, e Å−3   2.468, -1.314 4.173, -2.365  2.932, -2.466  0.352, -0.365 
Completeness to 2θ 
limit 
0.968 0.937 0.947 0.972 
 
 
